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Abstract
The biochemical processes occurring within a living cell span a spectrum of scales in space and time,
ranging from the nano- to the macro-scale. We note that a single cellular process often operates on
multiple spatial and temporal scales, and thus it becomes necessary to combine modeling techniques in
multiscale approaches, in which different levels of theory are synergized to describe a system at a
number of scales or resolutions. In this work we apply a multiscale modeling framework to investigate the
molecular regulatory mechanisms governing the activation of the ErbB receptor tyrosine kinases, a family
of kinases which are commonly over-expressed or mutated in human cancers, with a focus on the HER3
and HER4 kinases. Our multiscale model of HER3, a kinase which, until recently, has been considered
kinase-dead, presents evidence of HER3 catalytic activity and demonstrates that even a weak HER3 signal
can be amplified by other cellular signaling mechanisms to induce drug resistance to tyrosine kinase
inhibitors in silico. Thus HER3, rather than the commonly-targeted EGFR and HER2 kinases, may represent
a superior therapeutic target in specific ErbB-driven cancers. In the second major study, we construct a
multiscale model of activity in the HER4 kinase, which has been shown to perform an anti-cancer role in
certain tumor cells, by steering the cell toward a program of cellular differentiation and away from a
program of uncontrolled proliferation. Our HER4 model, which applies a combined computational and
experimental approach, elucidates the molecular mechanisms underlying this HER4-mediated ‘switch’ to
the cellular differentiation program, with the ultimate aim of exploiting or modulating the HER4 pathway
as a potential therapy in specific ErbB-driven cancers. Furthermore, the model provides structural insights
into the effects of several HER4 somatic mutations which have recently been discovered in a subset of
cancer patients, and which abrogate the anti-cancer effects of HER4 activity. We have illustrated that
multiscale modeling provides a powerful and quantitative platform for investigating the complexity
inherent in intracellular signaling pathways and rationalizing the effects of molecular perturbations on
downstream signaling events and ultimately, on the cell phenotype.
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ABSTRACT
MULTISCALE MODELING OF THE ERBB RECEPTOR
TYROSINE KINASE SIGNALING NETWORK
THROUGH THEORY AND EXPERIMENT
Shannon E. Telesco
Ravi Radhakrishnan

The biochemical processes occurring within a living cell span a spectrum of scales in
space and time, ranging from the nano- to the macro-scale. We note that a single cellular
process often operates on multiple spatial and temporal scales, and thus it becomes
necessary to combine modeling techniques in multiscale approaches, in which different
levels of theory are synergized to describe a system at a number of scales or resolutions.
In this work we apply a multiscale modeling framework to investigate the molecular
regulatory mechanisms governing the activation of the ErbB receptor tyrosine kinases, a
family of kinases which are commonly over-expressed or mutated in human cancers, with
a focus on the HER3 and HER4 kinases. Our multiscale model of HER3, a kinase which,
until recently, has been considered kinase-dead, presents evidence of HER3 catalytic
activity and demonstrates that even a weak HER3 signal can be amplified by other
cellular signaling mechanisms to induce drug resistance to tyrosine kinase inhibitors in
silico. Thus HER3, rather than the commonly-targeted EGFR and HER2 kinases, may
vi

represent a superior therapeutic target in specific ErbB-driven cancers. In the second
major study, we construct a multiscale model of activity in the HER4 kinase, which has
been shown to perform an anti-cancer role in certain tumor cells, by steering the cell
toward a program of cellular differentiation and away from a program of uncontrolled
proliferation. Our HER4 model, which applies a combined computational and
experimental approach, elucidates the molecular mechanisms underlying this HER4mediated ‘switch’ to the cellular differentiation program, with the ultimate aim of
exploiting or modulating the HER4 pathway as a potential therapy in specific ErbBdriven cancers. Furthermore, the model provides structural insights into the effects of
several HER4 somatic mutations which have recently been discovered in a subset of
cancer patients, and which abrogate the anti-cancer effects of HER4 activity. We have
illustrated that multiscale modeling provides a powerful and quantitative platform for
investigating the complexity inherent in intracellular signaling pathways and rationalizing
the effects of molecular perturbations on downstream signaling events and ultimately, on
the cell phenotype.
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Chapter 1
Introduction
1.1 Multiscale modeling of cellular processes
The biochemical processes occurring within a cell span a spectrum of scales in space and
time, ranging from the nanoscale to the macroscale. As a result, many different modeling
techniques are commonly used to represent the system of interest, several examples of
which are highlighted in Figure 1.1. Fig. 1.1 illustrates the different levels of theory
available to simulation, where the x-axis displays the range of time scales and the y-axis
the various length scales. In the lower-most corner of Figure 1, we find the most accurate,
yet most computationally demanding, method: electronic level,

or quantum

mechanics/molecular mechanics (QM/MM), simulations. At each time step of a QM/MM
simulation, the interactions between the nuclei of a selected subset of atoms in a protein
are computed using a quantum chemical electronic structure calculation, and therefore
this type of simulation is typically used to investigate chemical reactions occurring during
enzyme catalysis. At a lower level of resolution, molecules can be represented at the
atomic scale in molecular dynamics (MD) simulations (Fig. 1.1), which are employed to
study conformational changes in proteins. The largest MD simulations to date comprise
more than one million atoms and can be run for hundreds to thousands of nanoseconds on
current super-computers. The third level of theory represented in Fig. 1.1 focuses on
cellular-level simulations to investigate specific signaling networks in biological systems
of interest, and is most relevant for events occurring on the order of milliseconds to

1

hours.. In this type of model it is typical for the molecular reactions to be represented as a
system of ordinary differential equations (ODEs), or, if spatial information is relevant, as
a system of partial differential equations, and solved numerically to produce time courses
for expression levels of various model species. In this way, the interactions among
am
various signaling components can be quantitatively investigated. The final modeling
scale represented in Figure 1.1 is the genetic or transcriptional
anscriptional scale, which is used to
analyze the interactions between transcr
transcription
iption factors (TFs) and genes which produce the
ultimate celluar phenotype. Of course, one can imagine extending
xtending the axes in Figure 1.1
to include other scales, such as the tiss
tissue or whole organism levels, but the range
illustrated here represents the scales which are investigated in this thesis.

Figure 1.1. Multiscale modeling hierarchy.
The highest level of resolution applied in this thesis is the quantum, or electronic-level
electronic
scale,
which is used to map catalytic pathways in enzymes and proteins. The largest scale employed is
that of gene expression and transcriptional activation.

2

We note that a single cellular process often operates on multiple spatial and temporal
scales,
s, and thus it becomes nece
necessary
ssary to combine modeling techniques in multiscale
approaches,, in which different levels of theory are synergized to describe a system at a
number of scales or resolutions
resolutions. Multiscale modeling has been applied to a variety of
biological systems

46, 143, 165, 193

to help quantify the complexity inherent in intracellular

signaling networks and to provide a bridge betweent the microscopic and mesomeso or
macroscopic time and length scales (Fig. 1.2).. Multiscale modeling provides a powerful
and quantitative methodology for studying the effects
cts of molecular perturbations, such as
mutation or phosphorylation of proteins, on downstream signaling events,
events including gene
expression and the ultimate cellular phenotype.

Figure 1.2. Multiscale modeling example.
On the left is a schematic of a typical signaling model; on the right, the model is displayed at
increased (atomic-level)
level) resolution to better define the effects of molecular perturbations on the
selection of downstream signaling cascades.

3

1.2 The ErbB family of receptor tyrosine kinases
The ErbB family of kinases is a set of four homologous receptor tyrosine kinases (RTKs):
EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4. RTKs are
single-pass transmembrane proteins which play an important role in intracellular
signaling by translating extracellular cues (ligands or growth factors) into activation of
specific cell signaling cascades

73, 152

. In humans, there are currently 58 known RTKs

divided into 20 families. The ErbB family of RTKs are composed of an extracellular
ligand-binding domain, a transmembrane segment, an intracellular protein tyrosine kinase
domain, and a C-terminal tail harboring tyrosine phosphorylation sites

151

. Under

physiological conditions, ligand binding promotes homo- or heterodimerization of the
receptors and activation of their cytoplasmic domains 106, 206. Dimerization results in autoor trans-phosphorylation of tyrosine residues in the C-terminal tail segments, which serve
as docking sites for signaling molecules containing SH2 or PTB domains156. The major
signaling cascades activated by the ErbB family include the Ras-Raf-MEK-MAPK and
the PI3K-Akt pathways, both of which result in transcription of genes involved in cellular
proliferation, differentiation, and migration31. Aberrant activation of the ErbB network is
frequently associated with cellular transformation and clinical malignancies such as lung,
gastric, and breast cancers

29, 79, 102, 117, 164, 200

. Overexpression of HER2 results in

constitutive, ligand-independent activation of kinase signaling and is found in 20-30% of
human breast cancers, where it is correlated with an aggressive tumor phenotype 168, 195.
The ErbB signaling network presents a “bow-tie” architecture, in which multiple
inputs and outputs are linked through a set of core processes

31

. The ErbB kinases are

capable of binding to a variety of ligands, improving the flexibility and robustness of the
ErbB signaling network by allowing for cross-talk between the ErbB kinase dimers and
4

compensating for any reduced signaling of individual ErbB members in a given cell type.
For example, HER2 does not currently have a known ligand, and the kinase activity of
HER3 is weaker than that of the other ErbB RTKs18. However, HER2/HER3
heterodimers are extremely relevant in cellular signaling, and their over-expression is
correlated with oncogenic transformation in many types of cancer

2, 68

. While the

response to extracellular signals occurs only through the four ErbB kinases, and is then
channeled through a conserved, relatively small collection of core biochemical
interactions, the ErbB network again expands through the activation of transcription
factors and positive as well as negative feedback mechanisms, culminating in gene
expression and the ultimate cellular phenotype (proliferation, differentiation, migration).

1.3 Structure of the ErbB RTK
Activation of the ErbB kinases initiates with the binding of ligand to the extracellular
domain of the ErbB RTK. In the ErbB family, the extracellular domain is locked in an
auto-inhibited state, which is then released through the ligand binding event. There are
several mechanisms through which ligand binding facilitates the dimerization of RTKs,
including “ligand-mediated” dimerization, in which the ligands bridge the two receptors
without the receptors making direct contact, and “receptor mediated” dimerization, in
which the ligands make no direct contribution to the dimer interface104. The ErbB family
represents an extreme case of “receptor mediated” dimerization56,

128

. The ErbB

extracellular domain consists of four sub-domains, with auto-inhibitory interactions
occurring between domains II and IV in a tethered conformation (Figure 1.3A)19, 20, 26, 49.
Ligands in the ErbB family are bivalent and bind to Domains I and III, which induce a

5

conformational change to release the tethered conformation and expose a dimerization
arm in domain II, allowing the dimerization arm to contact another ErbB RTK molecule.
Activation of the ligand-binding domain of the ErbB receptor triggers
conformational changes within its cytoplasmic domain. In order to effect phosphoryl
transfer of the γ-phosphate of ATP to tyrosine residues on target substrates, several key
loops within the kinase domain must be appropriately positioned 75. Residues 812 to 818
(EGFR numbering) comprise the catalytic loop (C-loop), which is crucial in facilitating
the phosphoryl transfer reaction. The αC helix (residues 729-742) and the nucleotidebinding loop, or N-loop (residues 695 to 700), are responsible for coordination of the
ATP and substrate tyrosine. The activation loop (A-loop) comprises residues 831 to 852
and governs activation of the kinase by regulating accessibility of the target substrate to
the C-loop. The A-loop undergoes a significant conformational extension upon activation
(Fig. 1.3B), uncovering the catalytic machinery and enabling binding of the tyrosine
substrate to the C-loop172.
In most protein kinases, the activation loop assumes its catalytically competent
conformation only if it is first phosphorylated on a regulatory tyrosine residue within the
A-loop73, which corresponds to Y845 in EGFR (Y877 in HER2). Members of the EGFR
family appear to be unique in not requiring A-loop phosphorylation for their activity186.
However, several biochemical studies have demonstrated that phosphorylation of Y845
in EGFR significantly alters downstream signaling events, such as activation of STAT5b
and EGF-induced DNA synthesis, potentially by altering the molecular environment in
the A-loop and influencing recruitment of signaling mediators involved in downstream
processes15,

90

. Furthermore, Xu et al.203 have reported that mutation of Y877 to

6

phenylalanine in COS-7 cells results in decreased autophosphorylation of Y1248, a
tyrosine located in the C-terminal tail of HER2. Therefore, it is possible that
phosphorylation of the A-loop tyrosine residue augments ErbB kinase activity.

Figure 1.3. Activation scheme for the ErbB family.
(A) The inactive kinase (brown N-lobe) is auto-inhibited through the A-loop and αC-helix
(purple). Introduction of the asymmetric dimer interface rotates the αC-helix to the active state
(orange N-lobe). (B) Enhanced view of the inactive and active kinase domains, where the A-loop
and αC-helix are shown in purple. (C) Hydrophobic core (cyan) in the inactive and active
conformations. (D) C-spine (left, yellow) and R-spine (right, yellow) in the inactive and active
conformations.

Recent structural studies have revealed highly conserved hydrophobic “spines” within
kinases, which are considered to be important for defining their catalytic state

93, 94

(Fig.

1.3D). The regulatory spine (R-spine) consists of four hydrophobic side chains (M742,
L753, H811, F832 in EGFR) anchored by an aspartic acid in the αF-helix (D872 in
EGFR). The R-spine spans several key regulatory sub-domains, and coordinates the
motion of the N- and C-lobes of the kinase93. The catalytic spine (C-spine) involves eight
hydrophobic side-chains (V702, A719, L774, V819, L820, V821, T879, L883 in EGFR)
which support and coordinate the adenine ring of ATP in the active state94. Similarly, in
7

the inactive state there is a small hydrophobic ‘core’ formed between the αC-helix and
the A-loop, which maintains the kinase in the inactive conformation (Fig. 1.3C).
Disruption of this hydrophobic core by single point mutations has been shown to activate
EGFR29, 111, 131, 132, 172.

1.4 Allosteric activation of the ErbB kinase domain
Many protein kinase domains are inhibited through steric hindrance, in which a protein
segment blocks the kinase active site to reduce the efficacy of the kinase. Dimerization
positions two kinase domains in close proximity to each other, and, although the kinase
efficiency is greatly reduced, it is theorized that each kinase exhibits sufficient activity to
phosphorylate its dimerization partner. Phosphorylation prevents the protein segment
from binding into the active site and allows the kinase to fully function. In the insulin71
and FGFR118 family of kinases, the A-loop serves as the inhibitory segment, while the
juxtamembrane domain serves a similar auto-inhibitory role in MuSK 188, Flt3 61, KIT 119,
and the Eph

201

family. In the Tie2162 kinase, a segment of the C-terminal tail acts as the

auto-inhibitor.
The ErbB family of receptor tyrosine kinases employs an alternative method of
auto-inhibition

of

catalytic

activity,

in

that

phosphorylation

of

the

A-loop or any other protein segment does not activate the kinase. Rather than operating
via steric hindrance of the active site, there are collective auto-inhibitory interactions
preventing the proper coordination among key sub-domains in the kinase91, 208. Activation
of the kinase domain is achieved through dimerization, though in this case, the dimer
interface itself serves as the activating mechanism. Recent structural studies demonstrate

8

that EGFR and HER4 are activated through an asymmetric dimerization mechanism
analogous to that of a cyclin bound to an activated cyclin-dependent kinase (CDK)141, 208.
In this asymmetric arrangement, the C-lobe of the activator kinase interacts with the Nlobe of the CDK-like kinase, activating the CDK-like kinase through allosteric contacts.
The dimer interface is dominated by hydrophobic interactions between the C-lobe of the
activator kinase and the αC helix of the kinase undergoing activation. A sequence
alignment of the ErbB kinase domains reveals that the residues involved in the N- and Clobe faces of the dimer are essentially invariant among the family members, suggesting
that the other ErbB kinases are likely to be activated by a similar asymmetric
dimerization scheme.
Specifically, the αC-helix in the inactive ErbB kinase is rotated away from the
catalytic site, preventing key interactions from forming. Introduction of the activating
asymmetric

dimer

interface

(Fig.

1.3A)

forces

the

αC-helix to sample a different conformational space, steering the helix toward the active
state. Furthermore, the juxtamembrane domain serves as a latch to facilitate the formation
of the asymmetric dimer interface84, 144, 185.

1.5 Regulation of ErbB signaling
Following the activation of RTKs, there are several mechanisms, including receptormediated endocytosis and cellular phosphatase activity, which modulate the length of
time the kinase is active on the cell surface. Upon ligand-induced activation, RTKs are
internalized, a process which removes the active RTK as well as the ligand from the cell
surface39,

142, 170

. The predominant pathway for internalization in RTKs is clathrin-

9

mediated endocytosis, in which the RTKs are rapidly endocytosed through clathrincoated pits. One member of the ErbB family, HER4, utilizes an alternative method of
internalization, namely, proteolytic cleavage194, which constitutes a biochemical switch
and is involved in proper cardiac and neural development 58, 65.
Protein tyrosine phosphatases (PTPs) counterbalance RTK activity by removing
the phosphate group on the phosphotyrosine residues. The interplay between the RTKs
and PTPs serves as an important cellular switch to regulate the full activation of the
RTKs and thereby the cellular fate decisions

189

. Prior to RTK activation, PTPs are in

constant activity to reduce any residual phosphorylation resulting from receptor crosstalk. Given a sufficient concentration of ligand, RTK activation overcomes local PTP
activity to initiate signal propagation145. In some cases, ligand binding stimulates
recruitment of PTPs which bind and dephosphorylate target RTKs, hence stabilizing the
inactive RTK conformation at the cell surface and inhibiting further signaling

179

. The

bivalent relationship between PTPs and RTKs therefore constitutes a versatile regulatory
unit in cellular signaling.
Another family of cytoplasmic proteins which play a role in the activation and
regulation of RTKs are the recently discovered cytohesins in EGFR

12

(and the proteins

Dok7 in MuSK 77). These proteins modulate RTK activity in both a positive and negative
fashion, depending on their concentration. Increased levels of such proteins activate the
RTKs without any ligand binding events, while low levels of cytohesins prevent RTK
activation, even in the presence of ligand. An emerging view is that cytohesins are
important in the scheme of ErbB dimerization and activation, although their specific
regulatory role remains an open question.

10

1.6 Mutation of the ErbB kinase domain and relevance to cancer
Deregulation and mutation of RTKs have been correlated with cancer almost
immediately after their discovery and purification in the early 1980s. The v-erbb
oncogene in the avian erythroblastosis virus that was capable of inducing acute leukemia
encoded a constituently active form of the homologous ErbB kinase protein42. With the
growing research focus on RTKs, the correlation between deregulation of RTKs and a
variety of ailments, especially cancer, has only grown stronger. Deregulation of RTKs in
cancer can occur at several stages: (1) increased ligand production through enhanced
local autocrine activation; (2) specific gene translocations to produce kinase fusions with
altered signaling profiles; (3) RTK over-expression at the cell surface; (4) mutation of the
RTK protein to modulate activity; and (5) deregulation of phosphatase and endocytosis
mechanisms to increase RTK signal propagation.
Clinically identified activating kinase domain mutations have been discovered in
many types of cancer (Table 1.1). The results presented in Table 1.1 are curated from the
Catalog of Somatic Mutations In Cancer (COSMIC 52), which contains a comprehensive
listing of all known cancer mutations. The oncogenic mutations cluster near the kinase
sub-domains known to play a role in kinase activation (Table 1.1). In Kit, the
predominant clinically identified activating mutations are focused in the juxtamembrane
domain and the A-loop, both of which alter the auto-inhibitory function of the
juxtamembrane domain. In the FGFR family, the kinase mutations are centered on the Aloop, which serves as the auto-inhibitory segment. EGFR is cis-inhibited through auto-
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Lung
PL 111, 131
αC 111, 131,

Colon

Skin

αCβ4 70, 95
HC 111, 131,

–

αCβ4 200

αCβ4:103

–

Breast

Prostate

132, 169

EGFR

αC 35

αC:28

132, 169

ErbB2
ErbB4
PDGFRα

AD1 169
αC 103
αCβ4 21,
164, 175

–

JM:37
CT:36

CSF1R/Fms

–

AL: 171

αCβ4:103
αC:158

–

AL: 171

–

–

–

–

–

–

–

αC:34, 190
AL:9, 34,

–

–

–

–

–

AL:140

–
–

9, 34,

JM:

190, 198

Kit/SCFR

JM:16

–

190

Flt3/Flk2
VEGFR2/
KDR
FGFR1

–
CT:

–

37

AL:36

–
–

FGFR2

–

–

FGFR3

–

–

FGFR4
Met

AL:37
JM:37, 92

–
αC:110

–

57

JM: *
αC:57*
AL:57*
AL:64, 63,
109

–
–

TM:5 AL: 5

–

–

–

–

–

–

–

–
–

–
–

Table 1.1. Clinically identified mutations in RTKs with the most lethal tumor types.
* denotes a loss-of-function mutation, JM: juxtamembrane domain, PL:P-loop, αC: αC-helix, αCβ4: αC-β4 loop, HC: Hydrophobic Core, AL: A-loop, AD1: Asymmetric Dimer Interface in ErbB
family, AD2: Asymmetric Dimer Interface in Ret, CT: C-terminal Tail.

inhibitory interactions in the αC helix, and is released by the asymmetric dimer interface.
The activating kinase mutants observed in EGFR-driven cancers are dominated by two
mutations, which account for ~4500 of the 5000 total mutations (Figure 1.4): a point
12

mutation (L834R) within the hydrophobic core as well as a small in-frame deletion
involving residues 747 to 751 in the αC helix. The HER2 RTK is prevented from forming
heterodimers due to its association with the molecular chaperone protein Hsp90 through
the uniquely hydrophobic αC-β4 region30,

202

, which is where the majority of the

activating HER2 mutations occur (Figure 1.4). HER4 is not as well studied as EGFR and
HER2; however, it has recently come under scrutiny as a potential therapeutic target. It is
worth noting that few kinase mutations occur in the critical catalytic residues of the Cloop, as they would be likely to abolish kinase activity altogether. The increased kinase
activity in the ErbB cancer mutants increases the dependency of the tumor upon the ErbB
RTK; in effect, the tumor becomes “oncogenically addicted”196 and thus inhibition of the
RTK represents a viable route for cancer therapeutics. EGFR and one of its small
molecule inhibitors, Gefitinib, is a canonical example of the relationship among RTKs,
cancer, and targeted therapeutics. The initial discovery of Gefitinib in 1994 was met with
much excitement as a potential cancer therapeutic since it would be a low-dose targeted
oral cancer drug. In two phase II clinical trials of Gefitinib for advanced non-small cell
lung cancer (following progression of the cancer with chemotherapy), patients exhibited
symptom improvement rates of approximately 40% and 1-year survival rates of 25–35%
54, 97

. The favorable results from the phase II trials gained FDA approval for Gefitinib in

2003, prior to phase III clinical trials. However, the phase III clinical trials of Gefitinib
versus placebo as a second-line therapy did not show any statistical significance in
survival in the overall population, although there was a therapeutic benefit to a sub-group
of
non-smokers

Asian
184

. Examination of the tumors revealed sets of mutations in the EGFR

13

tyrosine kinase domain 111, 131, 132. The subset of tumors harboring these EGFR mutations
are exceptionally sensitive to inhibition through Gefitinib, to the extent that Gefitinib has
equal or greater efficacy than standard chemotherapy treatments in EGFR mutationpositive patients

41, 126

. There are several other small molecule tyrosine kinase inhibitors

(TKIs) as well as antibodies already approved by the FDA and in use in the clinical
setting (Table 1.2).

Figure 1.4. Non-unique mutations cataloged in cancer samples for the ErbB family.

Name
Bevacizumab (Avastin)

Target
VEGF

Cetuximab (Erbitux)
Panitumumab (Vectibix)
Ranibizumab (Lucentis)
Trastuzumab (Herceptin)
Pegaptanib (Macugen)
Dasatinib (Sprycel)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Imatinib (Gleevec)
Lapatinib (Tykerb)
Nilotinib (Tasigna)

EGFR
EGFR
VEGF
Erb2
VEGF
Src/Bcr-Abl
EGFR
EGFR
Bcr-Abl
EGFR/Erb2
Bcr-Abl
VEGFR1/2/3
PDGFR/c-kit
RAF/VEGFR2/PDGFRB
VEGFR2/PDGFRB
c-kit/FLT3

Pazopanib (Votrient)
Sorafenib (Nexavar)
Sunitinib (Sutent)

Company
Genentech
Imclone/Bristol-Meyers
Squib
Amgen
Genentech
Genentech
OSI/Pfizer
Bristol-Meyers Squib
Genentech/OSI
AstraZeneca
Novartis
GSK
Novartis

Class
Monoclonal antibody
Monoclonal antibody
Monoclonal antibody
Monoclonal antibody
Monoclonal antibody
RNA Aptamer
Small molecule
Small molecule
Small molecule
Small molecule
Small molecule
Small molecule

GlaxoSmithKline
Onyx/Bayer

Small molecule
Small molecule

Pfizer

Small molecule

Table 1.2. FDA approved RTK inhibitors and antibodies currently in use.
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Given the importance of the ErbB RTKs in human cancer, it is necessary to understand
their activation mechanisms at the molecular level to motivate the design of therapeutics
with higher specificity. This is especially important since, after sustained use of TKIs, the
cancers tend to adapt through resistance mutations. In EGFR, the predominant mutation
observed after extended treatment with Gefitinib is the T766M mutation133; the T766M
resistance mutation was correctly predicted in EGFR through homology with resistance
mutations seen in BCR-ABL, which was verified in vitro 14 and discovered several years
later in patients

7, 43, 96

. Computational methodologies offer a powerful, quantitative, and

complementary alternative for the study of intracellular kinase domains which, if utilized
correctly, can predict resistance mutations 53.

1.7 Anticancer role of HER4 kinase
Although deregulation of the ErbB kinases is associated with many types of human
cancer, one member of the ErbB family, HER4 kinase, is thought to play a beneficial role
in certain cancers. In particular, HER4 expression, which is required for the
differentiation of mammary epithelial cells during pregnancy, is associated with an anticarcinogenic function and a favorable outcome in certain cellular contexts48. One
mechanism by which HER4 is thought to impede tumor progression in mammary cells is
through the activation of genes that promote cellular differentiation and inhibit
proliferation, in effect, steering the cell away from a program of uncontrolled growth and
instead toward a program of differentiation

80, 187

. HER4 is unique from the other ErbB

receptors in that binding of the ligands neuregulin (NRG) or heparin-binding epidermal
growth factor (HB-EGF) induces proteolytic cleavage of the 80 kDa kinase domain,
termed the s80 or soluble cleavage product, and translocation of s80 to the nucleus, where
15

it complexes with the transcription factor (TF) STAT5a to regulate expression of genes
involved in mammary cell differentiation pathways, including the milk protein genes βcasein and whey acidic protein (WAP)117, 197. Hence studies are underway to determine
the molecular pathways that are stimulated by the soluble HER4 protein, particularly the
network of transcriptional regulatory elements that are activated upon nuclear
translocation of HER4 and STAT5a. Delineation of the transcriptional regulatory
network associated with HER4/STAT5a activity would enable the exploitation of the
pathway for targeting of malignant cells. Specifically, activation of HER4 signaling in
aggressive breast tumors would present a novel therapeutic approach to suppress growth
of these malignancies.
The HER4-mediated proliferation-to-differentiation switch in mammary cells may
be encoded in terms of differential spatial and temporal regulation of HER4 activity. The
phenotypic response of the mammary cell to HER4 stimulation is associated with a
specific subcellular context, and the shuttling of HER4 among various compartments may
determine the cellular decision to proliferate or differentiate. For instance, the membranebound HER4 kinase may dimerize with HER2 to produce a mitogenic response in the
mammary cell, whereas the soluble HER4 domain (s80) translocates to the nucleus to
effect cellular differentiation. Hence a comparison of HER4 activity at each relevant
spatio-temporal scale would aid in delineation of the mechanisms by which the
proliferation-to-differentiation switch is regulated.
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1.8 Application of multiscale modeling to the ErbB signaling network
In this dissertation, we apply a multiscale modeling framework to investigate the
molecular regulatory mechanisms governing the activation of the ErbB RTKs, with a
focus on the HER3 and HER4 kinases. Chapter 2 presents a multiscale model of activity
in the HER3 RTK, a kinase which, until recently, has been considered kinase-dead (see
Section 2.1). In Chapter 2, we present evidence of HER3 activity and, through our
multiscale model, we investigate the implications of HER3 activity for ErbB signaling
dynamics and development of TKI resistance. Chapter 3 extends our analysis of HER3 to
the other members of the ErbB family (EGFR, HER2, HER4) to facilitate a comparison
of the activation and regulatory mechanisms across the ErbB family members. Chapters 4
and 5 present a multiscale model of activity in the HER4 RTK, beginning with molecular
simulations of the HER4 dimer activation mechanism and extending the model to the
cellular scale through a signaling model of the HER4 differentiation pathway in
mammary cells. The HER4 multiscale model includes both a computational modeling
and an experimental component. Chapter 6 presents our main conclusions and also
summarizes future directions in which our work may be expanded.
Our multiscale models of ErbB kinase activity, which investigate the molecular
regulatory mechanisms in the ErbB kinases, will help to elucidate structure-function
relationships in drug-resistant cell lines and motivate the development of more
efficacious TKI therapies targeting ErbB-mediated cancers.
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Chapter 2
Multiscale Modeling of Pseudokinase Activation and
Drug Resistance in the HER3/ErbB3 Receptor
Tyrosine Kinase Signaling Network
Adapted from: Telesco SE, Shih AJ, Jia F, Radhakrishnan R. A Multiscale
Modeling Approach to Investigate Molecular Mechanisms of Pseudokinase
Activation and Drug Resistance in the HER3/ErbB3 Receptor Tyrosine
Kinase Signaling Network. (2011) Molecular BioSystems 7(6):2066-80.
Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon M. The ErbB3/HER3
Intracellular Domain is Competent to Bind ATP and Catalyze
Autophosphorylation. (2010) Proc Nat Acad Sci 107(17):7692-7.

2.1 Introduction
Approximately 10%, or 48 of the 518 protein kinases encoded by the human genome, lack at least
one of three catalytic amino acid motifs in the kinase domain, including the Val-Ala-Ile-

Lys (VAIK) motif in subdomain II, in which the lysine residue facilitates the positioning
of the ATP molecule, the His-Arg-Asp (HRD) motif in subdomain VIb, which contains
the catalytic aspartic acid residue responsible for deprotonating the substrate hydroxyl
group, and the Asp-Phe-Gly (DFG) motif in the A-loop, which contains the Mg2+coordinating aspartic acid residue that orients the β and γ phosphates of ATP 18, 113. These
kinases, termed ‘pseudokinases’, are therefore commonly regarded as catalytically
inactive. However, not all kinase domains that lack one or more of the conserved
catalytic motifs are inactive. The kinase WNK1 is catalytically active despite lacking the
crucial lysine in its VAIK motif, as a lysine residue in subdomain I performs the function
18

of the missing amino acid 116. In a recent structural and biochemical study, Mukherjee et
al.

121

resolved the crystal structure of the pseudokinase domain of Ca2+/calmodulin-

activated serine threonine kinase (CASK), which lacks both of the canonical Mg2+coordinating residues, and determined that CASK employs an unusual phosphorylation
mechanism in which the kinase preferentially binds unchelated nucleotides, and is hence
capable of catalyzing phosphotransfer despite lacking the conserved DFG motif. It is
therefore plausible that other pseudokinases are not truly inactive, but may employ
alternative modes of ATP binding and phosphoryl transfer.
In the ErbB family of receptor tyrosine kinases (RTKs), which includes epidermal
growth factor receptor (EGFR/ErbB1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4
(HER4), ligand binding followed by receptor homo- or heterodimerization performs a
crucial role in regulating critical cellular processes including migration, differentiation,
and proliferation

13, 31, 82, 106, 206

. EGFR, HER2, and HER4 all observe the canonical

mechanism of phosphate transfer. HER3, however, is the only member of the ErbB
family that has long been regarded as an inactive pseudokinase due to amino acid
substitutions in the conserved kinase domain. Until recently, HER3 activity has been
largely undermined, as it contains an asparagine residue (N815) in place of the catalytic
aspartic acid residue that is responsible for deprotonating the substrate hydroxyl group
138

. In addition, a crucial glutamate residue in the αC helix, which indirectly participates

in ATP-binding, is replaced by a histidine (H740) in HER3. Hence it has been widely
believed that HER3 is dependent on interactions with the other active ErbB receptors for
its biological activity.
However, it was recently demonstrated that HER3 does, in fact, exhibit robust
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residual kinase activity that may be crucial for ErbB signaling. Two recent studies by
Jura et al.

85

and Shi et al.

163

resolved the crystal structure of the HER3 kinase domain,

revealing an inactive-like conformation. In addition, Shi et al. 163 demonstrated that, when
clustered at a membrane surface, the purified HER3 intracellular domain is capable of
robust autophosphorylation, albeit at a level 1000-fold weaker than the active EGFR
kinase, and that the kinase domain binds ATP with an affinity similar to that of other
active kinases. In the same study

163

, our quantum mechanics molecular mechanics

(QM/MM) simulations suggested that HER3 may catalyze phosphoryl transfer from its
inactive-like kinase conformation via an alternative pathway, which explains the 1000fold slower rate of phosphoryl transfer in HER3 compared to EGFR: the alternative
pathway involves the migration of the substrate tyrosyl –OH proton directly to the O1γ
oxygen of ATP, hence obviating the requirement for the catalytic aspartate residue. Our
study suggests the intriguing possibility that therapeutic targeting of the robust activity of
HER3, rather than the routinely-targeted EGFR and HER2 kinases, may provide a more
effective treatment strategy for specific ErbB-driven cancers. However, a major question
arising from our work is: what is the physiological relevance, if any, of weak HER3
activity to ErbB signaling in the cell?
This question is clinically pertinent as over-expression and activating mutations of
the ErbB kinases are implicated in cellular transformation and clinical malignancies
including lung and breast cancers

29, 79, 102, 117, 125, 164, 199

. Recent studies have

demonstrated that mechanisms of resistance to tyrosine kinase inhibition (TKI) of EGFR
and HER2 in the treatment of certain human malignancies are mediated by HER3
107, 157

44, 66,

. In this scenario, it is hypothesized that incomplete inhibition of HER2 catalytic
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activity restores phosphorylation of HER3 in the context of HER2/3 heterodimers. As
HER3 contains six PI3K-binding sites in its C-tail, leaky HER3 phosphoryation induces
proliferative signaling through the PI3K-AKT pathway

157

. However, the detailed

molecular mechanism of this process remains an open question. Indeed, it is possible that
HER3 catalytic activity is involved in the TKI resistance mechanism.
To explore the implications of HER3 activity for ErbB signaling and TKI
resistance, a multiscale modeling approach is advantageous. Multiscale computational
modeling has been applied to a variety of biological systems

46, 108, 143, 165, 193

to help

quantify the complexity inherent in intracellular signaling networks. As the biochemical
processes within a cell occur on multiple spatial and temporal scales, a multiscale
modeling approach is necessary to represent a hierarchy of interactions ranging from the
molecular (nm, ns) to cellular signaling (µm, ms) length and time scales. Multiscale
modeling provides a powerful and quantitative methodology for studying the effects of
molecular perturbations, in our case, HER3 catalytic activity, on downstream signaling
events, i.e., the ErbB signaling network and development of TKI resistance.
In light of the implication of HER3 in TKI resistance mechanisms, the recent
interest in catalytic mechanisms of pseudokinases and particularly in the potential for
HER3 activity demonstrated by Shi et al.163, we pursue a multiscale modeling study of
the HER3 kinase system at the molecular and cellular levels (Fig. 2.2). A variety of
modeling techniques, ranging from atomic-level molecular dynamics (MD) simulations
to systems-level modeling, are applied to investigate the non-canonical catalytic
mechanism employed by the HER3 kinase and the physiological relevance of this activity
to mechanisms of drug resistance in an ErbB-driven tumor cell in silico. Specifically, we
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construct and assess several homology models of the HER3 kinase to provide a
framework for comparing the ErbB kinase active sites and identifying the molecular
features that distinguish HER3 from the other nodes (EGFR and HER2) in our multiscale
model of HER3 activity. The results of our molecular-scale simulations support the
characterization of HER3 as a weakly active kinase that, in contrast to its fully-active
ErbB family members, depends upon a unique hydrophobic interface to coordinate the
alignment of specific catalytic residues required for its activity. Translating our molecular
simulation results of the uniquely active behavior of the HER3 kinase into a
physiologically relevant environment (Fig. 2.2), our HER3 signaling model demonstrates
that even a weak level of HER3 activity may be sufficient to induce AKT signaling and
TKI resistance in the context of an ErbB signaling–dependent tumor cell, and therefore
therapeutic targeting of HER3 may represent a superior treatment strategy for specific
ErbB-driven cancers.

2.2 Materials and Methods
2.2.1 Homology modeling of the HER3 kinase domain
Several crystal structures of the ErbB kinases in the inactive conformation were selected
as templates for modeling of the HER3 kinase domain. The templates included the crystal
structures of EGFR (PDB code 2GS7)

208

, HER4 (PDB code 3BBT)

141

, as well as a

combination of the EGFR and HER4 structures. The coordinates of the inactive
conformations of the kinases were downloaded from the Protein Data Bank and a
sequence alignment between HER3 and each template was performed in MODELLER 51,
150

. Missing residues were built using the loop modeling algorithm in MODELLER and

the structures were further refined by performing additional energy minimization steps.
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The hydrogen atoms were added by employing the hbuild routine in CHARMM27

112

.

The final models for the inactive HER3 kinase domain were assessed for stereochemical
quality using PROCHECK

99

. The program VMD was used to display and animate all

structural models 74.

2.2.2 Molecular dynamics (MD) simulations
The HER3 kinase crystal structure (PDB code 3LMG) solved by Shi et al.

163

was

prepared for molecular dynamics simulation according to the procedure outlined in our
previous studies165,

181

. Briefly, the structure was explicitly solvated using the TIP3P

model for water 81 and with the buffering distance set to 15 Å. Sodium (Na+) and chloride
(Cl-) ions were added to achieve net electroneutrality of the system and an ionic strength
of 75 mM. The ions were positioned at points of electrostatic extrema using a DebyeHuckel potential calculated within the program Solvate 1.0
performed with NAMD

136

62

. All simulations were

using CHARMM27 force-field parameters. To prepare the

system for MD simulation, the solvated structure was energy-minimized using a
conjugate gradient algorithm to remove unfavorable contacts. The system was then
heated to 300 K using the temperature reassignment method in NAMD. Constant
pressure and temperature (NPT) simulations were performed at 300 K and 1 atm to
equilibrate the volume of the solvation box. Temperature and pressure were maintained
using a Langevin piston coupling algorithm 47. Following the NPT simulations, constant
volume and temperature (NVT) simulations were performed in NAMD. Finally, a 10 ns
production run was completed using the same parameters as in the NVT simulations.

2.2.3 Hydrogen bonding analysis
CHARMM was used to analyze the hydrogen bonds present in the 10 ns trajectory for
23

each system according to the procedure outlined in our previous studies 165, 181. Hydrogen
bonds were defined by a bond length cutoff of 3.4 Å and an angle cutoff of 150º. Bonds
that fulfilled these criteria and were present in at least 60% of the trajectory were
tabulated in CHARMM. Salt bridges were defined as hydrogen bonds occurring between
an acidic and a basic residue and satisfying a bond length cutoff of 1.6 Å. All hydrogen
bonds and salt bridges were also visualized in VMD

74

for the duration of the 10 ns

simulation.

2.2.4 Principal component analysis
A principal component analysis (PCA) was applied to the 10 ns trajectory to identify the
main eigenvectors (3N directions) along which the majority of the complex motion is
defined. The calculation is based on the diagonalization of the variance-covariance matrix
of the atomic fluctuations along each MD trajectory to yield the set of eigenvectors (PCs)
and associated eigenvalues. The eigenvectors represent the independent modes of atomic
motion, and the eigenvalues reflect the contribution of the corresponding eigenvectors to
the global fluctuation of the protein. PCA computes the covariance matrix:
       
where (i,j=1,…,3N), and N is the total number of atoms with positions given by Cartesian
coordinates x. The resulting matrix is diagonalized to compute the 3N independent
(uncorrelated) eigenvectors, {ξi}, and the eigenvalues, {λi}, sorted in descending order.
The angle brackets denote the time average over the entire trajectory. PCA was
performed on the entire protein backbone (i.e. all Cα atoms), and also an active site
region that comprises all catalytic sub-domains, including the A-, C-, and N-loops and the
αC helix. The program CARMA 59 was used to project the atomic fluctuations along the
24

MD trajectory.

2.2.5 Solvent accessible surface area (SASA) and water density fluctuation analysis
SASA values were calculated in VMD

74

using the measure SASA module with a probe

radius 1.4 Å larger than the van der Waals radius. The SASA was calculated for each step
in the trajectory, from which the mean and standard deviation were computed. As an
alternative measure of hydrophobicity in heterogeneous environments, following the
procedure established in
recording the ratio of

1, 60



, normalized water density fluctuations were computed by

  ⁄  , where

,

σN and 〈N〉 are the control volume of

interest, the standard deviation, and mean associated with the number of water molecules
within 5 Å of a specified hydrophobic sub-region in the HER3 kinase. Although results
are presented for a cutoff of 5 Å, other cutoffs ranging from 3-15 Å were investigated and
similar trends in



  ⁄



were recorded.

2.2.6 Systems model of ErbB signaling
The computational systems model was derived from that of Schoeberl et al.

154

. Mass-

action reactions describing ligand-induced ErbB receptor homo- and heterodimerization,
receptor internalization and degradation, constitutive dimerization, and activation of the
PI3K-AKT signaling pathway were included. The HER3-specific ligand neuregulin-1β
(NRG-1β) was assumed to induce EGFR-HER3, HER2-HER3 and HER3-HER3 dimers.
To represent HER3 catalytic activity, we implemented HER3 homodimerization and
trans-autophosphorylation, resulting in induction of PI3K-AKT signaling. HER3mediated kinase phosphorylation was assumed to be 1000-fold slower than that of EGFR,
based on previous experiments and QM/MM simulations

163

. The ErbB kinase inhibitor

lapatinib was implemented in the model according to Schoeberl et al.

154

; lapatinib was
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assumed to inhibit activation but not dimerization or ligand binding of the EGFR and
HER2 kinases. All simulations were performed in MATLAB 7.10 (MathWorks, Natick,
MA) and sensitivity analysis was conducted using SBToolbox 2.1
211

153

and SBML-SAT

. Normalized, time-integrated sensitivities of each nonzero species with respect to

pAKT were calculated by varying each species (one at a time) and simulating the
perturbed model response. The sensitivity analysis was performed according to the
procedure implemented in SBML-SAT211. Briefly, the normalized sensitivity, Sij, was
computed:
 

 ⁄
 ⁄

where Oi is the time-integrated response of the ith model output (such as pAKT level)
and pj is the jth parameter (rate constant or initial condition). The SBML version of the
model has been submitted to the BioModels Database100,

105

. The signaling process

diagram (Figure 2.2C) was constructed using the Systems Biology Graphical Notation
(SBGN)101.

2.2.7 Quantum mechanics molecular mechanics (QM/MM) simulations
ATP and a 7-residue peptide representing the Y1068 phosphorylation site in EGFR were
placed in the TKD based on its superposition with the EGFR TKD structure (PDB code
2GS6) determined in complex with a bisubstrate analogue of ATP and peptide

208

. Two

Mg2+ ions were then placed in complex with ATP based on the structure of protein kinase
A (PKA) in its active conformation (PDB code 1ATP)

209

. The ground state of each

ternary complex was obtained from energy minimizations of these model structures to
ensure uniformity in reactant states across all systems prior to the QM/MM simulations.
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The resulting models were then prepared for QM/MM simulations in which the quantum
region contained the two Mg2+ ions, water molecules within 5 Å of the Mg2+ ions,
segments of the ATP and peptide substrate and two catalytic residues (N815 and D833 in
HER3, D813 and D831 in EGFR). The system was subjected to 1200 steps of the adopted
basis Newton-Raphson minimization. For QM/MM molecular dynamics simulations, the
system was first heated to 300 K and subjected to constant temperature dynamics using a
Langevin thermostat for 10 ps using a 1 fs step of integration. We describe the reaction
pathways in terms of several simple artificial reaction coordinates, χj, as described

147

.

For phosphoryl-transfer through the associative mechanism, χ1 is the distance between
the reactive tyrosyl oxygen and the ATP γ-phosphate; χ2 is the distance between the
tyrosyl O- and ATP O2/3β, and χ3 is the ATP Pγ- ATP O2/3β distance. For phosphoryltransfer through dissociative mechanisms, in addition to these three distances, χ4 includes
the coordinate for proton abstraction, namely the distance between the tyrosyl OH- and
D830:Oδ2. Restrained minimization as well as restrained sampling simulations were
performed along χ using the QM/MM Hamiltonian with a potential bias term. Reaction
paths were computed by energy minimizations in the presence of restraints and
recalculating single-point energies in their absence.

2.3 Results
2.3.1 QM/MM simulation of the HER3 phosphoryl transfer mechanism
Based on the experimental observations of HER3 phosphorylation163, we hypothesized
that the weak kinase activity of HER3 might utilize a mechanism distinct from that seen
in other kinases, and might be carried out by the ‘inactive-like’ state. Activity from the
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configuration seen in the HER3 TKD crystal structure is suggested by the finding that a
V836A mutation prevented ATP binding and HER3 ICD autophosphorylation, in contrast
with the activating effects of analogous mutations in EGFR and HER4. The lack of
sequence conservation with other ErbB kinases in the N-lobe region, which would make
‘receiver’ contacts in the asymmetric dimer described by Zhang et al. 208, also argues that
HER3 regulation is unique in this family. We therefore undertook quantum mechanics
molecular mechanics (QM/MM) simulations to delineate the energy landscape of
phosphoryl transfer from ATP to a substrate tyrosine catalyzed by the HER3 structure,
and compared the outcomes with those seen in parallel computational studies of EGFR.
Experimental and theoretical studies have demonstrated that, in phosphoryl
transfer by kinases and polymerases, nucleophilic attack on the target phosphate proceeds
via a conformation that resembles a trigonal-bipyramidal transition state

98, 174

, and that

phosphoryl transfer can occur through either an associative or a dissociative mechanism.
A conserved aspartate (D813 in EGFR, D166 in protein kinase A) is proposed to function
as a base acceptor for proton transfer from the hydroxyl group of the substrate, as
depicted by the red arrows in Figure 2.1A (pathway I). The presence of an asparagine at
this location in HER3 (N815) precludes this pathway, and requires that proton transfer
occurs via an alternative mechanism (Figure 2.1B). Indeed, our QM/MM simulations
reveal an alternative pathway in HER3 and EGFR (pathway II) that is characterized by
migration of the substrate tyrosyl –OH proton to the O1γ oxygen of ATP, and
subsequently to the ATP O2β oxygen (green arrows in Figures 2.1A and B). Phosphoryl
transfer in HER3 coincides with this proton transfer step, and occurs exclusively through
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Figure 2.1. Schematic QM/MM pathway for phosphoryl transfer in EGFR and HER3.
Mg2+ ions are marked, as are the catalytic aspartates (D831 in EGFR, D833 in HER3), the
proposed catalytic base in EGFR (D813) and its replacement in ErbB3 (N815). Two potential
pathways for proton migration are shown. Pathway I (red) involves proton abstraction from the
substrate tyrosine –OH group by D813 of EGFR, and pathway II (green) involves proton
migration to the O1γ oxygen of ATP. δI and δII denote distances between the proton of the
substrate tyrosine hydroxyl and either the Oδ2 oxygen of D813 in EGFR δI or the O1γ oxygen of
ATP (δII). The nucleophilic attack distance, λa (between the tyrosine oxygen and the ATP Pγ), and
the bond cleavage distance, λc (distance between the ATP Pγ and ATP O2/3β), are noted.
(C-F) Energy changes along the reactions involving Pathway II (green) or Pathway I
(red). States correspond to ‘R’ (reactant); ‘TS’ (transition state with trigonal bipyramidal
geometry around Pγ); ‘P’ (product representing the completion of phosphoryl-transfer with proton
bound to O1γ of ATP; and ‘P2’ (product with proton transferred to O2β of ATP). (C) Energy
changes for ErbB3. Symbols bounded by black squares represent the forward scan; gray squares
represent the reverse scan. (D) Energy changes for EGFR utilizing pathway II. (E) Phosphoryltransfer catalyzed by EGFR via the dissociative mechanism (utilizing pathway I for proton
migration – via D813). (F) Associative phosphoryl-transfer comcomitant with pathway I for
EGFR has an estimated Ea of 24 kcal/mol.
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an associative mechanism, with characteristic values of 1.9 Å for the formation (λa) and
cleavage (λc) of bonds in the transition state, and an estimated activation energy (Ea) of
23 kcal/mol (Figure 2.1C). Parallel QM/MM simulations of EGFR in its active
configuration showed that pathways I and II (which are mutually exclusive) can both be
utilized for transfer of the tyrosyl –OH proton, and compete with one another. Phosphoryl
transfer concomitant with proton transfer through pathway II in EGFR occurs only
through an associative transition state, with an estimated Ea of 24 kcal/mol (Figure 2.1D)
– equal to that seen for HER3. When proton transfer occurs through pathway I, which
involves proton abstraction by D813, the estimated Ea is significantly lower for the
dissociative mechanism (Figure 2.1E), at 16 kcal/mol, but is 24 kcal/mol for the
associative mechanism (Figure 2.1F).
Thus, our QM/MM simulations argue that phosphoryl transfer can occur in HER3
(and indeed EGFR) without abstraction of the tyrosine –OH proton by the catalytic base
aspartate. The proton instead migrates to the O1γ oxygen of ATP, through pathway II in
Figure 2.1B. Phosphoryl transfer concomitant with this pathway can be catalyzed by
HER3 in the ‘inactive-like’ conformation, although it is predicted to be several orders of
magnitude slower than the most favorable reaction channel in EGFR (i.e., for pathway I
through a dissociative mechanism), which is consistent with our previous experimental
observations. The finding in our QM/MM studies that this mechanism can also operate in
EGFR further suggests that mutating D813 in this receptor may not completely abolish
kinase activity. Indeed, a D813A-mutated variant of EGFR has been reported to retain its
ability to promote EGF-dependent DNA synthesis and MAP kinase activation despite
exhibiting greatly reduced receptor autophosphorylation

33

. A low level of
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autophosphorylation in D813A-mutated EGFR, similar to that shown for HER3, may
therefore be sufficient to mediate certain key aspects of its signaling.

2.3.2 Topology of the multiscale model of HER3 activity
Our experimental and computational study163, which elucidated the robust activity of the
HER3 kinase and suggested an alternative catalytic pathway in HER3 (see discussion of
QM/MM simulations in Section 2.3.1), raised the possibility that HER3 may play an
active role in ErbB signaling dynamics. To investigate the relevance of our results to
ErbB activity in a cellular context, we propose a pathway model of the HER3 signaling
network (Figure 2.2A), in which ligand stimulation of the HER3, EGFR, and HER2
RTKs results in induction of the PI3K-AKT cascade. The ligand-induced coupling of the
EGFR, HER2, and HER3 nodes to the PI3K-AKT pathway has been extensively
validated computationally and experimentally13, 22-24, 146, 176, 178, although thus far HER3
has been postulated to play a passive role in the ErbB-AKT signaling network, in that its
phosphorylation (and hence, recruitment of PI3K/AKT) depends upon the catalytic
activities of the EGFR and HER2 RTKs. Here we propose that HER3 can activate
independently of its ErbB family members, a hypothesis which is reflected in the
topology of our HER3 signaling pathway (Fig. 2.2A), and is based on a combination of
recent in silico, in vitro, and in vivo evidence of HER3 activity. Namely, the in vitro
kinase assays performed by Shi et al.

163

demonstrated that, in the absence of its ErbB

family members, the purified HER3 kinase is capable of robust autophosphorylation, a
result that was further supported by our QM/MM simulations of an alternative catalytic
pathway in HER3. Additional in vitro evidence of HER3 activity derives from
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observations of tyrosine phosphorylation of ligand-induced HER2 and HER3 RTKs in
cells that express only these two ErbB receptors146. Given current models of ErbB
receptor activation, in which one kinase domain in an ErbB dimer allosterically activates
its neighbor and itself becomes trans-phosphorylated83,

208

, it is not clear how HER2

could be trans-phosphorylated in HER2-HER3 heterodimers through this mechanism
unless HER3 has kinase activity of its own. Furthermore, previous experimental studies
have demonstrated that HER3 is a key mediator of resistance to various tyrosine kinase
inhibitors (TKIs) currently in use

8, 44, 76, 115, 157

, although the resistance mechanism

remains an open question. In particular, Sergina et al. 157 reported observations of HER3mediated resistance and pAKT signaling in various TKI-treated tumor cell lines as well
as in vivo.
In the current study, we aim to further substantiate the inclusion of HER3 as a
uniquely and independently-active node in our ErbB pathway model (Fig. 2.2A), in order
to quantitatively evaluate the implications of HER3 activity for ErbB signaling dynamics
and mechanisms of HER3-mediated drug resistance in an ErbB-driven tumor cell in silico
(Fig. 2.2C). Our multiscale model of HER3 activity begins with atomic-level simulations
of the HER3 kinase crystal structure (Fig. 2.2B), in order to identify the molecular
features which distinguish HER3 from the other nodes (EGFR, HER2) in our proposed
ErbB signaling network. Moreover, our molecular simulations address clinically-relevant
questions regarding the mechanism and specific types of interactions that enable HER3 to
maintain its robust activity.
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Figure 2.2. Representation of the multiscale model of HER3 activity.
(A) Schematic of the HER3 network model topology, in which ligand stimulation of
EGFR:HER3, HER2:HER3, and HER3:HER3 dimers induces the AKT cascade. (B) The HER3
node in (A) is examined at molecular resolution. The molecular model comprises two parts:
homology modeling to refine the HER3 kinase crystal structure, and molecular dynamics
simulations of the refined HER3 structure to identify the molecular features which distinguish
HER3’s unique mechanism of activity from that of the EGFR and HER2 nodes in the HER3
network model. (C) Process diagram of the HER3 network model in SBGN notation (see
Methods). The aim of the HER3 network model is to investigate the implications of HER3
activity for ErbB signaling dynamics and mechanisms of HER3-mediated drug resistance in an
ErbB-driven tumor cell in silico. Note that, for clarity, only HER3 dimers are illustrated in (C),
although EGFR:HER3 and HER2:HER3 dimers are also present in the network model.
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2.3.3 Homology modeling of the HER3 kinase domain
As the recently-resolved HER3 crystal structure85,

163

is missing several amino acid

residues in catalytically important sub-domains, we applied a homology modeling
algorithm to build in these residues and construct a complete HER3 kinase structure for
our molecular simulations182. An additional advantage of our homology modeling
analysis is that it provides a means of deriving insights into a structural comparison of the
ErbB kinase active sites and the molecular features which distinguish HER3 from the
other nodes (EGFR and HER2) in our HER3 pathway model (Fig. 2.2A). As the HER3
kinase domain shares a relatively high level of sequence identity with its ErbB family
members (54% and 63% identity with EGFR and HER4, respectively) (Fig. 2.3), and the
crystal structures of these kinases have been determined
(PDB code 2GS7)

208

and HER4 (PDB code 3BBT)

141, 172, 208

141

, we selected EGFR

as templates for homology

modeling of the HER3 kinase in the inactive-like conformation. In addition, we applied
the multiple templates (MT) algorithm in MODELLER150 to generate a HER3 kinase
model based on a combination of the EGFR and HER4 crystal structures. To verify that
EGFR and HER4 were the most suitable templates available for modeling HER3, a
search was performed in MODELLER’s internal database for other proteins that might
have high sequence identity with HER3. The ErbB receptor kinases were confirmed to be
the most homologous structures for modeling of the HER3 kinase domain.
The protein sequence selected for alignment of the kinase domains included residues 678957 (EGFR) and 683-962 (HER4); we opted to exclude the flexible C-tail from the
alignment, as its sequence is highly variable among the ErbB kinases. A total of 50
models were generated from each of the templates (EGFR, HER4, and multiple
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templates) by satisfying a set of static and dynamic spatial restraints in MODELLER. In
addition, we applied the loop-modeling algorithm in MODELLER51 to remodel the
flexible A-loop (residues 833-855 in HER3), as the HER3 crystal structure is lacking
these amino acids. The top models (shown in Fig. 2.4) were selected based on
stereochemical quality and the Discrete Optimized Protein Energy (DOPE) method

161

,

which is an atomic distance-dependent statistical potential optimized for model
assessment in MODELLER.

Figure 2.3. Multiple sequence alignment of the kinase domains of the ErbB RTK family.
Residues highlighted in gray are conserved among all four ErbB kinases, whereas residues
highlighted in yellow are unique to HER3. The HER3 kinase shares a relatively high level of
sequence identity with its family members (54%, 55% and 63% identity with EGFR, HER2, and
HER4, respectively). The key catalytic sub-domains (A-loop, C-loop, N-loop, αC-helix, and β3αC loop) are labeled.
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A comparison of the most energetically favorable models derived from each template
revealed several similarities in structure and in DOPE energies: overall, the C-lobes of
the kinase models are similar, as are the DOPE profiles, although the DOPE scores in the
A-loop region are lowest for the HER4- and MT-based models (Fig. 2.4B). However, in
comparing the top homology-modeled structures to the HER3 crystal structure, we
observed several conformational differences, which can be better understood by first
describing the major structural features that distinguish the HER3 crystal structure from
the EGFR and HER4 structures. A unique feature of the catalytic site in the HER3 crystal
structure is the truncated N-terminus of the αC helix (Fig. 2.4A); in the EGFR and HER4
kinase crystal structures, the helix is fully formed. The molten terminus of the HER3 αC
helix forms a loop, referred to as the β3-αC loop, which interacts with specific subregions of the catalytic site, including the short 310 helix in the A-loop, to form a
hydrophobic interface that maintains the weakly-active conformation of HER3 and is not
observed in EGFR or HER4

180

. F734, which is located in the β3-αC loop and

corresponds to an Asn in EGFR and HER4, appears to nucleate the hydrophobic interface
(Fig. 2.4A)

180

, and V836, L839 and L840, which are located in the 310 helix, form

hydrophobic contacts with the truncated αC helix. The extensive set of residues
stabilizing the hydrophobic interface and the 310 helix are unique to HER3 and function
to maintain the distinctive catalytic site conformation resolved in the HER3 crystal
structure.
In comparing our top homology-modeled structures to the HER3 crystal structure,
we focused on the unique set of interactions in the β3-αC loop, αC helix and 310 helix
(Fig. 2.5A). The side-chain conformations of the aliphatic residues in the 310 helix,

36

Figure 2.4. The top HER3 homology models.
The structures were based on (A) the EGFR template, (B) the HER4 template, (C) Multiple
templates and (D) the loop-modeled HER3 crystal structure. The structures are color-coded
according to the RMSD, where red regions indicate large RMSD values and blue regions
represent small RMSD values (closely aligned structures). The original unrefined model for each
HER3 structure is shown in yellow. The top structures form a dominant cluster of conformations
in each HER3 model, indicating a pronounced energy minimum and a higher level of accuracy in
the best structural prediction.

including V836, L839, and L840, were correctly predicted in the models derived from
EGFR, HER4, and MT. This result is not entirely surprising, as the inactive EGFR and
HER4 templates also contain the 310 helix in the A-loop. However, F734, which serves to
nucleate the hydrophobic interface in the HER3 crystal structure, points away from the
hydrophobic pocket in the homology models. The reason for the altered F734
conformation is depicted in Fig. 2.5A, which illustrates that the homology models contain
a fully formed αC helix in place of the truncated helix and extended β3-αC loop (which
37

contains F734) in the HER3 crystal structure. In addition, the H740 ring in the αC helix,
which stabilizes the 310 helix in the HER3 crystal structure via contacts with G835 in the
DFG motif, is flipped away from G835 in the homology models. The D838-R814 bond,
which bridges the 310 helix and the C-loop in the HER3 crystal structure, is conserved in
the HER4- and MT-based models, whereas the residues are unbonded in the EGFR-based
model. The HER4-based model more closely mimics the extended β3-αC loop in the
HER3 crystal structure, as the apex of the loop projects away from the catalytic site.

Figure 2.5. Superposition of the top HER3 models constructed from the ErbB templates.
The following templates were used: EGFR (blue), HER4 (yellow), multiple templates (brown), as
well as the HER3 crystal structure (red) (PDB code 3LMG). Key residues contributing to the
hydrophobic interface in HER3 are highlighted. (B) DOPE energy plots for the top HER3 models
based on each ErbB template after A-loop refinement. The HER4- and MT-based models exhibit
lower DOPE energies in certain regions, including the sequence spanning residues 775-800. The
DOPE energy plot for the HER3 crystal structure (PDB code 3LMG) is illustrated for reference.
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Although none of the homology models correctly predict the molten αC helix, several
features of the HER4- and MT-based models, including the D838-R814 bond,
approximate the HER3 crystal structure more closely than does the model derived from
the EGFR template. Additionally, the DOPE plots for the top structures (Fig. 2.5B) reveal
smaller (more favorable) DOPE energies for the HER4- and MT-based models,
especially for residues 775-800, which exhibit an energy peak in the EGFR-based model,
and residues 840-860 in the A-loop. These results may be attributed to the closer
evolutionary ties between HER3 and HER4, as HER3 and HER4 are thought to have
emerged from a gene duplication event separate from the one that led to EGFR and
HER2 173. Indeed, Jura et al. 85 postulate that the N-lobe dimer observed in their resolved
HER3 and HER4 crystal structures but not in their EGFR structure may be a consequence
of the evolutionary homology between HER3 and HER4. In addition to providing a
complete HER3 kinase structure for our molecular simulations, our homology modeling
analysis presents a framework for identifying the molecular features that contribute to
HER3’s unique catalytic conformation, which further validates the treatment of HER3 as
a distinctive node in our proposed ErbB pathway model (Fig. 2.2A).

2.3.4 Molecular dynamics simulations of the HER3 kinase
While our homology modeling analysis of the HER3 crystal structure provides insights
into specific amino acid motifs and conformational features that distinguish HER3 from
its fully-active ErbB family members, in order to identify the most significant molecular
interactions that contribute to potential mechanisms of HER3 activity, it is necessary to
provide a dynamic picture of the HER3 kinase. To address the dynamic behavior of the
HER3 kinase, we performed 10 ns molecular dynamics (MD) simulations of the complete
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HER3 crystal structure (PDB code 3LMG)

163

in an explicitly solvated state (see

Methods). The HER3 structure was stable for the duration of the simulation, as indicated
by the time-course plots of the root mean square deviation (RMSD) of the backbone
atoms. We then performed a series of analyses of the MD trajectory to answer the
following questions: does HER3 behave similarly to an active kinase (i.e., fully-active
EGFR, HER2 and HER4) at the atomic level? Furthermore, what types of molecular
interactions enable HER3 to maintain its weak yet robust activity? These questions are
important for justifying, at molecular resolution, the representation of HER3 as a
uniquely active node in our ErbB pathway model (Fig. 2.2A).

PCA reveals that the dynamic behavior of HER3 at the molecular level diverges from that
of an inactive ErbB kinase
Principal component analysis (PCA) was applied to the 10 ns MD trajectory of the HER3
crystal structure to characterize the most significant global motions of the HER3 kinase.
The PCA calculation is based on the diagonalization of the variance-covariance matrix of
the atomic fluctuations along the MD trajectory to yield the set of eigenvectors (PCs) and
associated eigenvalues. The eigenvectors represent the independent modes of atomic
motion, and the eigenvalues reflect the contribution of the corresponding eigenvectors to
the global fluctuation of the protein.
Motion along the first eigenmode for the complete HER3 kinase was compared to
PCA trajectories for the inactive and active conformations of EGFR, HER2 and HER4
that had been previously simulated by us

181

; overall the global motions of the kinases

were conserved across the ErbB family members. To determine whether the PCA pattern
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was also conserved in HER3’s unique catalytic site, we applied PCA to an active site
region which included the A-, C-, and N-loops and the αC helix. Figure 2.6 illustrates that
motion along the first eigenmode in the inactive EGFR, HER2 and HER4 systems is
dominated by A-loop movement, with smaller fluctuations in the other catalytic subdomains, whereas the active ErbB systems exhibit a uniform level of motion across the
sub-domains, with lower-amplitude fluctuations. Despite the crystallization of the HER3
kinase in an inactive-like conformation, the PCA pattern in HER3 appears to diverge

Figure 2.6. Motion along the first PC of the MD trajectory for the ErbB systems.
The structures are color-coded according to the RMSD, where red regions indicate largeamplitude fluctuations and blue regions indicate small-amplitude fluctuations. Despite the
crystallization of the HER3 kinase in an inactive-like conformation, the HER3 PCA pattern
resembles that of the fully-active ErbB kinases (EGFR, HER2, HER4), in terms of the concerted
and low-amplitude fluctuations of its catalytic sub-domains (A-loop, N-loop, C-loop, αC helix).

from that of the other inactive ErbB kinases and instead resembles that of the active ErbB
kinases, in terms of its concerted and low-amplitude sub-domain fluctuations. The
normalized PCA variance-covariance matrices for vector displacements of atoms further
emphasize and quantify the coupling among the catalytic sub-domains in the HER3
system, for example, between the C-loop (residues 814-820 in HER3) and A-loop/310
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helix (residues 828-840). We reason that the interactions among the A-, C-, and N-loops
and the αC helix in the active ErbB systems (i.e., active EGFR, HER2 and HER4, and
weakly-active HER3) are crucial for alignment of the key sub-domains for catalysis.
Consistent with this view, our PCA demonstrates that at the atomic level, the sub-domain
motions of the HER3 system deviate from those of an inactive ErbB kinase.

Hydrogen bonding analysis indicates that the molecular mechanism of catalysis in HER3
is distinct from that operating in its fully-active ErbB family members
To identify specific interactions that could be contributing to the distinct pattern of global
motion in the HER3 kinase in the inactive-like conformation, individual salt bridges and
hydrogen bonds were tabulated for the HER3 system through a hydrogen-bonding
analysis of the 10 ns MD trajectory (Table 2.1) and compared to the bonds present in the
other ErbB systems

165, 183, 181

. The major difference that we observed between the

inactive and active ErbB systems is a significantly greater number of bonds that couple
the catalytic sub-domains of the kinases in the active systems compared to the inactive
systems. Table 2.1 highlights several of these bonds (EGFR numbering will be used
here): E734-K851 is a key salt bridge which couples the A-loop and αC helix and is
conserved across the active conformations of EGFR, HER2 and HER4, and the L834R812 and K836-V810 bonds bridge the A-loop and C-loop to maintain the A-loop in its
extended, active conformation. We hypothesize that the tight coupling of the subdomains in the active ErbB systems may help to correctly position the catalytic residues
during assembly of the active site for phosphoryl transfer 181.
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Table 2.1. Hydrogen bonding analysis of the HER3 MD trajectory.
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By contrast, the bonding pattern in HER3 is distinct from the active and inactive states of
its ErbB family members in its scarcity of hydrogen bonds (Table 2.1). HER3 lacks many
of the bonds present in the other ErbB kinases due to substitutions in its amino acid
sequence: E738 (EGFR numbering), which coordinates the α and β phosphates of ATP
by forming a salt bridge with K721 in the αC helix, is mutated to a His in HER3. In
addition, E734, which couples the A-loop and αC helix by bonding to K851, is an Ala in
HER3. The few bonds that are present in HER3 help to maintain its distinctive active site:
the D838-R814 bond, which bridges the 310 helix and the C-loop in HER3, does not
appear in the other ErbB kinases. HER3’s unique hydrogen bonding network (or lack
thereof) suggests that the molecular mechanism of catalysis in HER3 is distinct from that
operating in its fully-active ErbB family members (EGFR, HER2, HER4).

Hydrophobic analysis of the ErbB kinases reveals that HER3 critically depends upon a
coordinated set of hydrophobic interactions for its weak yet robust activity
In the active conformation, EGFR, HER2 and HER4 rely on an extensive network of
hydrophilic interactions to maintain their active sites in a catalytically competent state,
whereas the inactive conformations exhibit characteristic hydrophobic interactions, a
feature that helps to differentiate the inactive and active states. In ErbB-mediated
signaling, the introduction of the ErbB dimer interface alters the hydrophobicity of the
region and, in conjunction with allosteric effects, perturbs the conformational sampling
space of the protein to induce a shift toward the active conformation 141, 166, 208.
To quantify these hydrophobic interactions, we computed the solvent accessible
surface area (SASA) and water density fluctuations (see Methods) for the HER3 MD
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trajectory and compared the results to the EGFR, HER2 and HER4 trajectories previously
simulated by us

167

. In particular, we focused on several highly conserved hydrophobic

regions which are considered to be important for defining the catalytic state of the ErbB
kinases93, 94: the catalytic spine (C-spine), regulatory spine (R-spine), hydrophobic core,
and β3-αC loop. Figure 2.7 displays the correlation between the mean SASA and the
normalized water density fluctuations for each hydrophobic region in the inactive and
active conformations of each ErbB kinase. The SASA analysis is a reliable measure of

Figure 2.7. Correlation between the SASA and water density fluctuations.
(A) hydrophobic core, (B) β3-αC loop, (C) C-spine and (D) R-spine. Dark and light markers
represent the active and inactive ErbB systems, respectively. The ErbB kinase systems are
represented as follows: EGFR (square), HER2 (circle), HER3 (diamond), and HER4 (triangle).
Quadrant I represents a perturbation-sensitive region, quadrant II defines a hydrophilically
favorable region, and quadrant IV represents a hydrophobically favorable region.
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hydrophobicity for smooth hydrophobic interfaces but does not always correlate perfectly
with free energies of solvation of hydrophobic groups near irregular hydrophobic
surfaces, which are often found in proteins. The normalized water density fluctuation
calculation (see Methods), which quantifies the hydrophobicity of heterogeneous
surfaces, provides an alternative to the SASA analysis and proposes that increased
normalized water density fluctuations signify a more hydrophobic region, where a
normalized value of 1 indicates a neutral surface

1, 60

. Thus the correlation between the

SASA and water density fluctuations produces additional insights into region
hydrophobicity that are not revealed by either analysis independently. Specifically, we
have designated four ‘quadrants’ in each correlation subplot (Fig. 2.7): quadrant II
represents a hydrophilically favorable region, quadrant IV defines a hydrophobically
favorable region, and quadrant I, which is characterized by high SASA (more
hydrophilic) and large water density fluctuations, represents a fragile or perturbationsensitive region. The quadrants facilitate the identification of key patterns that may
emerge from a comparison of the hydrophobic interactions in the ErbB systems.
The HER2 system, in general, lies within the hydrophobically favorable region
(quadrant IV), which may be rationalized in terms of HER2’s unique ability to bind the
molecular chaperone Hsp90 through a hydrophobic interface, a point that is elaborated in
our previous studies

166, 183, 181

. In the hydrophobic core, which includes segments of the

αC helix and the A-loop and helps to maintain the ErbB kinases in the inactive
conformation

93, 94

, HER3 demonstrates characteristic hydrophobic interactions that are

similar to the inactive EGFR and HER4 systems. Fig. 2.7A illustrates that HER3, as well
as the inactive EGFR and HER4 systems, lies within the ‘perturbation-sensitive’
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quadrant, indicating that the hydrophobic core is a potential fragile point of the protein, in
which single point mutants would be expected to disrupt the local interactions. Indeed, it
has been reported that mutations in the hydrophobic core of EGFR and HER4 result in
activation of the kinase, due to destabilization of the inactive state141, 160, 208. By contrast,
an analogous mutation in HER3 abolishes ATP-binding and phosphorylation activity 163,
indicating that hydrophobic interactions in the core promote HER3 activity, rather than
maintain an autoinhibited state as they do in EGFR and HER4. Furthermore, the β3-αC
loop, which is uniquely extended in HER3 and lies proximal to the hydrophobic core,
represents a perturbation-sensitive node in HER3 (Fig. 2.7B). Thus mutations in this
region would also be expected to inactivate the HER3 kinase. Our results support the
conclusion that HER3 critically depends upon a coordinated set of hydrophobic
interactions for its weak yet robust activity from the inactive-like conformation, whereas
EGFR and HER4 employ similar interactions to maintain their autoinhibited status from
the inactive-like conformation. We propose that these hydrophobic contacts, including
the interactions in the β3-αC loop, account for the tightly coordinated sub-domain
motions observed in our PCA analysis of the HER3 system, in contrast to the hydrogen
bond-mediated mechanism underlying the coordinated sub-domain motion in the active
ErbB systems.
The hydrophobicity of the C-spine and R-spine, whose function is to coordinate
the motions of the N- and C-lobes of the EGFR and HER4 kinases in the active
conformation

93, 94

, was also quantified (Fig. 2.7C, D). In the C-spine and R-spine

hydrophobicity plots, the inactive and active conformations of EGFR and HER4 are
clearly delineated with respect to the SASA, with the active systems exhibiting a
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preferential hydrophobic stabilization (low SASA). The SASA of the HER3 C-spine falls
within range of the inactive EGFR and HER4 systems, reflecting that, despite its weak
activity, there is no corresponding ‘fully-active’ state for HER3 as for the other ErbB
kinases. This inability to ‘fully’ activate can be attributed to the lack of the crucial
hydrogen bonding network identified earlier, which is required to stabilize the active-like
kinase conformation. The SASA of the HER3 R-spine deviates from the values for the
inactive EGFR and HER4 systems, and instead demonstrates low SASA (high
hydrophobicity). This result can be rationalized by the increased hydrophobicity of the Rspine, which includes segments of the truncated αC helix in HER3, hence positioning the
HER3 system in the hydrophobically-favorable quadrant of the R-spine hydrophobicity
plot (Fig. 2.7D).
The results of our molecular-scale simulations support the characterization of
HER3 as a weakly active kinase that, in contrast to its fully-active ErbB family members,
depends upon a unique hydrophobic interface to coordinate the alignment of specific
catalytic residues required for its activity. Thus the MD simulations substantiate, at a
molecular level of resolution, the inclusion of the weakly-active HER3 node in our ErbB
pathway model (Fig. 2.2A). Moreover, our results highlight the most significant
molecular interactions that contribute to potential mechanisms of HER3 activity, which
will be clinically relevant in terms of informing the design of small-molecule inhibitors
targeted to the HER3 kinase. Now that we have provided support for the topology of our
ErbB pathway model (Fig. 2.2A), it is necessary to quantitatively evaluate the model by
incorporating appropriate kinetic parameters (Fig. 2.2C). This is an important step in our
multiscale modeling scheme, as the ErbB signaling model represents the translation of
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our observations of the robust activity of the HER3 kinase into a physiologically relevant
context, with the aim of rationalizing the clinical implications of HER3 catalytic activity
for elucidating mechanisms of drug resistance in ErbB-driven tumor cells.

2.3.5 Systems model of ErbB signaling defines a mechanism for HER3-mediated
TKI resistance
To investigate the implications of HER3 activation for ErbB signaling dynamics in a
cellular context, we constructed a systems-level model (Fig. 2.2C) derived from that of
Schoeberl et al.

154

, and informed our model with the HER3 phosphorylation rate

constants calculated from the experiments reported by Shi et al.

163

. EGFR, HER2 and

HER3 species were included in the model (HER4 was omitted as in the model by
Schoeberl et al., to reflect its undetectable levels in most cancer cell lines) and allowed to
form EGFR-HER3, HER2-HER3, and HER3-HER3 dimers upon binding to the ligand
NRG-1β (as NRG-1β is a HER3-specific ligand, it is not able to induce EGFR or HER2
homodimers146). To represent HER3 catalytic activity, we implemented HER3
homodimerization and trans-autophosphorylation in our model, resulting in induction of
PI3K-AKT signaling (Figure 2.2C). Based on the previous experimental results
indicating a 1000-fold weaker phosphoryl transfer mechanism operating in HER3 163, we
assumed that the rate of HER3 phosphorylation is 1000-fold slower than that of EGFR.
The addition of the HER3 homodimer species does not significantly alter the signaling
dynamics of the model; levels of phosphorylated HER3 (pHER3), pHER2 and pAKT
peak within minutes of NRG-1β stimulation (Figure 2.8), whereas pEGFR exhibits a
weak signal due to poor induction of EGFR dimers by NRG-1β. Thus the phosphorylated
HER2/3 heterodimer remains a predominant species in the model, although levels of
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pHER3 are slightly higher due to activation and trans-autophosphorylation
phosphorylation of HER3
homodimers.

pAKT
Figure 2.8. Time course plots for (A) pHER3, (B) pHER2, (C) pEGFR and (D) pAKT.
For each phosphorylated ErbB species, data was normalized to the maximum pHER3 signal
observed, to facilitate comparison of the RTK activation levels. For pAKT, data was normalized
to the maximum pAKT signal observed.

To identify the key proteins that direct signaling in our model of the ErbB network,
which includes HER3 catalytic activity, parameter sensitivity analysis was performed
with respect to pAKT. Figure 2.9A displays the normalized sensitivity of pAKT to
various species in the model: it is clear that HER3 and NRG
NRG-1β
β represent the most
sensitive species in the signaling network, followed by HER2 concentration. EGFR is not
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a strong determinant of the extent of AKT phosphorylation, as expected from the weak

Figure 2.9. Parameter sensitivity analysis of the HER3 signaling model.
The normalized, time-integrated sensitivity of pAKT to key molecular species was computed in
response to NRG-1β=25 nM by making a 0.1% change in each species concentration for (A) the
model representing weak HER3 activity, and (B) the model representing weak HER3 activity in
the presence of the EGFR/HER2 inhibitor lapatinib. Sensitivity to certain species, including
HER3, HER2 and the ErbB phosphatase, changed upon addition of lapatinib.

ability of NRG-1β to elicit EGFR dimers. EGFR displayed a negative sensitivity because
an increase in EGFR-HER3 dimerization results in fewer HER2-HER3 dimers, which
produce the most pAKT. PTEN (the PIP3 phosphatase) and the ErbB phosphatase
(labeled as PTP in Fig. 2.2C) also exhibited a negative sensitivity in the analysis, as these
phosphatases negatively regulate the signaling network through dephosphorylation of key
molecular species.
As previous experimental studies have demonstrated that HER3 is a key mediator
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of resistance to various tyrosine kinase inhibitors (TKIs) currently in use 8, 44, 76, 115, 157, we
next tested whether weak HER3 catalytic activity could explain potential resistance
mechanisms. Previously postulated mechanisms include leaky HER2-catalyzed
phosphorylation of HER3 (i.e., incomplete inhibition of HER2 catalytic activity by the
TKI) 69, 76, 157, which remains a plausible hypothesis. However, these models of resistance
do not consider the potential for HER3 catalytic activity, due to HER3’s formerly
assumed inactive pseudokinase status. Thus we incorporated the TKI lapatinib, which
inhibits EGFR and HER2 catalytic activity, into our model of HER3 signaling using rate
constants obtained from Schoeberl and colleagues

154

, and simulated the effects of the

TKI on pAKT induction upon NRG-1β stimulation. Figure 2.10, which displays
normalized levels of pEGFR, pHER2 and pHER3 for increasing concentrations of
lapatinib, illustrates that phosphorylated EGFR and HER2 are effectively inhibited at
sufficiently high TKI concentrations, as expected. The pHER3 and pAKT signals are
slightly more persistent; at the maximum simulated lapatinib concentration (2 µM) and
25 nM NRG-1β, pHER3 and pAKT levels persist at 3-4% of their respective no-inhibitor
control levels (Fig. 2.10C-D). Although Fig. 2.10 demonstrates that the implementation
of HER3 catalytic activity allows HER3 to escape TKI inhibition and sustain a weak
level of AKT signaling, this weak activity is not expected to be phenotypically
observable. Indeed, we computed the IC50 for lapatinib/pHER3 to be 94 nM (for 25 nM
NRG-1β), which agrees with published in vitro and simulated values ranging from 100152 nM 154.
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Figure 2.10. Dose-response
response curves of lapatinib treatment in the HER3 signaling model.
The response to the TKI was computed following a 30 minute pre
pre-incubation
incubation with lapatinib and
10 min stimulation with increasing concentrations of NRG1
NRG1-β.. Results for pEGFR, pHER2 and
pHER3 were normalized to the no
no-inhibitor
inhibitor control value for 100 nM pHER3 to facilitate
comparison of the profiles
les for the three ErbB kinases. Results for pAKT were normalized
norm
to the
no-inhibitor
inhibitor control value for 100 nM pAKT.

Figure 2.9B compares the results of pAKT sensitivity analysis of the lapatinib-treated
lapatinib
model to those of thee inhibitor
inhibitor-free model in Fig. 2.9A.
A. It is apparent that sensitivity to
HER3 and NRG-1β increases,
ncreases, whereas sensitivity to EGFR and HER2 decreases, as
lapatinib sequesters EGFR and HER2 molecules. The negative normalized sensitivity to
the ErbB phosphatase
osphatase also increases (Fig. 2.9
2.9B),
B), as the pool of ErbB dimers has
diminished due to sequestratio
sequestration of EGFR and HER2 by lapatinib. Thus a single alteration
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to the signaling model (in this case, addition of lapatinib) significantly redefines the most
perturbation-sensitive nodes in the network.
Although the pAKT signal induced by HER3 phosphorylation in our in silico
lapatinib-treated cell is relatively weak, in an actual physiological context, a tumor cell
may employ several resistance mechanisms at once

50, 76, 120, 157

. Indeed, previous

experimental studies have demonstrated that leaky HER2 phosphorylation of HER3 in
TKI-bound HER2/3 heterodimers is amplified by additional resistance mechanisms, such
as inhibition of cellular phosphatases by TKI-mediated production of reactive oxygen
species (ROS), and increased expression of HER3 at the plasma membrane 66, 127, 157. To
test whether weak HER3 activity during lapatinib treatment could be augmented by other
processes, we simulated the lapatinib-treated model for decreased initial concentrations
of the ErbB phosphatase, which represents a sensitive node in our pAKT sensitivity
analysis (Fig. 2.9B). The pAKT signal was recorded in response to 2 µM lapatinib, as this
concentration lies within the range of TKI concentrations shown to induce drug resistance
in various tumor cell lines 50, 76, 157. At the lowest concentration of phosphatase tested (1%
of its nominal value represents a limiting phosphatase concentration with respect to
HER3), even low levels of pAKT induced by HER3 signaling were amplified for varying
concentrations of NRG-1β (Figure 2.11A). As an alternative resistance mechanism, we
simulated the lapatinib-treated model for augmented levels of plasma membrane-bound
HER3, which represents another highly sensitive node in our sensitivity analysis of the
lapatinib-treated model (Fig. 2.9B). It has been demonstrated that in certain cases of TKI
resistance, the tumor cell responds to the reduction in pAKT levels by upregulating
vesicular transport of HER3 from the cytoplasm to the plasma membrane

127, 157

. Figure
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2.11B illustrates that for a 2-fold increase in surface HER3 levels, the pAKT signal is
amplified for varying concentrations of NRG-1β, in similarity to our results for decreased
phosphatase concentration. The extent of amplification is not as pronounced for 5 nM
NRG-1β as for 25-100 nM NRG-1β, as the Kd for HER3/NRG binding is 10 nM.
Figure 2.11C displays the results of decreased phosphatase levels combined with
increased HER3 concentration, a phenomenon that, in effect, shifts the HER3
phosphorylation/dephosphorylation equilibrium and has been observed in various tumor
cell lines

157

. For 25 nM NRG-1β, the pAKT signal is restored to nearly 60% of its no-

inhibitor control level, and pAKT levels are nearly 100% regained for 100 nM NRG-1β,
effectively recreating drug resistance in silico. Our data parallels the experimental studies
performed by Sergina and colleagues

157

, which describe HER3-mediated resistance and

pAKT signaling in various TKI-treated tumor cell lines as well as in vivo. Thus our
model demonstrates that even a weak level of HER3 signaling may be physiologically
relevant in the context of an ErbB-driven tumor cell, and illustrates several routes through
which HER3 signaling may be compounded by other previously postulated resistance
mechanisms to generate TKI resistance.
Based on our model results182, we propose two potential therapeutic strategies for
overcoming TKI resistance in certain tumor cell lines: (a) treatment with an anti-HER3
monoclonal antibody (mAb) to prevent HER3 dimerization, or (b) treatment with a TKI
specific for HER3 in addition to dampening the amplifying mechanisms using inhibitors
of vesicular trafficking (for blocking upregulation of surface HER3) or antioxidants (for
inhibition of TKI-produced ROS), which have been shown to overcome TKI resistance in
vitro 157. Our data suggest that application of a TKI targeting HER3 would be ineffective
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as a standalone strategy and would require supplementation with an additional therapy, as
even a weak level of HER3 activity resulting from incomplete TKI inhibition is sufficient
to induce drug resistance.

Figure 2.11. Levels of pAKT expressed following a 30 minute pre-incubation with 2 µM
lapatinib and 10 min stimulation with increasing concentrations of NRG-1β.
(A) Decreased expression of the ErbB phosphatase (1% of nominal value), (B) increased
expression (2-fold) of HER3 at the cell surface, and (C) combination of decreased ErbB
phosphatase and increased surface HER3. The control represents the pAKT signal in the presence
of inhibitor only (no amplification mechanism).
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2.4 Discussion
In this work we applied a multiscale modeling approach to investigate the non-canonical
catalytic mechanism employed by the ErbB kinase HER3, a RTK formerly categorized as
an inactive pseudokinase, and the physiological relevance of this activity to mechanisms
of drug resistance in an ErbB-driven tumor cell in silico. The results of our molecularscale simulations support the characterization of HER3 as a weakly active kinase that, in
contrast to its fully-active ErbB family members, depends upon a unique hydrophobic
interface to coordinate the alignment of specific catalytic residues required for its
activity182. Translating our molecular simulation results of the uniquely active behavior of
the HER3 kinase into a physiologically relevant environment, our HER3 signaling model
demonstrated that even a weak level of HER3 activity may be sufficient to induce AKT
signaling and TKI resistance in the context of an ErbB signaling–dependent tumor cell,
and therefore therapeutic targeting of HER3 may represent a superior treatment strategy
for specific ErbB-driven cancers.
Our homology modeling analysis of the HER3 kinase, using the EGFR and HER4
structures as templates, provided a framework for highlighting the key structural
differences between the catalytic site of HER3 and the other ErbB kinases, and for
identifying the molecular features that distinguish HER3 from the other nodes (EGFR
and HER2) in our multiscale model of HER3 activity. The homology modeling results
reflected close evolutionary ties between HER3 and HER4, suggesting that despite
employing different catalytic mechanisms, these two kinases may share other molecular
regulatory mechanisms, such as autoinhibition through N-lobe dimer formation

85

. We

also determined that the application of multiple templates in the initial sequence
alignment improved the stereochemical quality of our HER3 homology model. This
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methodological result is relevant as our homology modeling platform may be extended to
other pseudokinases that have not yet been crystallized. Indeed, several putative
pseudokinases share structural features with HER3, among them JAK2, TYK2, guanylate
cyclase D (CYGF) and protein serine kinase H (PSKH2), all of which lack the catalytic
aspartate in the HRD motif

18

. Application of our modeling and analysis procedure to

these other kinases will facilitate identification of residues that may compensate for the
lack of key catalytic motifs in the pseudokinase domains and provide insight into how
unusual modes of phosphoryl transfer may have evolved in eukaryotic pseudokinases.
At the atomic level, our molecular dynamics simulations and PCA analysis of the
HER3 kinase crystal structure revealed that the HER3 system exhibits tightly coordinated
fluctuations of its catalytic sub-domains, which may facilitate the alignment of key
catalytic residues involved in phosphoryl transfer. Despite sharing a pattern of concerted
sub-domain motion with its fully-active ErbB family members, the HER3 system
appeared to achieve this state through a unique mechanism, namely, a tightly coordinated
set of hydrophobic contacts. By contrast, an extensive network of hydrophilic interactions
is employed by EGFR, HER2 and HER4. The hydrogen bonding analysis and
hydrophobicity calculations demonstrated that the conserved hydrophilic contacts present
in the active sites of EGFR, HER2 and HER4 are replaced in HER3 by a unique
hydrophobic interface formed by the extended β3-αC loop, the molten αC helix and the
310 helix in the A-loop

180

. Thus our atomic-level simulations suggest that the ErbB

kinases may have evolved two different modes of achieving the shared goal of
prearranging the catalytic machinery for phosphoryl transfer. Moreover, the MD results
highlight the most significant molecular interactions that contribute to potential
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mechanisms of HER3 activity, which will be clinically relevant in terms of informing the
design of small-molecule inhibitors targeted to the HER3 kinase.
Employing a systems model, we extended our results to the cellular level to
rationalize the clinical implications of HER3 catalytic activity for elucidating
mechanisms of resistance to TKIs in ErbB-driven tumor cells. To this end we
implemented weak HER3 catalytic activity in a signaling model of the ErbB kinase
network and tested the effects of the TKI lapatinib on phosphorylation of AKT in our in
silico system. The simulation results revealed that, through dimerization and transautophosphorylation, HER3 is able to escape TKI inhibition and sustain a weak level of
AKT signaling, which may be amplified by additional resistance mechanisms, as we
illustrated for decreased expression of the ErbB phosphatase and increased expression of
HER3 at the plasma membrane, to recreate drug resistance in silico. Our results parallel
the experimental studies performed by Sergina et al.

157

, which demonstrate HER3-

mediated resistance and pAKT signaling in various TKI-treated tumor cell lines as well
as in vivo. Furthermore, our model is sufficiently versatile to rationalize additional
experimental results obtained by Sergina and colleagues: in their study it was observed
that siRNA-induced knockdown of HER2 abrogates drug resistance, which suggests that
HER2 is critically involved in the resistance mechanism, for example, by providing an
activation stimulus for HER3 in the context of a HER2/3 dimer. Our model could be
altered to reflect this result by implementing HER3 phosphorylation in the context of a
HER2/3 heterodimer, rather than a HER3 homodimer. In fact, HER3 catalytic activity
may be explicitly represented by several different model topologies, but the implication
for the cell phenotype is the same: namely, that a weak level of HER3 activity may
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induce drug resistance through amplification by additional resistance mechanisms, and
therefore HER3, rather than the routinely-targeted EGFR and HER2 kinases, may
represent a more viable candidate for inhibition in the context of an ErbB signaling–
dependent tumor.
Indeed, TKI therapy will remain limited in its efficacy until drugs that target the
HER3 kinase become routinely available. Recently, Schoeberl and colleagues evaluated
the in vitro and in vivo efficacy of a novel therapeutic anti-HER3 antibody, MM-121, and
reported that MM-121 reduced ligand-dependent phosphorylation of HER3 and
abrogated resistance to the TKI gefitinib by preventing reactivation of HER3

155

.

Although HER3 activity is weak compared with that of other RTKs, HER3 may remain
catalytically active in situations where the activities of its ErbB family members have
been attenuated by kinase inhibitors, such as lapatinib or gefitinib, which do not target
HER3. Since the catalytic site of HER3 differs structurally from the other ErbB kinases,
it may be possible to design TK inhibitors that demonstrate improved selectivity for
HER3 as the target kinase. A clinically valuable feature of our multiscale modeling
approach is that the flow of information between models occurs in a bidirectional
manner, so that it is possible to apply the results of our ErbB signaling model, which
indicate that targeting of HER3 may be a superior therapeutic strategy for certain ErbBdriven cancers, to the design of molecular inhibitors of HER3 activity at the atomic scale.
In this way, our atomic and subatomic simulations of HER3 activity inform our systems
model, and the systems model, in turn, informs the atomic/subatomic-level simulations
(i.e., design of molecular inhibitors or mAbs against HER3). Thus multiscale modeling
provides a powerful and quantitative platform for investigating the complexity inherent in
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intracellular signaling pathways and rationalizing the effects of molecular perturbations
on downstream signaling events and ultimately, on the cell phenotype.
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Chapter 3
Molecular Simulation of Structure, Dynamics, and
Function in the ErbB Receptor Tyrosine Kinases
Adapted from: Telesco SE and Radhakrishnan R. Atomistic Insights into
Regulatory Mechanisms of the HER2 Tyrosine Kinase Domain: a Molecular
Dynamics Study. (2009) Biophys J. 96(6):2321-2334.
Shih A, Telesco SE, Choi S, Lemmon M, Radhakrishnan R. Conserved
Hydrophobic and Hydrophilic Bond Interaction Networks in ErbB Family
Kinases. (2011) Biochemical Journal 436:241-51.
In Chapter 2, we focused on the unique activity of the HER3 tyrosine kinase in order to highlight
the implications for elucidating mechanisms of drug resistance in specific human cancers. In
Chapter 3, we extend our molecular dynamics study to the remaining ErbB family members
(EGFR, HER2, HER4) to compare and contrast mechanisms of regulation and activation in the
ErbB RTK family. We bias certain sections of this chapter toward the HER2 kinase, as HER2
exhibits several structural and functional features which are unique among the ErbB RTKs.

3.1 Introduction
Considering the high degree of sequence similarity and structural homology across the
ErbB family members, we sought to elucidate the degree to which molecular mechanisms
of activation are conserved across the ErbB RTKs, and to identify differences in overall
function that arise from variability in primary structure. Recently, we and others have
hypothesized the existence of distinct networks of intramolecular non-covalent bonds that
characterize the active and inactive conformations of kinases (for Lyn

129, 130

, Abl

38

,
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EGFR 38, 134, 165 and HER2 181), with transitions between the activation states necessitating
a shift in these bond networks. In this Chapter, we present bioinformatics and fluctuation
analyses of molecular dynamics trajectories of the ErbB kinase domains and relate
sequence similarities to correspondence of specific bond-interaction networks and
collective dynamical modes. We investigate how the various stimuli/perturbations, such
as dimerization, phosphorylation, and mutation, impact both the active and inactive
conformations of the ErbB kinase domains.
Although the ErbB kinases share certain structural and functional features, one
family member, HER2 kinase, stands out in several ways. HER2, the only ErbB family
member for which a crystal structure of the kinase domain has not yet been resolved, is
unique in that it does not require ligand-binding in order to dimerize with other ErbB
RTKs, and hence its extracellular domain is constitutively poised for dimerization. In
order to counterbalance this easily perturbed activation state, a number of regulatory
mechanisms exist for HER2, such as auto-inhibition of HER2 kinase domain
dimerization through binding of chaperone proteins30, 203, 202. In this Chapter, we explore
several of these regulatory mechanisms, which are crucial for preventing constitutive
activation and uncontrolled proliferative signaling, and are disrupted in many HER2driven cancers.
HER2 is further distinguished from its family members in regard to the role
played by several of its key catalytic domains, including the A-loop. In most protein
kinases, the A-loop assumes its catalytically competent conformation only if it is first
phosphorylated on a regulatory tyrosine residue within the A-loop

73

. The regulatory

tyrosine residue is Y877 in HER2 (Y845 in EGFR). Although phosphorylation of EGFR
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on Y845 has been observed experimentally, phosphorylation does not seem to be
required for catalytic activity, as EGFR possessing a Y845F mutation is fully active

186

.

Contrastingly, the role of A-loop phosphorylation in HER2 is controversial, as several
studies have highlighted the importance of Y877 phosphorylation for kinase activity
207

. Xu et al.

203

17,

have reported that mutation of Y877 to phenylalanine in COS-7 cells

results in decreased autophosphorylation of Y1248, a tyrosine located in the C-terminal
tail of HER2. Therefore, it is possible that phosphorylation of Y877 augments HER2
kinase activity.
In this Chapter, we perform molecular dynamics (MD) simulations of inactive and
active EGFR, HER2, and HER4 kinase structures to elucidate details of the mechanism
by which the ErbB RTKs are regulated and activated. We investigate the dimer-mediated
allosteric activation of the ErbB kinases through dynamics simulations of a HER2/EGFR
heterodimeric system as well as EGFR and HER4 homodimers, and delineate the role of
phosphorylation of the A-loop tyrosine residue, Y877, through the free energy
perturbation (FEP) method.

3.2 Materials and Methods
3.2.1 Homology modeling of the HER2 kinase domain
The HER2 kinase domain was modeled in homology to EGFR, with which it shares 83%
sequence identity, using the program MODELLER 51, 150. The coordinates of the inactive
EGFR kinase domain were downloaded from the Protein Data Bank (PDB code 2GS7)
208

and a sequence alignment between EGFR and HER2 was performed in MODELLER.

Missing residues were built using the loop modeling algorithm in MODELLER and
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hydrogen atoms were added by employing the hbuild routine in CHARMM27

112

. The

structure of the active HER2 kinase domain was based on the model generated by
Bagossi et al. 6. The Bagossi model, which was constructed in homology to active EGFR
(PDB code 1M14) 172, was refined by applying the loop-modeling routine to segments of
missing residues and by performing additional energy minimization steps. The final
models for the inactive and active HER2 kinase domains were assessed for
stereochemical quality using PROCHECK 99.

3.2.2 Molecular dynamics simulations
Models for ErbB1 (EGFR) kinase were derived from the 1M14 (active) and 2GS7
(inactive) structures

172, 208

. Models for HER4 were derived from the structures of Qiu et

al., PDB ID: 3BCE and 3BBW

141

. Models for kinase dimers were constructed based on

the asymmetric dimer interface described in

208

atomistic, explicitly solvated-system in NAMD
112

. Each system was simulated as a fully
135

, using the CHARMM 27 forcefield

. The MD simulations and analyses were performed as described in Section 2.2.

3.2.3 Construction of the ErbB dimer systems
The ErbB dimer systems were modeled on the structure of the EGFR homodimer
published by Zhang et al.

208

. The structures were minimized to remove unfavorable

contacts and hydrogen atoms were added using the hbuild routine in CHARMM. The
dimers were explicitly solvated using the TIP3P water potential with the buffering
distance set to 15 Å for a total system size of approximately 120,000 atoms. Sodium
(Na+) and chloride (Cl-) ions were added to achieve net electroneutrality of the system
and an ionic strength of 75 mM. All Na+ and Cl- ions were placed at least 8 Å away from
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any protein atoms and from each other. Minimization and MD steps were performed as
for the monomeric systems, except that the production simulations were run for 20 ns.

3.2.4 Free energy perturbation (FEP) simulations
The free energy perturbation (FEP) method

212

was employed to compute the Helmholtz

free energy difference between the Y877-unphosphorylated and phosphorylated HER2
structures. Calculations were performed using the alchemical free energy perturbation
feature in NAMD

11,

136

. The Helmholtz free energy difference between two

thermodynamic states connected by M intermediate, nonphysical substrates in the NVT
ensemble is expressed as:
∆F = −

1

M +1

β

i =1

∑ ln〈exp{− β [ν ( x; λ
β=

i +1

) − ν ( x; λi )]}〉 λi

1
k BT

where kB is the Boltzmann constant, T is the temperature, and ν ( x; λi ) is the potential
energy function that depends upon the Cartesian coordinates of the system {x}, and the
coupling parameter, λi, that connects the initial and the final states of the transformation.
The dual-topology paradigm
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was utilized, in which the initial and the final state are

defined in terms of distinct, noninteracting topologies. Four different simulations were
performed, including the transformation of Y877 to pY877 for the solvated
unphosphorylated HER2 structures (inactive and active), and the transformation of
pY877 to Y877 for the solvated phosphorylated HER2 systems. Each perturbation was
divided into 48 windows with 20 ps of equilibration and 80 ps of data collection per
window, producing a total of 4.8 ns of simulation time for each FEP transformation.
66

Harmonic positional restraints were imposed on the sodium and chloride ions, and system
electroneutrality was maintained by transforming counterions during the course of the
alchemical perturbation. Estimation of error was based on two different sets of
coordinates, ie, performing the alchemical transformations on configurations obtained
after 5 and 10 ns of MD trajectory, and errors are reported in terms of the standard
deviation from the mean ∆F. Another source of error involves the end points of the
transformation, which correspond to the creation or elimination of a group of atoms and
are subject to van der Waals clashes that result in end-point catastrophes 10, 137. To obtain
an accurate estimate of the free energy at the diverging end points, we increased the
number of windows at the beginning and end of the FEP simulations, collecting data at
several points with λ values close to 0 or 1.

3.3 Results
3.3.1 Molecular dynamics simulations of the ErbB kinases
Following molecular dynamics simulation of each active or inactive monomeric kinase
system for at least 10 ns, the time evolution of the RMSD was used to monitor
equilibration and to track any reorganization of the A-loop and αC-helix conformations;
no conformational switching towards active or inactive states was observed (Figure 3.1
illustrates the RMSD plots for the HER2 systems). Whereas the majority of the protein
backbone, including the C-loop and the N-loop, aligns closely between the inactive and
active states, the A-loop and αC-helix conformations differ considerably. In transitioning
from the inactive to the active conformation, the αC-helix rotates toward the C-lobe, with
the rotating end shifting by ~9 Å toward the base of the cleft between the N- and C-lobes.
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The helix is also extended by two turns in the active conformation compared with the
inactive conformation. In the inactive kinase, the A-loop
loop maintains a ‘closed’
conformation (mainly through inter
inter-region
region hydrogen bonds) and partially blocks the
catalytic site. By contrast, the A
A-loop
loop appears ‘unfurled’ in the active kinase, and lies
against the C-lobe.

Figure 3.1. RMSD forr all backbone atoms in the A
A-loop of the following HER2 systems.
systems
(A) the Y877-unphosphorylated
unphosphorylated active and ((B) the Y877-unphosphorylated
unphosphorylated inactive trajectories,
and (C) the Y877-phosphorylated
phosphorylated active and ((D) the Y877-phosphorylated
phosphorylated inactive trajectories.
The RMSD is plotted in reference to the initial active structure ((red)) and in reference to the initial
inactive structure (blue).
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3.3.2 PCA reveals a tightly coordinated motion in all active ErbB members
A principal component analysis (PCA) was applied to each MD trajectory in order to
characterize the global motions of the ErbB kinases. An objective of the PCA is to
delineate the differences in atomistic fluctuations among the inactive and active
structures, as conformational rearrangement of the kinase domain is expected to correlate
with dramatic changes in the dynamical behavior of the protein. PCA of the ErbB
structures was performed on an active site region which comprises all domains critical for
catalysis, including the A-, C- and N-loops and the αC helix. Specifically, the Cα atoms
of the C-loop/A-loop region (residues 843-888 in HER2) and the αC helix/N-loop region
(residues 725-778 in HER2) were chosen as the active site, and the analysis was applied
to the NVT-equilibrated trajectory for each monomeric structure (Fig. 3.2). The PCA
revealed that motions occurring within the active sites of the inactive and active ErbB
monomers differ significantly, particularly in the A-loop. The inactive EGFR monomer
exhibits large-amplitude motion in both the αC-helix and the A-loop (4.95 and 7.34 Å,
respectively), with smaller fluctuations in the N-loop and C-loop (4.17 and 3.65 Å,
respectively). By contrast, the active EGFR monomer demonstrates a uniform level of
motion across all four subdomains of the active site with low-amplitude fluctuations (23Å), and shows no significant local deformations. The HER2 and HER4 kinase
monomers demonstrate similar motions, as shown in Figure 3.2. The inactive HER4
kinase exhibits a dominant motion in the A-loop (6.46 Å), while the N-loop, C-loop, and
the αC-helix undergo smaller lateral motions (4.45 Å, 2.64 Å, and 2.30 Å, respectively).
In the active conformation, the HER4 kinase presents a fluctuation profile similar to
EGFR: the subdomains all have similar small-amplitude motions (2-3 Å) with no large
local deformations. Thus, for the three homologous members of the ErbB family, which
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have a high degree of sequence similarity, not only are the principal motions conserved
across the systems, but the characteristic differences between the inactive and active
kinase conformations are maintained in character. We reason that the interactions among
the A-, C-, and N-loops and the αC helix in the active ErbB systems are crucial for
alignment of the key domains for catalysis. The correlation between the A-loop and Cloop is especially pronounced, ensuring appropriate positioning of the catalytic aspartate,
D845, and the coordinating aspartate, D863, for the phosphoryl transfer reaction. This
finding suggests large (and possibly similar) differences in the internal network of bonds
between the two activity states of each kinase, which will be discussed in the following
section.

Figure 3.2. PCA of the key subdomains in the inactive and active ErbB kinases.
The motions are overlaid sequentially where the large-amplitude motion in each frame is
highlighted in red and the low-amplitude motion is highlighted in blue. The inactive
conformations exhibit large, localized motion while the active conformations demonstrate
smaller, coordinated motions. Note that Fig. 2.6 also compares the PCA results for HER3.
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3.3.3 Hydrogen bonding analysis reveals a conserved network of interactions in the
active ErbB kinases
In order to identify specific interactions which could be contributing to the differences in
global motions of the inactive and active systems and to investigate the mechanistic basis
for the coupling of the A- and C-loops, individual salt bridges and hydrogen bonds were
tabulated for each ErbB system through a hydrogen bonding analysis of the 10 ns
trajectories. The hydrogen bonds for HER2 are illustrated in Figure 3.3, and are labeled
according to the numbered residue pairs listed in Table 3.1. Our analysis reveals that six
hydrogen bonds occur in the C-loop of the active HER2 structure, the majority of which
link the C-loop and the A-loop (Table 3.1). Specifically, R844-L866, N850-T862, V842R868, and L852-K860 connect the C-loop to the N-terminal end of the A-loop, while the
L846-W888 bond couples the C-loop and the C-terminal end of the A-loop.
Contrastingly, only two hydrogen bonds bridge the C-loop and the A-loop in the inactive
HER2 system (Table 3.1). The extensive hydrogen bonding that preferentially links the
A- and C-loops in the active conformations of the kinase provides a rationale for the
cooperative fluctuations between these regions as revealed by the results of the PCA.
The EGFR and HER4 systems revealed a similar bonding pattern in the inactive
and active states (see Reference 166 for a complete list of bonds present in the EGFR and
HER4 kinases). Hence the similarity in the pattern of specific interactions that
preferentially bridge the A- and C-loops in the active conformations of the EGFR, HER2,
and HER4 kinases suggests that the tight coupling of the A- and C-loops may be a
general feature of the architecture of ErbB receptor kinases which likely aids in the
assembly of a catalytically competent active site.
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Figure 3.3. Hydrogen bondi
bonding analysis for HER2 (A) inactive and (B) active.
active
Labels correspond to the numbered residue pairs listed in Table 3.1. Only those bonds which
couple the key subdomains of the kinase (A
(A-loop, C-loop, and αC
C helix) are shown to highlight
the preferential bridging of the subdomai
subdomains in the active conformation. The A-loop
A
is shown in
red, C-loop in purple,, and α
αC helix in gray.

We extended the evaluation
uation of hydrogen bonds to the A
A-loop and αC helix, as these
regions undergo the most pronounced structural shifts upon transition from the inactive to
the active state of the ErbB kinases. In similarity to the hydrogen bonding pattern in the
C-loop, we observe
bserve a considerable difference in the number of interactions in the A-loop
A
and αC
C helix of the active and inactive HER2 systems (Table 3.1 and Fig. 3.3).
Specifically, there are four hydrogen bonds and two salt bridges in the A-loop
A
of the
inactive HER2 structure compared to nine hydrogen bonds and two salt bridges in the
active A-loop. The αC
C helix reflects a more marked distinction between the two systems,
as two salt bridges occur in the active structure while salt bridges are entirely lacking in
the inactive
nactive system. The majority of bonds in the active system connect the key domains
of the kinase; for instance, the E766
E766-K883 and D769-R868
R868 bonds link the A-loop
A
and the
αC
C helix (Fig. 3.3B). Furthermore, the R844
R844-L866, N850-T862, V842-R868,
R868, L852-K860
L852
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and L846-W888 bonds couple the A-loop and the C-loop. The EGFR and HER4 kinases
reveal a similar bonding pattern166. Hence, the network of specific hydrogen bonds that
bridge the key subregions of the kinase (A-loop, C-loop, and αC helix) provides a
rationale for the concerted motion of these subdomains observed in the PCA.

Label*

Subregion

Inactive HER2

Active HER2

1

αC helix

–

A763 HN, S760 OG

2
3

αC helix
αC helix

N764 HN, S760 O

N764 HN, S760 O

–

E766 OE1/2, R756 HE

4

αC helix/A-loop

–

E766, K883

5

αC helix/A-loop

–

D769 OD1/2, R868 HH12

6
7

αC helix
αC helix

–

E770, K753

Y772 O, G776 HN

–

8

αC helix

–

V773 O, V777 HN

9
10
11

αC helix
C-loop/A-loop
C-loop/A-loop

M774 O, L785 HN

–

V842 O, G865 HN

–

–

V842 O/HN, R868 HN/O

12

C-loop/A-loop

–

R844 HE, L866 O

13
14

C-loop/A-loop
C-loop

–

L846 O, W888 HE1

A848 O, L807 HN

–

15

C-loop/A-loop

–

N850 O, T862 HN

16
17

C-loop
C-loop/A-loop

V851 O, L806 HN

V851 O, L806 HN

L852 HN, K860 O

L852 HN, K860 O

18

A-loop

D863, K753

–

19
20

A-loop
A-loop

–

L870 HN, R840 O

–

D871 O, R840 HE/HH12

21

A-loop

D873 OD1/2, R897 HE

–

22
23
24

A-loop
A-loop
A-loop

–

E876 OE1/2, R898 HE

D880, R897

D880, R897

K883 HZ1/2, E757 OE1

–

†

* Labels correspond to the numbered hydrogen bonds illustrated in Figure 3.3.
†
Salt bridges are highlighted in bold.
Table 3.1. Hydrogen bonding analysis for the inactive and active HER2 systems.
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3.3.4 Variation among HER2, EGFR, and HER4 in the αC-β4 loop region of the
kinase
A recent study by Fan et al.

45

reported that HER2 is strongly autoinhibited relative to

EGFR and HER4, and that a mechanism for the autoinhibition involves sequence
variation in a loop connecting the αC helix and the β4 sheet. The HER2 kinase domain
shares 83% sequence identity with EGFR; in the αC-β4 loop, however, five of the eight
residues in HER2 differ from those in EGFR. Specifically, the polar residues in the αCβ4 loop of EGFR are replaced by nonpolar residues in HER2, which form a hydrophobic
patch that contacts another segment of hydrophobic residues located in the A-loop.
Residues comprising the hydrophobic patch in HER2 include V773, M774, G776, V777,
G778 and V782 in the αC-β4 loop, and I861, T862, F864, L866 and L869 in the A-loop.
This hydrophobic motif has been investigated by several groups in relation to its
association with various molecules, such as the molecular chaperone Hsp90 30, 202. Fan et
al. postulate that the hydrophobic interactions between the αC-β4 loop and the A-loop
stabilize the HER2 kinase in the inactive state, resulting in lower constitutive catalytic
activity relative to EGFR and HER4.
In light of these experimental findings, we extended our hydrogen bonding
analysis to the αC-β4 loop for HER2, EGFR, and HER4. In tabulating the bonds for each
system, we observe that both the inactive and active HER2 structures contain only two
hydrogen bonds in the αC-β4 region (Table 3.2). One of the bonds, S783-I861, is shared
by both systems and couples the αC-β4 loop to the A-loop. Contrastingly, EGFR and
HER4 contain a significantly greater number of hydrogen bonds in the αC-β4 loop. The
active EGFR and HER4 structures form ten and eight hydrogen bonds, respectively
(Table 3.2). Several bonds in active EGFR, including H749-I829, C751-I829, and H74974

V827, link residues in the αC-β4 loop and the A-loop, while other bonds, including S744Y740, V745-V741, and L753-M742, connect the αC-β4 loop and the αC helix. The active
HER2 system lacks many of these hydrogen bonds because hydrophobic interactions,
rather than hydrophilic contacts, predominate in the αC-β4 region. In particular, the
H749-I829 and H749-V827 bonds are absent in HER2 because the kinase contains a
relatively nonpolar tyrosine residue in the position analogous to the positively-charged
H749 in EGFR. Figure 3.4 contrasts the network of hydrogen bonds (in stick
representation) in the αC-β4 loop of the active EGFR system with the hydrophobic
residues (in van der Waals representation) in HER2. The individual bonds are labeled
according to the numbered residue pairs listed in Table 3.2.

Label*

HER2 Active

EGFR Active

HER4 Active

HER2 Inactive

EGFR Inactive

HER4 Inactive

1

–

A743, L679

A748, Q684

–

–

–

2

–

S744, N676

–

–

–

–

3

–

S744, Y740

S749, L745

G776, Y772

S744, Y740

S749, L745

4

–

V745, V741

M750, I746

–

–

–

5

–

–

–

–

–

M750, M747

6

G778, Y835

D746, Y803

–

–

–

–

7

–

–

H752, Y808

–

–

H752, Y808

8

–

H749, V827

–

–

–

–

9

–

H749, I829

H754, I834

–

H749, I829

H754, I834

10

S783, I861

C751, I829

V756, I834

S783, I861

C751, I829

V756, I834

11

–

R752, Q767

R757, Q772

–

–

–

12

–

L753, M742

L758, M747

–

L753, M742

L758, M747

* Labels correspond to the numbered hydrogen bonds illustrated in Figure 3.4B for EGFR kinase
in the active conformation.
Table 3.2. Comparison of the Hydrogen Bonding Network in the αC-β4 loop.
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The bonding analysis of the inactive ErbB systems reveals a trend similar to that in the
active systems. The inactive EGFR and HER4 conformations contain four and six
hydrogen bonds, respectively, in contrast to two bonds in the αC-β4 loop of inactive
HER2 (Table 3.2). The lack of hydrogen bonds in the αC-β4 loop of inactive HER2 is
consistent with the prominence of hydrophobic interactions in this region as proposed by
Fan et al. Despite sharing similar bonding patterns with EGFR in the A-loop and αC
helix, HER2 differs markedly from EGFR in the αC-β4 region due to the presence of the
hydrophobic patch of residues. The dearth of a hydrogen bonding network and the
dominance of hydrophobic interactions surrounding the αC-β4 loop in HER2 is thought
to contribute to its interaction with the molecular chaperone Hsp90

202

. As a mature

protein, only HER2 among the members of the ErbB family associates with Hsp90, as
EGFR and HER4 lack the segment of hydrophobic residues in the αC-β4 loop. It has
been proposed that binding of Hsp90 to the αC-β4 region in HER2 provides an inhibitory
mechanism for regulation of HER2 activity by preventing dimerization and subsequent
activation of the HER2 kinase 30.
The hydrophobic association between HER2 and Hsp90 is relevant to the effects
of clinical mutations in the HER2 kinase domain. HER2 gene mutations have been
identified in a cohort of non-small cell lung cancers (NSCLCs) which involve in-frame
duplications/insertions within exon 20, a region that corresponds to the αC-β4 loop in the
kinase domain. The most frequently occurring abnormality is the in-frame YVMA
insertion at residue G776 (G776YVMA), which has been shown to undergo markedly
higher tyrosine phosphorylation than wild-type HER2, resulting in increased
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tumorigenicity

195

. Another prevalent activating mutation is G776S, which has been

found

Figure 3.4. Hydrophobic
hobic interactions in HER2 in the αC-β4 loop.
(A) The patch of hydrophobic residues in the αC-β4
4 loop of the active HER2 structure. Residues
in the αC-β44 loop are colored green and residues in the A-loop
loop are colored orange. (B) The
hydrogen bonding
nding network in the αC-β4
4 loop of the active EGFR structure. The bonds are
labeled according to the numbering scheme in Table 3.2.
2. (C) Sequence alignment between HER2
and EGFR in the αC-β44 region of the kinase. Blue arrows indicate residues contributing to the
hydrophobic patch in HER2.

in gastric tumors

175

. Such mutations weaken the hydrophobic interactions surrounding

the αC-β44 loop and likely promote a hydrogen bonding network similar to those we have
h
identified
tified in EGFR and HER4
HER4,, which can disrupt the inhibitory stimulus provided by
HER2-Hsp90
Hsp90 association.

3.3.5 Activation in the ErbB dimer systems occurs through disruption
disr
of the
inactivating bonding network
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As postulated by Zhang et al. 208, the ErbB kinases undergo activation via an asymmetric
dimer mechanism. In order to investigate potential mechanisms of dimer-induced
dimer
activation, we constructed the following ErbB dimer systems: HER2
HER2-EGFR
EGFR heterodimer,
EGFR homodimer, and HER4 homodimer. The follow
following
ing results will be described for the
HER2-EGFR
EGFR heterodimer, but the results for the ErbB homodimers displayed similar
trends166. In the context of a HER2
HER2-EGFR heterodimer,
terodimer, the residues comprising the
dimeric interface for HER2 (kinase undergoing activation) include P707, Q711, M712,
I714, L768, L790, and V794, and for EGFR (activating kinase) include I917, Y920,
M921, V924, M928, I929, and V956 (Fig. 3.5). A second
d dimer was constructed in which
the Y877-phosphorylated
phosphorylated inactive HER2 monomer from the 10 ns equilibrated system
was input as the activated kinase. Both heterodimeric systems were solvated and
subjected to 20 ns of molecular dyna
dynamics simulation (see Methods). The objective was to
determine whether dimerization promotes the active state and if so, whether
phosphorylation of Y877 facilitates the activation mechanism.

Figure 3.5. Snapshot of the modeled HER2
HER2-EGFR heterodimer.
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Shown are the residues comprising the dimeric interface for the kinase undergoing activation
(HER2, pink) and for the activator kinase (EGFR, green). The residues that constitute the
interface for HER2 are P707, Q711, M712, I714, L768, L790, and V794 (highlighted in blue in
the inset). For EGFR, the interface residues are I917, M921, V924, I929, and V956 (highlighted
in purple in the inset).

PCA was performed for the 20 ns MD trajectories in order to characterize the extent of
correlation of atomistic fluctuations. As for the monomeric systems, the active site region
was chosen to include the Cα atoms of the A-, C-, and N-loops and the αC helix of HER2,
the kinase that is undergoing activation in the context of the heterodimer. In similarity to
the inactive monomeric simulations, the principal eigenmodes are dominated by A-loop
movement (Fig. 3.6). However, the phosphorylated heterodimer exhibits notable
fluctuations in the αC helix of HER2 (Fig. 3.6B), in similarity to the active monomeric
structures. We also observe a repositioning of the αC helix toward the active
conformation during the 20 ns MD simulation, shifting from an RMSD of 2 to 6
Angstroms relative to the inactive state. The HER2 structure in the unphosphorylated
dimer also exhibits a slight conformational rearrangement of its αC helix toward the
active state in response to the dimerization interface (Fig. 3.6A).
As in our analysis of the monomeric systems, we aimed to rationalize the pattern
of global motions in the dimers in terms of specific interactions. In order to identify
stabilizing bonds that are perturbed upon dimerization, we performed a hydrogen bonding
analysis for the 20 ns MD trajectories. An examination of the bonding network in the
heterodimeric systems reveals destabilization and severance of several interactions
present in the monomeric systems (Table 3.3). In the dimer featuring Y877unphosphorylated HER2 as the activated kinase, several bonds responsible for
maintaining the inactive state in the monomer are broken, including N764-S760 and
Y772-G776 in the αC helix. Indeed, disruption of these bonds is expected as a result of
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their position within the dimeric interface. Additional bonds that are disturbed include
G865-V842 and D873-R897
R897 in the A
A-loop. In the dimer involving Y877--phosphorylated

Figure 3.6. Global motions of the H
HER2-EGFR dimers as determined by PCA.
The structures represent displacements along the first eigenmode for (A) the Y877Y877
unphosphorylated system and (B) the Y877
Y877-phosphorylated
orylated system. The structures are colorcolor
coded according to the RMSD ((red and white indicate large fluctuations, blue indicates smaller
fluctuations) to illustrate the motions in individual residues. Insets reveal shifting of the αC helix
in the dimer (blue)) away from the inactive conformation ((green)) and toward the active
conformation (pink).

HER2 as the activated kin
kinase,
ase, several bonds expected to break are indeed severed,
including T759-E874,
E874, L785
L785-M774 and Y772-G776 in the αC helix. Key interactions in
the A-loop,
loop, such as G865
G865-H843, R868-R840, and V884-K887,
87, have also been perturbed.
Our findings indicate that the dim
dimerization
erization interface directly alters the pattern of
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stabilizing hydrogen bonds in the inactive system, in agreement with the allosteric
activation mechanism proposed by Zhang et al.

208

. Disruption of specific interactions in

the αC helix suggests that the pattern of hydrogen bonds in the dimer is shifting away
from the inactive state and that the kinase domain is more susceptible to perturbations
that would enable a conformational rearrangement toward the active state. Moreover, the
dimeric interface directly induces the repositioning of the αC helix toward the active
conformation even in the relatively short timescale of 20 ns.

Proximal, Broken*

Proximal, Unbroken

†

‡

Not Proximal, Broken

Y877-Unphosphorylated Dimer

Y877-Phosphorylated Dimer

–

T759-E874

N764-S760

–

Y772-G776

Y772-G776

–

L785-M774

K753-D863

K753-D863

E757-K883

E757-K883

L785-M774

–

G865-V842

–

–

G865-H843

–

R868-R840

D873-R897

–

–

V884-K887

* Refers to bonds containing residues that are proximal to the dimer interface (within 3 Å of at
least one of the dimeric interface residues for 75% of the production trajectory) and have broken
in the dimer trajectory.
†
Refers to bonds containing residues that are proximal to the dimer interface, but have not broken
in the dimer trajectory.
‡
Refers to bonds that are not proximal to the dimer interface, but have broken in the dimer
trajectory.
Table 3.3. Summary of broken and unbroken bonds for the HER2-EGFR dimer.

81

Several bonds remain unperturbed by the dimerization interface, and hence may pose
significant free energy barriers to the conformational change accompanying activation.
The D863-K753 interaction, which is one of the salt bridges involved in the dual
autoinhibitory mechanism in the monomeric simulations, persists throughout the dimeric
trajectories. We also note the importance of the K883-E757 bond, which is conserved
among all three inactive ErbB kinases, in governing stabilization of the inactive structure,
as it must break in order for the K883-E766 salt bridge to assemble in the active state.

3.3.6 Free energy perturbation analysis of the role of Y877 phosphorylation in
HER2
Several experimental studies have highlighted the importance of A-loop phosphorylation
in HER2 activation. In the Y877-phosphorylated active system, we identify a network of
hydrogen bonds that maintain the A-loop in the open conformation; as the A-loop
extends, it uncovers the catalytic loop and promotes access of peptides to the active site.
The hydrogen bonds fasten the A-loop to a segment of the αF helix (residues 896 to 901)
and to the region between the αE helix and the C-loop (residues 840 to 844), ensuring
that the A-loop remains in the active state (Fig. 3.7). Three hydrogen bonds, L866-R844,
V842-R868, and R840-L870, secure the A-loop at its N-terminal end (Fig. 3.7B).
Likewise, three bonds, Y877-F899, A879-R897, and E876-R898, fasten the A-loop at its
C-terminal end (Fig. 3.7C). It is noteworthy that several of the bonds, such as L866-R844
and Y877-R844, link residues in the A-loop and C-loop, underscoring the tight coupling
of these regions in the active state. However, the key residues required for kinase activity,
D863 (the coordinating aspartate) and D845 (the catalytic aspartate), do not participate in
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thee hydrogen bonding network and henc
hencee remain poised for catalysis. Based on these
results, we propose an activation model in which residues neighboring D863 and D845
compose hydrogen bonds that stabilize the A
A-loop
loop in the active state, while ensuring
availability
bility of the catalytic aspartate residues for kinase activity.

Figure 3.7. The stabilizing hydrogen bonds in the A
A-loop of the pY877 system.
The structures highlight the hydrogen bonds present at ((B) the N-terminal
terminal end of the A-loop
A
and
(C) the C-terminal
rminal end of the A
A-loop. The bonds maintain the A-loop
loop in the active state while
ensuring availability of D863 and D845 for catalysis. Hydrogen bonds are depicted as blue
dashed lines.

Intriguingly, we observe that phosphorylated Y877 performs a key fun
function
ction in linking the
network of hydrogen bonds that maintain th
the A-loop
loop in its extended form. The
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phosphoryl group forms bonds with R844, K883, and R868, thereby bridging the C- and
N-terminal ends of the A-loop (Fig. 3.8A). Furthermore, the main-chain oxygen of Y877
hydrogen-bonds with F899, contributing to the pattern of fastening interactions in the Aloop. Contrastingly, fewer hydrogen bonds occur in the A-loop of the Y877unphosphorylated active system, indicating that the absence of the phosphoryl group
results in a decreased number of intra-A-loop interactions (3.8B). We define a similar
role for phosphorylated Y845 in the active EGFR system. Y845-phosphorylated EGFR
shares eight of nine hydrogen bonds present in the A-loop of Y877-phosphorylated active
HER2, including bonds between the phosphoryl group and the A-loop181. Our results for
HER2 and EGFR suggest that the role of the phosphoryl group in Y877 (or Y845 in
EGFR) is to bridge the stabilizing bonds on either side of the A-loop in the active system.
In further support of this bridging mechanism of phosphorylated Y877 in HER2 and
Y845 in EGFR, we note an analogous function for the phosphorylated tyrosine residue in
insulin receptor tyrosine kinase (IRK), for which there exists a crystal structure of the
phosphorylated active form of the protein 72.
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Figure 3.8. Bridging role of pY8
pY877.
(A) Snapshot of the Y877
Y877-phosphorylated active HER2 system, illustrating the role of
phosphorylated Y877 in bridging the network of hydrogen bonds on either side of the A-loop.
A
The phosphoryl group forms bonds with R844, K883, R868 and F899, thereby connecting
c
the Nand C-terminal
terminal ends of the A
A-loop. Hydrogen bonds are depicted as blue dashed lines.
lines (B)
Snapshot of the unphosphorylated active HER2 system, showing the lack of stabilizing hydrogen
bonds due to the absence of the phosphoryl group.

Analysis
alysis of the MD trajectories for the inactive systems reveals that phosphorylation of
Y877 promotes formation of additional hydrogen bonds and salt bridges in the A-loop
A
(see Table S4 in

181

). The phosphoryl group hydrogen
hydrogen-bonds
bonds with R844 and K883,

spanning the A-loop
loop as it does in the active system. Additional pairs of residues include
G865-H843 and R868-R840,
R840, which parallel L866
L866-R844 and R868-V842
V842 in the active
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structure. Although phosphorylation of Y877 in the inactive system alters the hydrogen
bonding pattern so that it more closely resembles the network in the active system,
phosphorylation is insufficient for promotion of conformational shifting to the active
state within the short timescale of our 10 ns simulations.
To further investigate the effect of Y877-phosphorylation on kinase activity, we
employed the free energy perturbation (FEP) method to calculate the Helmholtz free
energy difference between the Y877-unphosphorylated and Y877-phosphorylated states
in the NVT ensemble. The alchemical transformations were performed using the dualtopology paradigm
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, in which the initial and the final states are defined in terms of

distinct, noninteracting topologies, and the interactions of the transformed atoms with
their environment are scaled in terms of a linear parameter, λ (see Methods for details).
Four different simulations were performed, including the transformation of Y877 to
pY877 in the unphosphorylated structures (inactive and active), and the transformation of
pY877 to Y877 in the respective phosphorylated systems. Replacement of Y877 with
phosphorylated Y877 resulted in a free energy change of -385.1 + 1.2 kcal/mol for the
active structure and -384.0 + 0.8 kcal/mol for the inactive structure, yielding a ∆∆F value
of -1.1 + 1.4 kcal/mol (Fig. 3.9A). The ∆F values for the reverse transformation, pY877
to Y877, were calculated in a similar manner, and were found to be 405.8 + 1.1 kcal/mol
for the phosphorylated active structure and 404.6 + 1.1 kcal/mol for the phosphorylated
inactive system, resulting in a ∆∆F value of 1.2 + 1.5 kcal/mol (Fig. 3.9B). The
individual ∆F values for the forward and reverse transformations differ slightly, as the
structures contain different numbers of water molecules and ions, yet the error estimates
are within the ranges that have been computed for other solvated systems

40, 67, 210

. The
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∆∆F
F values are significantly close and indicate that phosphorylation of Y877 provides a
small increase in stability of the active conformation relative to the inactive state,
although it is insufficient to significantly lower the kinase activation barrier. Additional
perturbations are required for full catalytic competency of the kinase, suggesting that
phosphorylation of Y877 is unlikely to be the primary stimulus for shifting to the active
state.

Figure 3.9. Evolution of the Helmholtz free energy as a function of the coupling parameter λ
for the HER2 systems.

87

FEP simulations were performed for (A) the transformation of Y877 to pY877 and for (B) the
transformation of pY877 to Y877 in both the inactive and active HER2 systems. Phosphorylation
of Y877 stabilizes the inactive and active structures, while removal of the phosphoryl group
results in an increase in the free energy.

It is noteworthy that differences in specific interactions between phosphorylated and
unphosphorylated systems identified in the FEP trajectories also appear in our hydrogen
bonding analysis. In the active structure, replacement of Y877 with pY877 produces
several new hydrogen bonds, including R844-Y877, K883-Y877, and R868-Y877, all of
which bridge the C- and N-terminal ends of the A-loop.

Toward the end of the

transformation, the main-chain oxygen of Y877 pairs with F899, which is consistent with
the pattern of hydrogen bonds highlighted in the previous section. The perturbation of
Y877 into pY877 in the inactive system effects formation of additional hydrogen bonds,
such as R844-Y877 and K883-Y877, which link the ends of the A-loop as they do in the
active system. Thus, the FEP results are consistent with our hydrogen bonding analysis,
validating the robustness of the identified interactions despite the differences in
simulation protocols.

3.4 Discussion
Given the involvement of the ErbB receptor tyrosine kinases in a wide range of human
diseases, including schizophrenia and various types of cancer
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, it is imperative to

understand their mechanism of activation at the molecular level. In this Chapter, we have
investigated the mechanisms important in ErbB kinase domain regulation, as well as the
molecular basis for HER2’s unique mode of activation. Our MD simulations provide us
with a framework for studying the atomistic behavior of the ErbB kinase domains in both
monomeric and dimeric contexts. We have characterized the global motions of the ErbB
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systems using principal component analysis and rationalized the differences in
fluctuations in terms of specific interactions, namely, salt bridges and hydrogen bonds.
Specifically, the existence of an extensive bonding network among the four key domains
of the kinase in its active state correlates with the concerted motions of the four main
loops as revealed by the PCA. The tight coupling of the A-loop and C-loop in the active
system is especially pronounced, leading us to postulate the significance of the
interaction in alignment of the catalytic residues. We also identify several commonalities
in hydrogen bonding patterns among the three ErbB kinases in the A-loop, C-loop, and
αC helix. Despite these shared trends in hydrogen bonds in the key activation loops, the
bonding pattern in HER2 differs markedly in the αC-β4 loop. HER2 lacks many of the
hydrogen bonds that occur in the αC-β4 loop in EGFR and HER4 due to the presence of
the hydrophobic patch of residues in the αC-β4 region. The unique hydrogen bonding
network in the αC-β4 loop in HER2 is relevant to the putative hydrophobic interaction
between HER2 and the molecular chaperone Hsp90. The association between HER2 and
Hsp90 serves a regulatory role in preventing HER2 dimerization and subsequent
activation 30. Unlike the other ErbB family members, the extracellular domain of HER2 is
poised for dimerization in the absence of ligand binding 27, rationalizing the requirement
for such tight regulatory mechanisms. The decrease in hydrophobic character and
concomitant increase in the degree of hydrogen bonding in the αC-β4 region of several
clinically identified HER2 mutants alters the mutant HER2 bonding patterns in similarity
to those of EGFR and HER4. Such mutations are expected to be activating by disrupting
the HER2-Hsp90 association.
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We extended our analysis of global kinase motions and hydrogen bonding
patterns to several different ErbB dimer systems, including a HER2-EGFR heterodimer,
as well as EGFR and HER4 homodimers. Molecular dynamics simulations of the dimeric
systems result in destabilization of several bonds present in the inactive monomeric
structures, including interactions in the αC helix, as the αC helix comprises much of the
dimerization interface for the activated kinase. The disruption of the hydrogen bonding
pattern in the dimers provides a rationale for the observed conformational rearrangement
of the αC helix toward the active state. Furthermore, we identify several interactions that
persist throughout the dimeric trajectories of the inactive states and are hence candidates
for further investigation through free energy methods such as umbrella sampling
simulations, as the molecular environment surrounding such residues may define the
pathway for conformational change and the associated barriers to activation. Owing to
the fact that the residues involved in the N- and C-lobe faces of the dimer are essentially
invariant among the ErbB family members, our results can in principle be extended to
predict the behavior of other ErbB dimer combinations.
We have also investigated the effect of phosphorylation of the regulatory tyrosine
residue, Y877 in HER2, on kinase activation. The results of our FEP simulations support
the hypothesis that phosphorylation of Y877 in HER2 is unlikely to provide a dominant
stimulus for activation. However, our structural and hydrogen bonding analyses of the
MD trajectories strongly suggest that phosphorylated Y877 contributes to the network of
fastening bonds in the A-loop by bridging the stabilizing residues at the C- and Nterminal ends of the loop, thereby considerably altering the conformational environment
surrounding the A-loop. Consistent with these findings, although phosphorylation of the
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analogous A-loop tyrosine residue Y845 is unnecessary for catalytic activity of EGFR, it
is known to significantly alter downstream signaling events, including activation of
STAT5b and EGF-induced DNA synthesis

15, 90

. Likewise, Ishizawar et al. have

postulated a role for phosphorylated Y877 in enhancing HER2-HER3 heterodimer
formation by potentially changing the conformation of the kinase and engaging other
molecules 78. Hence the involvement of phosphorylated Y877 in the network of fastening
interactions in the A-loop and the resultant alteration in the conformational environment
may influence recruitment of signaling mediators involved in mitogenesis and other
downstream processes. We also note that the residues involved in fastening the A-loop,
which include R897, R898, and F899 in the αF helix, warrant further investigation, as
mutation of these residues may destabilize the fastening bonding network and this effect
may further elucidate the role of Y877-phosphorylation in HER2. These predictions can
be experimentally tested and validated using HER2 mutagenesis assays.
The protein kinase genes are among the most frequently mutated in human
cancers, and several ErbB kinase domain mutants have been determined. Our simulations
provide insight into the effect of these mutations in the αC-β4 loop region of the ErbB
kinases through assessment of structural dynamics and hydrogen bonding patterns in the
kinase domains. Our results are consistent with a large body of experimental data 45, 72, 141,
202, 208

and provide a framework for highlighting the most crucial bonding interactions in

the monomeric and dimeric ErbB systems. Elucidation of the molecular regulatory
mechanisms will help establish structure-function relationships in the wildtype ErbB
kinases as well as predict mutations with propensity for constitutive activation. Such
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molecular variants in the EGFR, HER2, and HER4 RTKs are known to profoundly
impact specific therapies targeting ErbB-mediated cancers.
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Chapter 4
Multiscale Modeling of the Anti-cancer Role of the
HER4 Tyrosine Kinase: Molecular Scale
In Chapters 4 and 5, we present a multiscale model of another member of the ErbB
family, HER4/ErbB4. Chapter 4 focuses on molecular scale simulations of dimermediated activation in HER4, in order to elucidate the mechanisms by which the WT
kinase is regulated and activated, and to rationalize the effects of several HER4 somatic
mutants which have recently been discovered in a subset of cancer patients. Chapter 5
translates our molecular scale results of HER4 kinase activity into a cellular pathway
model of WT versus mutant HER4 signaling, in which the WT and mutant cells trigger
divergent signaling networks. Chapter 5 also discusses several experimental studies
which we have performed in a HER4-stimulated mammary epithelial cell line, in support
of our computational predictions.

4.1 Introduction
Whereas deregulation of the ErbB kinases is associated with many types of human
cancer, HER4 kinase has recently been shown play an anti-carcinogenic role in certain
tumors48. One mechanism by which HER4 is thought to impede tumor progression in
mammary cells is through the activation of genes that promote cellular differentiation and
inhibit proliferation, in effect, steering the cell away from a program of uncontrolled
growth and instead toward a program of differentiation

80, 187

. HER4 is unique from the
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other ErbB receptors in that binding of the ligands neuregulin (NRG) or heparin-binding
epidermal growth factor (HB-EGF) induces proteolytic cleavage of the 80 kDa kinase
domain, termed the s80 or soluble cleavage product, and binding of s80 to the
transcription factor (TF) STAT5a. The s80-STAT5a complex then translocates to the
nucleus to regulate expression of genes involved in mammary cell differentiation
pathways, including the milk protein genes β-casein and whey acidic protein (WAP)117,
197

. Hence studies are underway to determine the molecular pathways that are stimulated

by the soluble HER4 protein, particularly the network of transcriptional regulatory
elements that are activated upon nuclear translocation of HER4 and STAT5a. Delineation
of the transcriptional regulatory network associated with HER4/STAT5a activity would
enable the exploitation of the pathway for targeting of malignant cells. Specifically,
activation of HER4 signaling in aggressive breast tumors would present a novel
therapeutic approach to suppress growth of these malignancies.
The HER4-mediated proliferation-to-differentiation switch in mammary cells may
be encoded in terms of differential spatial and temporal regulation of HER4 activity. The
phenotypic response of the mammary cell to HER4 stimulation is associated with a
specific subcellular context, and the shuttling of HER4 among various compartments may
determine the cellular decision to proliferate or differentiate. For instance, the membranebound HER4 kinase may dimerize with HER2 to produce a mitogenic response in the
mammary cell, whereas the soluble HER4 domain (s80) translocates to the nucleus to
effect cellular differentiation. Hence a comparison of HER4 activity at each relevant
spatio-temporal scale would aid in delineation of the mechanisms by which the
proliferation-to-differentiation switch is regulated.
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Despite the unique role played by wild-type (WT) HER4 in certain tumor types,
several somatic mutations in the kinase domain of HER4 were recently discovered in
patients with breast, gastric, colorectal, and non-small cell lung cancer171. A study by
Tvorogov et al.191 analyzed the basal and ligand-induced phosphorylation levels of the 9
HER4 kinase domain mutants in various cell backgrounds, and found that two of the
mutations, G802dup and D861Y, disrupt the catalytic activity of the HER4 kinase,
whereas the remaining mutations do not appear to have an effect on HER4
phosphorylation. The group discovered that, despite loss of kinase activity, the two
mutant HER4 receptors were able to heterodimerize with HER2 and signal through the
ERK and PI3K/AKT pathways. However, kinase activity of HER4 was required for
ligand-induced activation of the STAT5a differentiation pathway, and as a result, the
HER4 mutants were unable to activate STAT5a signaling or cell differentiation. Not only
were the two mutants unable to induce cell differentiation, but when over-expressed in a
breast cancer cell line, they actively suppressed the formation of differentiated acinar
structures, in contrast to wild-type HER4, which induced differentiation. Thus the HER4
mutants exhibit a selective loss-of-function phenotype which is biased toward
proliferative signaling pathways and against the cell differentiation pathway.
In this Chapter, we begin by simulating and analyzing a molecular model of the
WT HER4 homodimer, in order to elucidate molecular mechanisms of activation in the
WT kinase. We then apply the results of our WT simulations to help rationalize the
effects of the clinically-identified HER4 somatic mutants on the cell phenotype.
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4.2 Materials and Methods
4.2.1 Construction of the HER4 homodimer
The HER4 homodimer system was modeled on the structure of the HER4 dimer
published by Qiu et al.141. We modeled the receiver kinase as a HER4 monomer in the
inactive conformation, and the activator kinase as a HER4 monomer in the active
conformation. The structure was minimized to remove unfavorable contacts and
hydrogen atoms were added using the hbuild routine in CHARMM112. The dimer was
explicitly solvated with the buffering distance set to 15 Å for a total system size of
approximately 120,000 atoms. Sodium (Na+) and chloride (Cl-) ions were added to
achieve net electroneutrality of the system and an ionic strength of 75 mM. All Na+ and
Cl- ions were placed at least 8 Å away from any protein atoms and from each other.
Minimization and MD steps were performed for a total of 10 ns. A second dimer was
constructed in which the receiver kinase is in the active form, to use as the target
structure for the TMD simulations. This dimer was also simulated (MD) for 10ns.

4.2.2 Targeted molecular dynamics (TMD) simulations
TMD simulations were implemented in NAMD135. In TMD simulations, a chosen subset
of atoms is steered toward a target structure, while the other atoms may also move in
response to this structural change. Hence, this approach can simulate large scale
conformational transitions in biomolecules which are otherwise difficult or impossible to
realize using conventional MD simulations. The RMSD between the current structure and
the target structure was used to calculate an additional steering force in TMD simulations,
which was applied on every atom from the chosen molecular subset, and is calculated as
follows:
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RMSD(t) represents the RMSD, for a chosen molecular subset, between the current
structure and the reference target structure at simulation time t. RMSD0(t) is the target
RMSD value at simulation time t. The force constant, k, was tested for values ranging
from 0.5-20 kcal/mol/Å2, and ultimately, a value of 20 was chosen. N represents the
number of atoms included in the target subset. During optimization of our TMD
simulations, a variety of molecular subsets were tested, including all backbone atoms of
the receiver kinase or of the catalytic site only. Ultimately, a subset which included the
heavy atoms of the catalytic site was chosen. TMD simulations were run for 25 ns with a
time step of 2 fs. The conformational transition from the initial to the target structure was
determined by decreasing the value of RMSD0(t) as a function of the simulation time.
The value of RMSD0(t) was linearly decreased to 0 Angstroms during the 25 ns TMD
simulation. Upon reaching the target structure, MD simulations were run to allow the
system to fully relax into the target conformation.

4.2.3 Analysis of the TMD trajectories
Several types of analyses were performed on the TMD trajectories. Hydrogen bonding
analysis was performed in order to define those bonds which broke or formed during the
course of the TMD simulation. Hydrogen bonds were defined by a bond length cutoff of
3.4 Å and an angle cutoff of 150º. Bonds that fulfilled these criteria and were present in at
least 60% of the trajectory were tabulated in CHARMM. Salt bridges were defined as
hydrogen bonds occurring between an acidic and a basic residue and satisfying a bond
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length cutoff of 1.6 Å. All hydrogen bonds and salt bridges were also visualized in
VMD74 for the duration of the 10 ns simulation.
Ramachandran plots were constructed for key residues, in order to track any flips or
changes in the dihedral angles phi and psi. The phi and psi angles were computed for the
specified residues for each frame of the TMD trajectory, using VMD. The residues
chosen included R841, L843, S749, and F872, as these residues undergo bonding changes
during transition to the active conformation.
Root mean square deviation (RMSD) values were measured for the dimer undergoing
TMD, with respect to the active (target) structure and the inactive (starting) structure. The
RMSD was measured with respect to the backbone atoms of the catalytic site, and also
with respect to the entire receiver kinase, to gauge the progression of the TMD system
along the activation pathway.

4.3 Results
4.3.1 Simulation of the HER4 homodimer
Based on the asymmetric dimer interface observed in both the EGFR and HER4 crystal
structures, we constructed a HER4 homodimer system in which an inactive HER4
monomer serves as the receiver kinase and an active HER4 monomer serves as the
activator kinase (see Methods). We note that the activator kinase may be in either the
active or inactive conformation, as the dimer interface is the same for both
conformations. The dimer interface residues comprise portions of the C-lobe in the
activator kinase and segments of the N-lobe (including the juxtamembrane segment and
the αC helix) in the receiver kinase (Fig. 4.1). The dimer system was solvated and
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energy-minimized
minimized prior to TMD simulation (see Methods), to remove any unfavorable
contacts.

Figure 4.1.. The ErbB dime
dimer system.
The system consists of an activator kinase (in either the inactive or active conformation) and a
receiver kinase (in the inactive conformation). The inactive state is displayed in yellow, the
starting state for the TMD simulation is shown in ora
orange, and the fully activated
ivated state is in purple.
During activation, the most significant motions occur in the A
A-loop and αC helix. The A-loop
A
extends to its open, active state, and the αC helix shifts into the catalytic site.

Recently, the 37-residue
residue segment connecting the ki
kinase
nase domain to the ErbB
transmembrane domain, or the juxtamembrane (JM) domain, has been shown to play an
important role in the complete activation of the ErbB RTKs144, 185. Red Brewer et al.144
demonstrated that mutations in the C
C-terminal
terminal 19 residues of the EGFR JM domain
abolish EGFR activation. Furthermore, Thiel and Carpenter185 showed that the deletion of
the JM region results in signif
significant
icant loss of EGFR kinase phosphorylation. Although the
molecular mechanism underlying the activating role of the JM region is unknown, a
recent crystal structure of the EGFR kinase dimer144, which included the complete JM
domain, revealed that the JM region in the recei
receiver
ver kinase makes extensive contacts with
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the C-lobe of the activator kinase, essentially forming a latch that ‘cradles’ the activator
kinase to stabilize the asymmetric dimer interface. Although there have been several
reported TMD studies of the EGFR dimer38,

134

, none have included the JM domain;

rather, they have utilized EGFR structures in which the receiver kinase is truncated at the
N-terminus of the kinase domain. Thus, not only do we report the first (which we are
aware of) TMD study of the HER4 dimer, our study is also the first to include the crucial
JM region.
In addition to the TMD simulations, we also constructed and simulated two
control systems: 10ns molecular dynamics simulations of a HER4 dimer in which the
receiver kinase is in the activated state, as well as in the inactive state. The purpose of the
control simulations is to provide a frame of reference for analysis of any significant
motions or changes in bond patterns observed in the TMD simulations. No significant
motions were revealed for either control simulation, although the active dimer is more
stable than is the inactive dimer. A principal component analysis of the control system
trajectories revealed that the inactive dimer does move slightly toward the active
conformation, in that there is a dominant shifting motion of its αC helix into the active
site, with relatively large fluctuations (Fig. 4.2A). As in our previous simulations of the
EGFR dimer (Fig. 4.2B), the dimer interface provides a stimulus to shift the inactive
receiver kinase (mainly, the αC helix) away from the inactive conformation and toward
the active state. The A-loop, which is not positioned directly in the dimer interface, does
not globally shift during the control simulations, and most likely requires other
perturbations in order to transition to its open, extended state. Within the short time scale
of our MD simulations, the presence of the dimer interface is insufficient to fully activate
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the receiver kinase, an event which, in actuality, would occur on the order of milliseconds
to seconds.

Figure 4.2. PCA of the HER4 dimer.
PCA of the 10ns control MD trajectories for (A) the HER4 homodimer system and (B) the EGFR
homodimer system. The PCA was performed on the catalytic site (A-loop,
loop, P-loop,
P
C-loop, αC
helix) of the receiver kinase
kinase.. Motions along the first eigenmode are displayed by superimposing
several frames from each PCA trajectory. The structures are colored according to the RMSD,
where blue regions indicate small fluctuations and red regions ind
indicate
icate larger fluctuations. The
fluctuations are quantified according to the scale bar at top.

4.3.2 Optimization of TMD simulation restraints
As the catalytic sub-domains
domains undergoing the most pronou
pronounced
nced conformational shifts
during the transition from the inactive to the active state are the A-loop
loop and αC helix, we
included these regions in our set of TMD restraints. P
Previous
revious TMD studies of the EGFR
kinase38, 134 were biased solely toward these regions; however, other regions of the kinase
may also be important in the activation mechanism. To incorporate a more global view of
the allosteric activation mechanism, we extended our list of TMD restraints to include the
entire catalytic site. However, it is important to not over
over-constrain
constrain the system, and so we
allowed the remainder of the kinase, including the JM domain, to move freely. Additional
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degrees of freedom are allowed in that the activator kinase is also completely free to
move, as it provides the activation stimulus, but does not undergo any well-defined
conformational changes itself.
We experimented with several different sets of restraints for the TMD
simulations. The spring constant used to apply force to the dimer system (see Methods)
was varied from k=0.5-20 kcal/mol/Å2. In addition to optimizing the force constant, we
varied the set of targeted atoms. Specifically, we tested the following sets of target atoms:
all backbone atoms of the receiver kinase, heavy atoms of the A-loop and αC helix, alpha
carbons of the catalytic site, and backbone atoms of the catalytic site. Restraining the
heavy atoms of the catalytic site produced the most successful result in terms of
achieving the target conformation. We also tested the application of restraints to the JM
domain, but as it is a terminus, this resulted in overconstraint of the system. The TMD
simulation time was varied from 2-25ns. The longer the simulation and the smaller the
force constant, the more accurate the results, and so we tested several different
combinations of simulation time and force constant. We found that the minimum force
constant required for our large dimer system (approximately 120,000 atoms) was k=5
kcal/mol/Å2, which, following a 10ns TMD simulation, shifted the dimer by 1 Angstrom
toward the target conformation. Application of a slightly larger force constant, k=10
kcal/mol/Å2, resulted in a small improvement, shifting the dimer by about 2 Angstroms
toward the active conformation. However, in running these simulations longer than 1012ns, we did not see an improvement in the RMSD, suggesting that, using a force
constant of 5-10 kcal/mol/Å2, a prohibitively long simulation is required for such a large
dimer system.
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A force constant of k=20 kcal/mol/Å2 proved to be the minimum value required to
achieve the target conformation in a reasonable simulation time, 25ns. In order to gauge
whether the dimer had achieved its active state, we calculated the RMSD with respect to
the active dimer (target
target structure) and also analyzed the pattern of hydrogen bond
changes during the TMD simulation. For the k=20,, 25ns simulation, the final RMSD of
the backbone atoms of the receiver kinase with respect to the target structure was
approximately 1.2 Angstroms, w
whereas
hereas the receiver had moved approximately 3.6
Angstroms away from the starting (inactive) conformation (Fig. 4.3). Due to the flexible
nature of the A-loop and several other loop regions in the kinase
kinase,, we do not aim to attain
ann RMSD of 0 Angstroms
Angstroms. Rather, we focus on the key changes in the hydrogen bonding
pattern and the catalytic sub
sub-domain
domain conformations. We also ensure that the A-loop is in
its open, extended form, allowing for the binding of peptide and ATP.

Figure 4.3. Transition of the HER4 ho
homodimer system during the TMD simulation.
The RMSD is plotted for all backbone atoms of the receiver kinase, with respect to the active
(target) structure (blue)) and with respect to the inactive (starting) structure (red).
(
Results are
shown for the simulation
tion in which t=25ns and k=20 kcal/mol/Å2.
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4.3.3 Analysis of global changes during the TMD simulation
Upon optimization of the parameters and restraints for the TMD simulation, the TMD
trajectory was analyzed using several methods. First, global changes in the HER4 system
were assessed, to gain insight into the sequence of molecular events required to achieve
the target (active) conformation. Figure 4.4 tracks the RMSD of the backbone atoms of
the A-loop and αC helix, two of the major catalytic sub-domains in the HER4 active site,
during the progression of the 25ns TMD simulation. Relative to the active (target)
structure, the A-loop moves from an RMSD of approximately 14 to 4 Angstroms, and
relative to the inactive (starting) structure, it moves from an RMSD of 1 to 12 Angstroms
(Figure 4.4). The αC helix moves from 4 to 2 Angstroms away from the active structure,
and from 1 to 4 Angstroms away from the inactive structure. Interestingly, the αC helix
becomes closer to the active conformation (relative to the inactive conformation) at
approximately 18ns, whereas the A-loop becomes closer to the active conformation a bit
later, at 21-22ns (Figure 4.4). This order of events (the αC helix shifting before the Aloop) can partially be rationalized by the location of the αC helix within the dimer
interface, such that it is expected to be directly impacted by this stimulus (dimer
interface). We have also observed this sequence of molecular events for the EGFR dimer.
This mechanism may be unique to the ErbB kinases in that other kinase families, such as
Src, are thought to undergo the reverse order of events (A-loop moves before αC
helix205).
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Figure 4.4. Transition of the A
A-loop and the αC
C helix toward the active (target)
(targ
conformation during TMD
TMD.
The RMSD is plotted for the backbone atoms of the A
A-loop and αC
C helix, in reference to the
active structure (red)) and the inactive structure ((blue).

4.3.4 Analysis of local interactions during the TMD simulation
In order to translate the global pattern of sub
sub-domain
domain motion that we observe for the
TMD system into changes in specific, or local, interactions, we next analyzed the TMD
trajectory for hydrogen bond
bondss and salt bridges which may have broken or formed during
the conformational
onal transition to the active state. As the pattern of hydrogen bonds
maintaining the inactive state differs significantly from the bond pattern in the active
state, we expect to obser
observe
ve these changes during the course of the TMD. Table 4.1
summarizes all bonds which have either broken or formed during the transition from the
inactive to the active conformation
conformation. The E743-K726
K726 salt bridge, which is conserved
among the active ErbB kinases and is required for the coordination of the α and β
phosphates of ATP, represents one of the key bonds which must form during kinase
activation. In the inactive state, there are two residues which sequester E743 and K726,
thus autoinhibiting kinase activation by preventing formation
ion of the key salt bridge.
bridge
These two ‘sequestering’ bonds are D
D836-K726 and R841-E743,
E743, which must break
during the activation process. Indeed, in our TMD simulation, these two bonds have
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broken, freeing the E743 and K726 residues to form the crucial salt bridge (Table 4.1 and
Fig. 4.5). Figure 4.5 tracks the change in bond length for the R841-E743 sequestering
bond during the course of the TMD simulation. In comparison to the 10ns MD control
simulation (Fig. 4.5, top panel), in which the R841-E743 bond spontaneously forms and
breaks during the course of the simulation, the bond successfully breaks (at t=18ns)
during the 25ns TMD simulation (Fig. 4.5, bottom panel). The Ramachandran plot in
Figure 4.6A tracks the change in the dihedral angles phi and psi for the R841 residue (see
Methods), revealing that the angle phi flips from a small negative value to a large positive
value during the conformational transition, facilitating breakage of the R841-E743 bond.
Other interactions which are severed during the TMD simulation include E730-K856,
which allows the E739-K856 bond (between the A-loop and αC helix) to form, and the
E847-R870 bond in the A-loop.

Bond
W712-E692
R695-Q768
E715-K689
P722-L773
K726-D836
L728-T766
E730-K856
E739-K856
E743-R841
E743-K726
S749-N681
R817-D846
E847-R870

TMD result
Broken
Formed
Broken
Formed
Broken
Broken
Broken
Formed
Broken
Formed
Weakened
Weakened
Broken

Table 4.1. Bonds formed or broken during the HER4 TMD simulation.
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Another important interaction is L843-R813,
R813, which does not appear in the inactive dimer,
but forms during the TMD simulation. This bond couples the A
A-loop
loop and C-loop
C
in the
active state, and helps to maintain the A
A-loop
loop in its open, extended form. In fact, several
bonds bridging the A-loop
loop an
and C-loop
loop occur in the active kinase, and can be considered
‘fastening bonds’, in that they stabilize the A
A-loop
loop in its activated conformation. Several
of these interactions
actions were observed to form during our TMD simulation. Figure 4.6B
depicts the Ramachandran
an plot for the L843 residue, in order to track any changes in the
dihedral angles phi and psi. It is apparent from the plot that the angle phi
ph flips from a
small negative value to a large positive value during the course of the TMD simulation,
facilitatingg the formation of the L843
L843-R813 fastening bond.

Figure 4.5. Bond distance for the E743
E743-R841 salt bridge during the TMD simulation.
The top panel displays the bond distance in the inactive dimer (10ns MD control simulation), in
which the bond spontaneously
ously breaks and forms during the course of the simulation. The bottom
panel displays the bond distance in the 25ns TMD simulation; at t=18ns,
=18ns, the bond breaks.
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In addition to the bonding pattern in the receiver kinase changing in response to the TMD
restraints, several inter-dimer
dimer bonds ((i.e., bonds between the receiver and activator
kinases) also broke during the 25ns TMD. Specifically, the D742
D742-K917
K917 bond, which
occurs between the αC
C helix of the receiver kinase and the C
C-lobe
lobe of the activator kinase,
is significantly
icantly weakened. The S764
S764-E896 bond
ond fully breaks during the TMD simulation.
Such inter-dimer bonds have not been explored in previous TMD simulations of the
EGFR kinase, yet may be worthwhile to investigate further, as interactions between
previously-overlooked
overlooked regions of the receiver and
d activator monomers may play a role in
kinase activation.

simulation
Figure 4.6. Ramachandran plots for key residues during the 25ns TMD simulation.
(A) R841, (B) L843, (C) S749, and (D) F872. Each data point marks a time point in the TMD
simulation; in this way,, any flipping of the dihedral angles can be detected.
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The bonding pattern in the JM region of the receiver kinase also shifts during the course
of the TMD simulation. The following bonds change: N681-S749 is weakened, E690S764 forms, and K689-E715 and E692-W712 break. In addition, one bond forms
between the JM domain of the receiver kinase and the C-lobe of the activator kinase:
L685-Q903. Figure 4.6C displays the Ramachandran plot for S749, revealing that the phi
angle flips from a negative to a postive value. Cross-referencing these JM residues with
the list of amino acids shown to abolish EGFR phosphorylation in the scanning alanine
mutagenesis assay performed by Red Brewer et al.144, we discovered significant overlap.
In particular, N681 (N676 in EGFR) and L685 (L680 in EGFR) both participate in JM
interactions that are altered during our HER4 TMD simulation, and mutation of the
analogous residues in EGFR was shown to abrogate kinase activity144. Thus our results
for the HER4 dimer are in agreement with the experimental results, which emphasize the
importance of the JM region as an important component of the activation mechanism in
the ErbB kinases (at least, EGFR and HER4).

4.3.5 Comparison to TMD of the EGFR dimer
In order to assess whether the TMD pathway is conserved across other members of the
ErbB family, we performed TMD simulations of an EGFR homodimer, based on the
EGFR crystal structure208. The full study is detailed in our previous work, but we will
highlight the most relevant points here, for comparison with our HER4 TMD results. The
EGFR TMD simulations were performed by applying the RMSD of the backbone atoms
of the αC-helix and the A-loop as the reaction coordinate (χi). The activation pathway
was divided into 20 smaller windows and each segment of the window was simulated
individually to ensure adequate sampling. To enhance the sampling of low probability
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events, a harmonic restraint
aint of constant k=20 kcal/mol/
kcal/mol/Å2 was applied along the reaction
coordinate, χi.
The TMD study of the EGFR dimer captured the transition of the kinase from the
inactive
ve to the active conformation. The PCA of the TMD trajectory
jectory is depicted in Figure
4.7A. The TMD study did not completely sample the activation pathway,
pathway though we
observed severall significant molecular events, including the extension of the A-loop
A
and
the rotation of the αC
C helix into the act
active site (Fig. 4.7A). Several specific interactions
were conserved across the EGFR and HER4 dime
dimerr TMD simulations, including breakage
of the E738-K836
K836 salt bridge (EGFR numbering), the formation of the crucial E738K721 salt bridge,, and the formation of th
thee fastening bonds between the A-loop
A
and Cloop. In similarity to the HER4 TMD results
results, the data for the EGFR TMD strongly
suggested that the αC helix shifts before the A
A-loop, contrary to the pathway mapped out
for the Src kinase Hck205. Despite
espite several differences in bonding events, the major
molecular events occurring in the HER4 TMD simulation are conserved in EGFR.
EGFR

Figure 4.7. TMD of the EGFR dimer.
(A) PCA of the EGFR dimer TMD simulation. The active (target) structure is shown in orange,
the inactive (starting) structure is in green, and the dimer undergoing TMD is colored according
to RMSD value (in red/white/b
red/white/blue).
lue). The PCA motions are overlaid sequentially, where red
regions indicate large motions and blue regions indicate smaller motions. The activator kinase is
shown in yellow. (B) The TMD pathway for the EGFR dimer,
mer, showing the transition from the
inactive state toward the active state.
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4.3.6 Rationalizing the effects of the HER4 somatic mutants
As discussed in Section 4.1, two of the nine clinically-identified HER4 somatic mutants
exhibit a selective loss-of-function phenotype in terms of the downstream signaling
pathways which are preferentially activated. Specifically, the mutants signal through the
proliferative ERK and PI3K/AKT pathways but not through the STAT5a differentiation
pathway. To provide insight into the molecular mechanisms by which the HER4 mutants
exert their preferential signaling effects, we assessed the mutants, D861Y (biochemical
numbering is D836 and will be used henceforth) and G802dup (biochemical numbering is
G777 and will be used henceforth), in the framework of our WT HER4 simulations. We
first constructed the mutant structures in MODELLER, using our equilibrated WT HER4
structure as the template. Energy minimization was performed in MODELLER to remove
any unfavorable contacts, and nearest neighbor amino acids were allowed to optimize
their positions. The D836Y mutation is located in the DFG motif, a highly conserved
amino acid segment which is positioned at the N-terminal end of the A-loop in many
eukaryotic kinases, and is critical for efficient phosphotransfer. Based on our WT HER4
simulations and our mutant D836Y structure, it is apparent that in the WT kinase, D836
forms a crucial set of interactions with N823 and D818 (C-loop), the catalytic aspartic
acid which deprotonates the hydroxyl group of the substrate tyrosine residue. The bulky
tyrosine side chain in the D836Y mutant appears to disrupt these interactions, which are
key in orienting the peptide substrate for phosphoryl transfer; thus the catalytic activity of
the kinase is predicted to be abrogated. Furthermore, in our TMD simulation of the WT
HER4 dimer, D836 sequesters the key activating salt bridge by bonding with K726, an
interaction which is released in the active kinase. Thus D836 serves important roles in
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both the inactive and active kinase conformations.
G777 forms part of the ATP-binding pocket in the HER4 kinase. Our structural
mutant model revealed that the G777dup mutation perturbed the relative orientation of
the energy-minimized neighboring residues, including H776, C778, and L779.
Furthermore, other neighboring residues which were perturbed played key roles in our
TMD simulation of the WT kinase. In particular, L773, which contributes to the ATPbinding pocket and is displaced in the G777dup mutant, bonds with P722 during the
TMD simulation of the WT HER4 kinase. Although ATP is not explicitly included in our
models, the disruption of the ATP-binding pocket introduced by the G777dup mutation is
expected to significantly impair the proper docking of ATP into the catalytic site. Thus
our simulations help to predict, at molecular resolution, the specific structural
perturbations which are likely to be introduced by the D836Y and G777dup mutants. Due
to the disrupted kinase activity of the HER4 mutants, they are unable to activate STAT5a
(which requires HER4 kinase activity). Thus there is a bias toward the cellular
proliferative signaling pathways which are induced by HER4 and ErbB heterodimers.
We also examined the two mutations in the context of the HER4 dimer interface.
Our WT simulations confirmed that the mutations are unlikely to disrupt dimerization of
HER4 directly, due to their position relative to our simulated dimer interface. The
message supported by our simulations is that the mutants abolish kinase activity but not
dimerization of HER4, a hypothesis which is underscored by the experiments of
Tvorogov et al.191. Although the effects of these mutants may be predicted through
analysis of the crystal structure of the HER4 homodimer, this gives only a static picture
of the impact of such perturbations. Thus our HER4 simulations provide a dynamic
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picture of the crucial roles played by D836 and G777 in the WT kinase activation
mechanism.

4.4 Discussion
In this chapter, we analyzed the WT activation pathway for the HER4 kinase through
simulations of a HER4 homodimer system. The simulations highlighted key molecular
interactions which we predict are important in the HER4 activation mechanism.
Specifically, we first assessed global patterns which emerged from simulation of the
HER4 dimer system. We discovered that the order of events, in terms of motions of the
individual catalytic sub-domains, involved the conformational shifting of the αC helix
before the A-loop, which can partially be rationalized by the location of the αC helix in
the dimer interface, such that it is expected to be directly impacted by this stimulus
(dimer interface). We also observed this sequence of molecular events for the EGFR
dimer. This mechanism may be unique to the ErbB kinases in that other kinase families,
such as Src, are thought to undergo the reverse order of events (A-loop moves before αC
helix). This difference may partially be due to the fact that phosphorylation of the A-loop
tyrosine residue is required for the activation of Src kinase, whereas it does not seem to
be necessary for ErbB kinase activation. Hence phosphorylation of the A-loop tyrosine
residue in Src kinase may induce the A-loop to move earlier in the activation process.
The global motions of the HER4 dimer system were then transduced into local
interactions through a hydrogen-bonding analysis of the dimer TMD trajectory. The
bonding analysis, which identified key interactions which either broke or formed during
the TMD simulation, highlighted a conserved auto-inhibitory mechanism. The E743K726 salt bridge, which is conserved among the active ErbB kinases and is required for
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coordination of the α and β phosphates of ATP, represents one of the key bonds which
must form during kinase activation. In the inactive state, there are two residues which
sequester E743 and K726, thus auto-inhibiting kinase activation by preventing formation
of the key salt bridge. These two ‘sequestering’ bonds are D836-K726 and R841-E743,
which must break during the activation process. Indeed, in our TMD simulation, these
two bonds have severed, freeing the E743 and K726 residues to coordinate the crucial
salt bridge. Additional local interactions which were highlighted include the formation of
specific bonds which couple the A-loop and C-loop, such as L843-R813, helping to
‘fasten’ the A-loop in its open, extended conformation.
In addition to the bonding pattern in the receiver kinase changing in response to
the TMD restraints, we also identified several inter-dimer bonds (i.e., bonds between the
receiver and activator kinases) which broke during the TMD simulation, including the
D742-K917 bond, which occurs between the αC helix of the receiver kinase and the Clobe of the activator kinase, and the S764-E896 bond. Moreover, the bonding pattern in
the JM region of the receiver kinase shifts during the course of the TMD simulation, a
result which is in agreement with previous experimental studies demonstrating that the
JM domain is a crucial contributor to the kinase allosteric activation mechanism144, 185.
These inter-dimer and JM domain interactions have not been explored in previous
simulations of the EGFR kinase, yet our results indicate that they warrant further
investigation, in order to piece together the complete activation pathway of the ErbB
kinases.
We then applied the results of our WT analysis to rationalize the effects of two
clinically-reported HER4 somatic mutations, D836Y and G777dup. We first constructed
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the mutant structures in MODELLER, using our equilibrated WT HER4 structure as the
template. Based on our WT HER4 simulations and our mutant D836Y structure, we
found that the D836Y mutation disrupted interactions with the catalytic base in the Cloop, which is crucial for effective phospho-transfer. Similarly, the G777dup mutant
perturbed the relative orientation of key residues in the ATP-binding pocket of HER4.
We were able to cross-reference specific perturbed residues with bonds that were broken
or formed during our TMD simulation of the WT HER4 kinase, underscoring the
importance of D836 and G777 in the activation of the WT kinase. Our results confirmed
the effects of the mutants on disruption of the catalytic site, and predicted resultant kinase
impairment. However, as the mutants retain the ability to dimerize with other ErbB
kinases, there is a bias toward cellular proliferative signaling and away from the
STAT5a-mediated differentiation pathway.
The HER4 mutants are unique among the ErbB kinases in that similar mutations
have been reported in EGFR and HER2, yet these mutations confer a gain-of-function
phenotype for EGFR and HER2

111, 131

. Specifically, tumors expressing these mutant

EGFR and HER2 RTKs demonstrate increased ErbB phosphorylation and kinase activity.
In addition, these gain-of-function mutations in EGFR and HER2 confer sensitivity of
tumors to specific TKIs, suggesting that these tumors have become addicted to signaling
through the mutant ErbB kinases. The mechanism by which these EGFR and HER2
mutants enhance ErbB signaling is thought to be through disruption of specific autoinhibitory interactions in the hydrophobic core of the kinase. By contrast, similar
mutations in HER4, which we have analyzed in this chapter, result in a selective loss-offunction phenotype, by abolishing HER4 kinase activity but not dimerization.
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Furthermore, these HER4 mutants do not demonstrate sensitivity to specific TKIs191, as
do the analogous EGFR and HER2 mutants.
Based on our hypotheses regarding the HER4 mutants, parallels can be drawn to
themes which emerged from our multiscale study of the HER3 kinase (see Chapter 2). In
particular, we have shown, through our multiscale studies of the HER3 and HER4
kinases, that ErbB kinases devoid of intrinsic kinase activity are not necessarily benign in
terms of their role in cell signaling and induction of cancer. Indeed, although the kinase
activity of the ErbB RTKs plays a crucial function in cell signaling, there are other,
equally important roles performed by the ErbB kinases, which allow for participation in
signaling despite lack of catalytic activity. In the case of HER3 kinase, we found that,
although HER3 exhibits relatively weak catalytic activity in comparison to the other
ErbB family members, it plays a key role in the development of drug resistance to certain
TKIs, due to its ability to synergize with other signaling processes in the cell (such as
upregulation of HER3 expression) to amplify its weak signal. In the case of HER4, the
kinase-dead HER4 somatic mutants retain the ability to induce proliferative signaling,
due to their ability to dimerize with other ErbB RTKs. Indeed, the various activities of
the ErbB kinases complement each other to produce a holistically functioning signaling
unit, thus compensating for any deficiencies in the individual ErbB proteins. In certain
tumor cells predisposed to uncontrolled signaling, this otherwise advantageous
evolutionary characteristic of the ErbB system can have deleterious consequences, as we
have illustrated in this Chapter focused on the HER4 somatic mutants.
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Chapter 5
Multiscale Modeling of the Anti-cancer Role of the
HER4 Tyrosine Kinase: Cellular Scale
In Chapter 4, we focused on the molecular mechanisms underlying the activation of the
HER4 kinase dimer, and rationalized the effects of two clinically-identified HER4
somatic mutants from the perspective of our WT HER4 simulation. In Chapter 5, we
translate our results into a cell signaling model representing the two divergent
(‘branching’) networks induced by the WT and mutant HER4 kinase: the JAK2/STAT5a
and PI3K/AKT pathways, respectively, in order to elucidate the parameters governing the
selection of one branch versus the other. As the PI3K/AKT signaling branch has been
extensively modeled, yet the HER4-mediated JAK/STAT branch has not, we undertake
experimental assays of HER4 signaling in a murine mammary epithelial cell line, HC11,
in order to provide parameters and more fully characterize the JAK/STAT branch of the
HER4 signaling pathway.

5.1 Introduction
As discussed in Chapter 4, several studies have indicated an anti-cancer role for the
HER4 kinase in various types of cancer, especially breast cancer, through steering of the
mammary tumor cells toward a program of cell differentiation and away from a program
of uncontrolled cell proliferation48,

122, 124, 177

. Several somatic mutants recently

discovered in HER4 abrogate this ability of HER4 to stimulate cell differentiation, and
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instead bias signaling toward various proliferative pathways, such as PI3K/AKT191. Thus
a better understanding of the molecular parameters governing the cell differentiation
pathway induced by HER4 will allow for potential modulation of this pathway in the
treatment of certain ErbB-driven cancers.
To

quantitatively

investigate

this

‘branched’

signaling

pathway

(i.e.,

PI3K/AKT/proliferation versus JAK2/STAT5a/differentiation) in HER4-stimulated
mammary cells, we present a signaling model of WT versus mutant HER4 induction. As
the PI3K/AKT signaling branch has been extensively studied and modeled, yet the
HER4-induced JAK2/STAT5a branch has not, we undertake experiments in a HER4stimulated mammary epithelial cell line, HC11, in order to more fully characterize the
JAK/STAT branch of the HER4 signaling pathway. HC11 is a murine mammary
epithelial cell line derived from the mammary gland of a female Balb/C mouse at midpregnancy, and has been extensively employed as an ex vivo model of mammary cell
differentiation in response to various hormones and ligands. Although the mammary
differentiation pathway has been investigated in response to various hormones and
ligands, it has not been well-studied in response to HER4. Indeed, to date, only a few
studies which examine the role of HER4 in STAT5-mediated mammary cell
differentiation have been performed

122, 197

. In these studies, it was demonstrated that

ligand-induced activation and phosphorylation of HER4 results in phosphorylation of
STAT5a, an event which is mediated (either directly or indirectly) by JAK2. Thus HER4
performs several different functions in terms of activating the JAK2/STAT5 pathway: it
is required for STAT5a phosphorylation (either directly or indirectly), and also to
chaperone the activated STAT5a dimer into the nucleus197. Indeed, these studies revealed
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that blocking either the kinase activity of HER4 or the ability of HER4 to cleave from the
cell membrane abrogated STAT5a nuclear translocation and stimulation of differentiation
genes122.
These same studies highlighted a role for crosstalk between the HER4 pathway
and other signaling cascades in the promotion of mammary cell differentiation.
Specifically, the prolactin (PRL) pathway was shown to synergize with the HER4
pathway to produce a greater level of STAT5a activation and gene expression than that
observed in either pathway independently123. Interestingly, knock-down of HER4
expression (using siRNA) or kinase activity resulted in a significant reduction of PRLmediated STAT5a phosphorylation and gene expression. Indeed, it was shown that the
PRL pathway critically depends upon HER4 for complete induction of STAT5a and
mammary differentiation.
Given the crucial role of HER4 expression and kinase activity in full induction of
the JAK2/STAT5a mammary differentiation pathway, we combine the results of our
HER4 systems model and experiments to more fully characterize this signaling network,
with the ultimate aim of motivating the modulation of this pathway for treatment of
specific ErbB-driven cancers.

5.2 Materials and Methods
5.2.1 Systems model of WT versus mutant HER4 signaling pathways
The computational signaling model was based on modules from two published signaling
models: the PI3K/AKT signaling branch was based on the model by Schoeberl et al.
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,

and the JAK2/STAT5a signaling branch was based on the model by Yamada et al.204.
Mass-action

reactions

describing

ligand-induced

ErbB

receptor

homo-

and
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heterodimerization, receptor internalization and degradation, constitutive dimerization,
and activation were included. The PI3K/AKT model was modified to include HER4
dimers (the original model excludes HER4, as HER4 expression levels are low in the
cancer cell lines on which the model is based). Hence all four ErbB RTKs are included in
the model, and allowed to dimerize in response to stimulation with either the neuregulin1β (NRG-1β) or HB-EGF ligands. The WT HER4 kinase was assumed to preferentially
induce the JAK/STAT5 pathway via HER4 homodimers, whereas the mutant HER4
kinase was assumed to preferentially induce the PI3K/AKT pathway via HER4
heterodimers. Levels of phosphorylated ppAKT and pSTAT5a nuclear dimers were
considered as read-outs of pathway activation for mutant and WT HER4 dimers,
respectively. All simulations were performed in MATLAB 7.10 (MathWorks, Natick,
MA).

5.2.2 HC11 cell differentiation assay
HC11 mammary epithelial cells, a kind gift from the Chodosh lab at UPenn, were grown
and maintained at 5% CO2 in complete medium (RPMI 1640, 10% FBS, 2 mM Lglutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 1 µg/mL hydrocortisone, 10
ng/mL murine EGF and 5 µg/mL insulin). To induce differentiation, cells were seeded in
6-well plates at a density of 2 x 104 cells/cm2 and allowed to grow to 100% confluence.
The cells were maintained at confluence for 2 days in serum-free/EGF-free medium to
induce competence. The competent cells were then stimulated for the indicated time
points (1-3 d) with ovine prolactin (PRL, 5 µg/mL; Sigma, St. Louis, MO), EGF (10
ng/mL; BD Biosciences, San Jose, CA), NRG-β1 (20 ng/mL; Peprotech, Rocky Hill, NJ),
HB-EGF (20 ng/mL; Peprotech, Rocky Hill, NJ), or a combination of PRL and HB-EGF
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to induce differentiation. Differentiation was monitored by following the formation of
blister-like structures or ‘domes’ that appear in confluent cultures and are thought to
result from fluid secretion. Throughout this Chapter, we refer to ‘Stage 1, Stage 2, and
Stage 3’ of the differentiation process: Stage 1 refers to growing the cells to confluence,
Stage 2 refers to maintaining the cells at confluence for 48h to induce a state of
competence, and Stage 3 refers to cell stimulation with HER4 ligand.

5.2.3 Reverse transcription-PCR
Total RNA from differentiated HC11 cells was prepared using TRIzol reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s instructions. Reverse
transcription was performed using Superscript II reverse transcriptase and oligo(dT)
primers (Invitrogen). PCR was performed using the following gene-specific primers:
mouse β-casein (forward 5’ ACT GTA TCC TCT GAG ACT G and reverse 5’ TCT
AGG TAC TGC AGA AGG TC, producing a 578-bp amplicon), mouse whey acidic
protein (WAP, forward 5’ TGC CTC ATC AGC CTT GTT CTT G and reverse 5’ CAG
CTT TCG GAA CAC CAA TGT TG, producing a 235-bp amplicon), and mouse keratin
18 as a housekeeping gene (forward 5’ CAT CGT CTT GCA GAT CGA CA and reverse
5’ GCT GAG ACC AGT ACT TGT CCA G, producing a 376-bp amplicon). RT-PCR
products were resolved on 2% agarose gels.

5.2.4 Transcription factor activation assays
Nuclear extracts from differentiated HC11 cells were isolated using the Nuclear
Extraction Kit from Active Motif (Carlsbad, CA). The nuclear extract was then used to
profile the activation of the STAT5a TF using the TransAM STAT family ELISA-based
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system from Active Motif (Carlsbad, CA). The TransAM system contains a 96-well plate
on which has been immobilized oligonucleotide containing the STAT consensus binding
site, 5’-TTCCCGGAA-3’. The active form of STAT contained in the nuclear extract
specifically binds to the oligonucleotide sequence, and primary antibodies are used to
detect specific subtypes of STAT, in our case, STAT5a. Subsequent incubation with an
HRP-conjugated secondary antibody provides a colorimetric readout of the relative
amount of activated STAT5a in the sample.
The activation of additional transcription factors, including glucocorticoid
receptor (GR) and C/EBP, were also tested. The consensus binding site for GR is 5’GGTACAnnnTGTTCT-3’, and for C/EBP, 5’-GCAAT-3’.

5.2.5 Quantitative real-time RT-PCR
The cDNA templates were synthesized from total RNA using SuperScript II reverse
transcriptase and oligo(dT) primer (Invitrogen, Carlsbad, CA). Quantitative PCR was
performed in a 96-well micro titer plate format on an Applied Biosystems 7300 real-time
PCR system (Applied Biosystems, Foster City, CA) using TaqMan Universal PCR
master mix and TaqMan Gene Expression Assays (Applied Biosystems) specific for the
genes of interest. Each experiment was repeated using three independent sources of RNA
and fold change relative to control was calculated and normalized to hPRT (endogenous
control) RNA levels. The PCR program used was: 2 min at 50 °C, 10 min at 95 °C, and
40 cycles of 15 sec at 95 °C, 1 min at 60 °C.
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5.3 Results
5.3.1 Branched signaling model of WT versus mutant HER4 pathways
The HER4 signaling model comprises two branches: PI3K/AKT, which is stimulated by
ErbB heterodimers and mutant HER4, and JAK2/STAT5a, which is induced by WT
HER4 homodimers. The PI3K/AKT pathway has been previously well-characterized and
modeled, whereas the HER4-JAK-STAT pathway has not (to our knowledge) been
modeled, and thus we delineate the major events here. Upon binding to NRG, HER4
(which can basally associate with JAK2, as has been shown experimentally123)
homodimerizes and becomes phosphorylated. The HER4-JAK2 complex then binds and
activates STAT5a, which becomes phosphorylated and dimerizes. We incorporate JAK2
into the model in this way to reflect that it is required for the HER4-mediated activation
of STAT5a, though the mechanism is currently unknown. The HER4-STAT5a dimer then
cleaves from the membrane and translocates to the nucleus; this event is built into the
model to reflect that STAT5a is unable to accomplish nuclear translocation without
HER4 as a chaperone197. STAT5a and HER4 dissociate in the nucleus, where STAT5a
induces expression of various genes. The only gene expression event which is explicitly
represented in our model is the expression of SOCS, which, upon translation into SOCS
protein, inhibits the JAK-STAT phosphorylation event in the cytoplasm. We note that
there are a total of four negative regulators present in the model, including SOCS, SHP-2,
which dephosphorylates the HER4-JAK2 complex, PPX, which represents the
cytoplasmic STAT5a phosphatase, and PPN, which represents the nuclear STAT5
phosphatase204.
Figure 5.1 displays time course plots for several model species, including
phosphorylated HER4-JAK2 dimer (‘pHER4-JAK2-dimer’), cytoplasmic STAT5
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(‘STATc’), phosphorylated nuclear STAT5a dimers (‘pStatn-pStatn’), and cytoplasmic
SOCS mRNA, in response to stimulation with 5 nM NRG. It is apparent that levels of
pHER4-JAK2 peak at approximately 30 minutes post-ligand stimulation, and levels of
phosphorylated nuclear STAT5a dimer peak at approximately 1 hour post-stimulation.
Due to the time lag during which STAT5a translocates to the nucleus and induces
expression of SOCS mRNA, levels of cytoplasmic mRNA do not peak until
approximately 2 hours post-induction.

Figure 5.1. Time courses for key species in the HER4-JAK-STAT model, 5 nM NRG.

In response to an in silico cell expressing WT HER4, the activation of HER4
homodimers and the JAK2/STAT5a signaling branch is increased, whereas the response
of the other ErbB dimers (and subsequent PI3K-AKT signaling) is significantly
dampened. Thus the JAK2/STAT5a cascade becomes the predominant signaling
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pathway. In response to ‘expression’ of mutant HER4, we tune the model parameters
such that signaling through HER4 homodimers is essentially turned off, and PI3K/AKT
is the predominant pathway induced by activated ErbB dimers (Fig. 5.2).

Figure 5.2. Time course plots for key species in the branched model for mutant HER4.

We find that our model recapitulates the major features of PI3K/AKT and JAK/STAT
signaling dynamics, including the importance of the STAT5 nuclear phosphatase in
governing both peak and steady state levels of nuclear pSTAT dimer. However, our
model is also the first (to our knowledge) to explicitly incorporate the HER4-JAK-STAT
signaling branch, which includes cleavage of the HER4 kinase domain from the
membrane and translocation of the HER4-STAT5a complex to the nucleus. We note that
additional rate constants, such as the rate of protease-induced cleavage of HER4, are not
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required for the current version of our model, but will be explicitly incorporated as they
become experimentally available.

5.3.2 Optimization of HER4-mediated HC11 cell differentiation assay
To more fully characterize the signaling dynamics in the HER4-mediated JAK/STAT
pathway, we performed RT-PCR in differentiating HC11 cells, a murine mammary
epithelial cell line (see Methods). Specifically, we assayed for the following read-outs of
HC11 mammary differentiation: levels of activated STAT5a and glucocorticoid receptor
(GR) as well as expression of the β-casein milk gene. STAT5a and GR are two key TFs
which are both activated during HC11 cell differentiation, and synergize on the β-casein
gene promoter.
Although transcription of the differentiation marker genes has not been
extensively investigated in HER4-stimulated HC11 cells, several studies have reported
expression of β-casein 24 to 72 hours after ligand stimulation, yet no detectable levels of
β-casein mRNA at earlier time points 123, 122. Indeed, we could not detect expression of βcasein at early time points (Figure 5.3) in response to the ligand NRG or HB-EGF.
Interestingly, we discovered that β-casein expression could be induced at earlier time
points only if FBS was kept in the cell medium during the differentiation process.
Whereas we had been serum-starving the cells initially, we increased the concentration of
FBS to 10% and observed β-casein production at several hours post-stimulation (Fig.
5.3). However, this gene expression is most likely due to other factors contained within
the FBS, and thus we omitted FBS from our differentiation protocol. In addition, we
noted that, although NRG and HB-EGF were unable to effect β-casein expression at early
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time points, prolactin
olactin (PRL) induced robust gene expression at all time points tested,
regardless of FBS concentration. Thus, despite sharing certain elements of signaling in
mammary cells, the PRL and HER4 pathways utilize distinct mechanisms to a certain
extent. We alsoo tested a range of ligand concentrations and time points, which are
discussed in the following sections, in order to optimize the differentiation assay.

Figure 5.3. RT-PCR of β--casein
casein gene expression in HC11 cells stimulated with NRG, HBHB
EGF, or PRL, in the presence or absence of FBS.
Several time points were assayed (2h, 5h and 6h are shown here) as well as several different
ligand concentrations. Keratin 18 was emp
employed as a housekeeping gene.

5.3.3 Glucocorticoid receptor is required for HER4
HER4-mediated
mediated signaling via
JAK2/STAT5a
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HER4 stimulation of the JAK2/STAT5a pathway has only recently been discovered; as a
result, much remains to be elucidated regarding the dynamics of this pathway and
interactions with other signaling cascades. Recently, Muraoka-Cook et al.123 highlighted
the synergy between the HER4 and prolactin (PRL) pathways. As summarized in Section
5.1, PRL-induced differentiation of mammary epithelial cells, in particular, HC11 cells,
has been studied extensively87, 88. It is postulated that, in vivo, interactions among the
PRL, insulin receptor, and HER4 pathways occur in a defined sequence during
differentiation of the mammary epithelium throughout pregnancy and lactation. In a
recent study in HC11 cells, Muraoka-Cook et al.123 revealed that the PRL and HER4
signaling cascades converge upon JAK2 to effect mammary cell differentiation. Indeed,
the group determined that in cells over-expressing kinase-dead HER4 or siRNA targeted
to HER4, PRL-induced differentiation was markedly diminished. They also found that
PRL induced phosphorylation of HER4 via JAK2, and that HER4 and PRL formed a
protein complex in stimulated cells. In addition, it was observed that stimulation of both
PRL and HER4 resulted in greater levels of activated STAT5a and β-casein expression
than either ligand alone, highlighting the synergy between the two pathways. Besides
PRL, it is currently unknown which other signaling cascades may be important in HER4induced mammary cell differentiation.
In our experimental studies, we included the steroid hydrocortisone (HC), which
signals through the glucocorticoid receptor (GR), in our HC11 differentiation assay, as
the few previous studies of HER4-mediated differentiation have included HC in the cell
growth medium (yet have not commented on its importance). However, we wondered to
what extent HC plays a role in the HER4 differentiation process. In cells stimulated with
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the HER4 ligand NRG-1β but not HC, no β-casein was expressed (Fig. 5.5). We also
tested the β-casein response upon stimulation with another HER4 ligand, HB-EGF, and
discovered the same result. However, upon addition of HC to the differentiation medium,
HER4 induced robust expression of β-casein (Fig. 5.4). HC was required in Stage 2 of the
differentiation process (see Methods) as well as Stage 3. Interestingly, HC was not
needed for PRL-mediated expression of β-casein, although it did enhance PRL signaling.
We therefore conclude that HC (and hence, GR), is required for HER4-mediated
differentiation of HC11 mammary cells: in particular, it is necessary for induction of cell
competence (Stage 2) as well as the early steps of differentiation (Stage 3).
Our results agree with previous ChIP studies which demonstrated the synergy
between PRL and GR87, 88. In these studies, HC11 cells were stimulated with PRL, and
various nuclear events were examined. In particular, the dynamics of assembly of various
transcription factors (STAT5, GR) on the β-casein promoter were analyzed. It was
discovered that stimulation with both HC and PRL was required for recruitment of the
RNA polymerase II to the β-casein promoter and for assembly of the complete
transcriptional activation complex, which included STAT5a (induced by PRL) and GR
(induced by HC). Our results suggest that HER4 operates via a mechanism similar to
PRL, in terms of synergizing with GR to effect maximal expression of β-casein. Indeed,
we find that HER4 cannot induce differentiation of HC11 cells on its own.
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Figure 5.4. RT-PCR of β-casein
casein gene expression in HC
HC11 cells at 48h.
NRG and HB-EGF
EGF require HC in order to stimulate gene expression, whereas only low
concentrations of PRL require HC. HC alone can stimulate β-casein
casein gene expression at
sufficiently high concentrations. NRG stimulates a higher level of β-casein
casein gene expression than
does HB-EGF. The bottom row (samples A
A-L)
L) represent the housekeeping gene, keratin 18.

5.3.4 Different ligands signaling through the same receptor trigger divergent
cellular outcomes
In the few previous studies of HER4
HER4-induced
induced differentiation of mammary cells, two
different HER4 ligands, NRG and HB
HB-EGF, were employed. Although HB-EGF
HB
can also
bind EGFR, thee previous studies had shown that in HC11 mammary cells, very little
EGFR is phosphorylated in response to HB
HB-EGF;
EGF; indeed, the predominant
phosphorylated ErbB receptor is HER4

122

. With this in mind, we tested the effects
effec of
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HB-EGF upon induction of STAT5a and β-casein expression, in order to compare to the
results obtained for NRG. Interestingly, we found that addition of HB-EGF resulted in
the opposite effect as stimulation with NRG: rather than stimulate β-casein expression,
HB-EGF inhibited β-casein (Figure 5.5). At 48h post-ligand stimulation, concentrations
as low as 10 ng/mL HB-EGF inhibited levels of β-casein. Higher concentrations of HBEGF, ranging from 50-500 ng/mL, resulted in a fold change in β-casein expression of
0.3-0.5. This result suggests that there is a basal level of β-casein expression in response
to HC alone (which is in the medium at Stage 2 of the differentiation process), and HBEGF suppresses the differentiation process, perhaps by biasing the cell toward an
alternative signaling pathway.
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Figure 5.5. qRT-PCR of β-casein expression levels for increasing ligand levels.
Error bars are reported as the result of 3 replicate samples, each run in duplicate.

By contrast, at 48h post-ligand stimulation, increasing concentrations of NRG induce
greater β-casein expression levels (Fig. 5.6). NRG concentrations ranging from 0.5-50
ng/mL result in a 1.3-2.5-fold increase in β-casein transcripts. Our result, which
demonstrates that NRG stimulates β-casein expression whereas HB-EGF inhibits it, is in
agreement with earlier work by Amin et al.3, 4. Amin et al. stimulated mammary

131

carcinoma cells with a variety of ErbB ligands, and showed that two different ligands
signaling through the same ErbB receptor could trigger different signaling cascades and
patterns of gene expression, and hence, different cellular decisions. In our study, we
cannot be certain that HB-EGF and NRG are solely stimulating HER4, as HB-EGF also
binds EGFR and NRG also binds HER3; however, based on earlier studies which showed
that HER4 is the primary ErbB receptor that is phosphorylated in response to the HC11
differentiation program123,
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, we can be sure that HER4 plays a dominant role in

response to these ligands in the context of HC11 cell differentiation. Thus, two
mechanisms by which NRG and HB-EGF may exert their opposing effects are:
stimulation of different ErbB heterodimer combinations (unlikely to be the primary
mechanism, based on earlier work), and recruitment of different signaling mediators via
the same receptor (HER4), potentially through specific allosteric changes upon receptorligand binding. Thus it is possible that the same receptor, through binding to different
ligands, can trigger divergent cellular outcomes (in this case, differentiation versus
inhibition of differentiation).

log(RQ)
(RQ=fold gene
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Figure 5.6. qRT-PCR results for β-casein in response to HB-EGF, NRG, PRL.
The first three samples (labeled -/-, -/+, and +/-, in reference to differentiation Stage 2/Stage 3)
refer to the presence (+) or absence (-) of HC in Stage 2 and Stage 3 differentiation medium.
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5.3.5 Interaction between PRL and HER4 signaling pathways
Based on the previous experimental studies, which suggested a synergistic interaction
between the PRL and HER4 signaling pathways in the differentiation of mammary
epithelial cells, we experimented with different ligand combinations. In response to
stimulation with both PRL and HB-EGF, we found that levels of β-casein decreased
(Figure 5.7), and this effect was amplified at lower PRL concentrations. Specifically, at a
constant PRL concentration of 10 ng/mL, increasing levels of HB-EGF decreased the βcasein signal; at 10 ng/mL PRL/10 ng/mL HB-EGF, the expression level was 10-fold
lower than that induced by 10 ng/mL PRL alone (Fig. 5.7). At 50 ng/mL PRL/10 ng/mL
HB-EGF, the expression level was 3.4-fold lower than that of PRL alone, and at 500
ng/mL PRL/10 ng/mL HB-EGF, the fold β-casein expression was halved, relative to 500
ng/mL PRL alone. Thus, the addition of HB-EGF has an inhibitory effect on PRLinduced cell differentiation, although this effect is dampened at higher PRL
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Figure 5.7. qRT-PCR results for β-casein expression in response to PRL and HB-EGF.
Top panel shows a constant PRL concentration of 10 ng/mL; bottom panel shows constant PRL
concentrations of 50 and 500 ng/mL.
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Interestingly, we obtained a similar result for stimulation with both PRL and NRG
(Figure 5.8). Addition of 50 ng/mL PRL/10 ng/mL NRG resulted in a 3.2-fold decrease
in β-casein levels, relative to 50 ng/mL PRL alone, and a combination of 500 ng/mL
PRL/10 ng/mL NRG resulted in a 1.4-fold decrease in β-casein expression. Although the
inhibitory effect of NRG on PRL-induced β-casein expression was not as pronounced as
the effect of HB-EGF, the inhibition was statistically significant. Thus our results suggest
that HER4 synergizes with the GR pathway yet antagonizes the PRL pathway, perhaps
due to a specific subpopulation of HC11 cells. Our data helps to parse the contributions
of these intersecting signaling cascades (HER4, PRL, GR), with the ultimate goal of
incorporating these interactions into a more complete model of HER4-induced mammary
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Figure 5.8. qRT-PCR for β-casein in response to a combination of PRL, NRG.
PRL is kept at a constant concentration of either 50 or 500 ng/mL. The addition of NRG inhibits
PRL-induced β-casein expression levels, although this effect is less pronounced than for HBEGF/PRL.

5.3.6 Temporal switch between two cellular decisions
In tracking the response of the HC11 cells to HER4 stimulation at various time points, we
came upon an intriguing observation. At early time points post-stimulation, NRG does
not exhibit any effect on β-casein expression, as we previously discussed. However, at
12h post-stimulation, we found that NRG actually decreased levels of β-casein, relative to
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the HC control (Fig. 5.9).
). At 24-48h post-stimulation,
stimulation, NRG began to increase β-casein
expression levels at sufficiently
ufficiently high ligand concentrations (Fig. 5.9). We reason that this
result has not been discovered previously, as the few studies examining the HER4H
STAT5a pathway focused on gene expression 24-48h post-stimulation.
stimulation. The mechanism
by which this ‘switch’ occurs is an area of future investigation, and may be due to
competition between different signaling pathways during the differentiation process.
Currently, our HER4 signaling model truncates at the point of activation and nuclear
translocation of STAT5a ((or AKT).. However, future iterations of the model will
incorporate this gene expression switch, which occurs on much longer time scales than
are currently represented in our model
model.

Figure 5.9. qRT
qRT-PCR time-course
course for NRG stimulation of HC11 cells.
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The time course of β-casein
casein gene expression ccorrelates
orrelates well with transcription
transcript
factor
activation dynamics for STAT5a and GR
GR. In our ELISA-based
based TF activation assay (see
Methods), we detected activity of both STAT5a and GR at various time points poststimulation (Fig. 5.10).. Fig
Figure 5.10A shows that, although levels of activated nuclear
STAT5a are highest 15-30
30 minutes post
post-stimulation,
stimulation, STAT5a activity persists until 24h
post-ligand stimulation. Similarly, the TF activation profile for GR (Fig. 5.10B)
5.10 shows
that levels
evels of activated nuclear GR are highest at early time points, but persist until 24h
post-stimulation. Our results agree with those of Kabotyanski et al. 87, 88, who assayed for
binding of various TFs (including STAT5a and GR) to the β-casein
casein gene promoter at
various time points following
wing stimulation with PRL
PRL,, and found that, although several of
the TFs assemble on the promoter at early time points, the RNA polymerase does not
bind and commence transcription until 24h post
post-stimulation.
stimulation. Thus, additional nuclear
events are required for assembly of the complete transcriptional apparatus and initiation
of β-casein expression.

Figure 5.10. TF activation assays for (A) STAT5a aand (B) GR.
The assays measure relative levels of activated TF in the nucleus, upon ligand stimulation. The
ratio of levels of activated STAT5a in a ligand
ligand-stimulated
stimulated cell versus an unstimulated cell is
recorded. For example, in panel (A), at t=15 min, theree is 4.9 times as much activated STAT5a in
cells stimulated with ligand relative to unstimulated cells. Both the STAT5a and the GR signals
persist until 24h post stimulation.
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5.4 Discussion
As HER4 may represent the only member of the ErbB family of RTKs to play an anticancer role in certain tumor contexts, it is crucial to quantitatively evaluate the signaling
dynamics of the HER4 pathway in the mammary cell environment. Here we have
translated the results from our structural studies of the WT HER4 kinase, which
corroborated the hypothesis that the HER4 somatic mutants abrogate the ability of HER4
to activate but not dimerize, into a cell signaling model of HER4 activity, which branches
into two different pathways: the JAK2/STAT5a network (induced by WT HER4) and the
PI3K/AKT cascade (induced by mutant HER4). We find that HER4 homodimers
predominantly induce the JAK/STAT5 pathway, although in an in vivo context, it is
likely that a combination of hormones and ligands (including PRL and HC) contributes to
the preferential stimulation of HER4 homodimers rather than other ErbB dimer
combinations, in response to ligands such as NRG (which can also bind to HER3). Our
model is able to recapitulate the major features of the PI3K/AKT and JAK/STAT
pathways, yet is the first, to our knowledge, to explicitly incorporate the HER4-JAKSTAT axis as well as the unique events occurring in the HER4-STAT5a pathway,
including cleavage of the activated HER4 kinase from the membrane and translocation
into the nucleus to effect gene transcription.
As the HER4-JAK-STAT pathway has not been well-characterized, we undertook
experimental analysis of a model mammary epithelial cell line, HC11, in response to
HER4 stimulation, to quantitatively assess several key aspects of the HER4-JAK-STAT
cascade. We found that several other signaling cascades are either necessary for or
synergize with the HER4 pathway; these cascades include the glucocorticoid receptor and
PRL pathways. Although the HC11 cells mimic many aspects of mammary gland
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differentiation (which occurs during the later stages of pregnancy), in an in vivo context,
it is likely that there is a defined sequence of events, in terms of the interactions among
HER4, PRL, and GR, which culminates in the differentiated mammary cell phenotype.
Our finding that the NRG and HB-EGF ligands decreased PRL-induced gene expression
could potentially be attributed to the presence of different HC11 sub-populations, in
comparison to previous studies123. We also discovered a temporal ‘switch’ whereby the
NRG ligand initially inhibits the expression of the β-casein milk gene (at 12h poststimulation), followed by a switch to activation of the β-casein gene at 24-48h post-ligand
stimulation. This event has not previously been noted, as there are few studies of the
HER4 differentiation pathway to begin with, and additionally, the previous studies
concentrate on gene expression at 24-48h. Although the molecular mechanism underlying
this switch has yet to be determined, we reason that it may constitute a cellular shift from
a program of proliferation to a program of differentiation: precisely the same shift that
can potentially be modulated to bias tumor cells toward the HER4 differentiation
pathway for therapeutic purposes. Future studies will examine the activation kinetics of
other molecular species, such as the TF C/EBP-β, which is known to be involved in
mammary cell differentiation, to determine whether they might play a role in mediating
this cellular switch.
Future iterations of our branched HER4 signaling model will incorporate these
additional layers of complexity revealed by our experimental analysis, including the
crosstalk among the HER4, GR, and PRL pathways, as well as the cellular ‘switch’ from
inhibition to activation of gene expression involved in cell differentiation. However, we
currently note that it is crucial to further investigate the interactions among the HER4,
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PRL, and GR pathways if HER4-mediated cancer therapies are eventually to be
considered in the clinic. We also emphasize the importance of considering the
complementary interactions among the ErbB kinases, especially in terms of rationalizing
ErbB mutation mechanisms. In the case of the HER4 somatic mutants, the mutations
effectively alter the cell fate by rendering HER4 dependent upon the other ErbB kinases
(and no longer able to signal as a HER4 homodimer). Indeed, the various activities of the
ErbB kinases complement each other to produce a holistically functioning signaling unit,
thus compensating for any deficiencies in the individual ErbB proteins. In certain tumor
cells predisposed to uncontrolled signaling, this otherwise advantageous evolutionary
characteristic of the ErbB system can have deleterious consequences, and must be
considered when designing therapeutics targeted to the ErbB family.
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Chapter 6
Conclusions and Future Directions
6.1 Summary of results
In this thesis, we have applied a multiscale modeling framework to investigate the
molecular regulatory mechanisms governing the activation of the ErbB RTKs (with a
focus on the HER3 and HER4 kinases), which play a key role in crucial celluar processes
as well as in various types of human cancer. Chapter 2 presented a multiscale model of
activity in the HER3 RTK, a kinase which, until recently, has been considered kinasedead. We applied our modeling scheme to investigate the non-canonical catalytic
mechanism employed by HER3 and the physiological relevance of this activity to
mechanisms of drug resistance in an ErbB-driven tumor cell in silico. The results of our
molecular-scale simulations supported the characterization of HER3 as a weakly active
kinase that, in contrast to its fully-active ErbB family members, depends upon a unique
hydrophobic interface to coordinate the alignment of specific catalytic residues required
for its activity. Translating our molecular simulation results of the uniquely active
behavior of the HER3 kinase into a physiologically relevant environment, our HER3
signaling model demonstrated that even a weak level of HER3 activity may be sufficient
to induce AKT signaling and TKI resistance in the context of an ErbB signaling–
dependent tumor cell, and therefore therapeutic targeting of HER3 may represent a
superior treatment strategy for specific ErbB-driven cancers.
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Chapter 3 extended our analysis of HER3 to the other members of the ErbB
family (EGFR, HER2, HER4) to facilitate a comparison of the activation and regulatory
mechanisms across the ErbB family members. We biased certain sections of Chapter 3
toward the HER2 kinase, as HER2 exhibits several structural and functional features
which are unique among the ErbB RTKs. Our analysis identified several commonalities
in hydrogen bonding patterns among the three ErbB kinases (EGFR, HER2, HER4) in the
A-loop, C-loop, and αC helix. We extended our analysis of global kinase motions and
hydrogen bonding patterns to several different ErbB dimer systems, including a HER2EGFR heterodimer, as well as EGFR and HER4 homodimers, and found that disruption
of the hydrogen bonding pattern in the dimers shifted the systems toward the active state.
Furthermore, we identified several interactions that persist throughout the dimeric
trajectories of the inactive states and are hence candidates for further investigation
through free energy methods such as umbrella sampling simulations, as the molecular
environment surrounding such residues may define the pathway for conformational
change and the associated barriers to activation.
Chapters 4 and 5 presented a multiscale model of activity in the HER4 RTK,
which has been postulated to play an anti-cancer role in certain tumor types. Our model
begins with molecular simulations of the HER4 dimer activation mechanism and extends
to the cellular scale through a signaling model of the HER4 differentiation pathway in
mammary cells. Chapter 4 focused on molecular scale simulations of dimer-mediated
activation in HER4, in order to elucidate the mechanisms by which the WT kinase is
regulated and activated, and to rationalize the effects of several HER4 somatic mutants
which have recently been discovered in a subset of cancer patients. The simulations
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highlighted key molecular interactions which we predict are important in the HER4
activation mechanism. We discovered that the order of events, in terms of motions of the
individual catalytic sub-domains, differed from those of other kinase families, such as
Src, a distinction which may partially be attributed to the fact that phosphorylation of the
A-loop tyrosine residue does not seem to be required for the activation of the ErbB
kinases. In addition to identifying global motions and hydrogen bonding events taking
place within the activated kinase, we also identified several inter-dimer bonds (i.e., bonds
between the receiver and activator kinases) which broke during the TMD simulation.
Moreover, the bonding pattern in the JM region of the receiver kinase shifted during the
course of the TMD simulation, a result which is in agreement with previous experimental
studies demonstrating that the JM domain is a crucial contributor to the kinase allosteric
activation mechanism. These inter-dimer and JM domain bonds have not been explored
in previous simulations of the EGFR kinase, yet our results indicate that they warrant
further investigation, in order to piece together the complete activation pathway of the
ErbB kinases.
Chapter 5 translated our molecular scale results of HER4 kinase activity into a
cellular pathway model of WT versus mutant HER4 signaling, in which the WT and
mutant cells trigger divergent signaling networks. In particular, induction of the
JAK2/STAT5a signaling pathway by WT HER4 in mammary epithelial cells culminates
in differentiation of the cells, whereas the HER4 somatic mutants preferentially signal
through PI3K/AKT, resulting in cell proliferation. The mechanism by which this cell fate
decision is made involves the ability of the HER4 mutants to dimerize with other ErbB
kinases (hence stimulating PI3K/AKT) but not activate (hence abrogating signaling
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through STAT5a). Thus the modulation of this cell fate decision may represent a
potential therapeutic strategy for specific ErbB-driven cancers. To provide insight into
the HER4-induced JAK2/STAT5a differentiation pathway in mammary cells, we
performed experiments in HER4-stimulated mammary epithelial cells, and discovered
several system properties which may be incorporated into our multiscale model of HER4
activity. Specifically, we highlighted the role of crosstalk between the HER4 pathway
and other signaling cascades, including the glucocorticoid receptor and prolactin
pathways, in promoting the HER4-induced differentiation signal, emphasizing that these
synergistic networks must be taken into account when considering potential therapeutic
modulation of the HER4 pathway. We also identified a temporal ‘switch’ in the
expression of cell differentiation genes, in which HER4 ligand initially inhibited
expression of these mammary cell differentiation genes but subsequently increased their
expression levels. This result may represent a particular stage in the proliferation-todifferentiation switch of mammary epithelial cells, and may be exploited in future studies
investigating HER4-mediated cancer therapeutics.
The protein kinase genes are among the most frequently mutated in human
cancers, and several ErbB kinase domain mutants have been determined. Our simulations
provide insight into the effect of these mutations in the ErbB kinases through assessment
of structural dynamics and hydrogen bonding patterns in the kinase domains.
Furthermore, we predict the importance of previously overlooked regions in regulation of
kinase activation. Elucidation of the molecular regulatory mechanisms will help establish
structure-function relationships in the wildtype ErbB kinases as well as predict mutations
with propensity for constitutive activation. Such molecular variants in the EGFR, HER2,
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and HER4 RTKs are known to profoundly impact specific therapies targeting ErbBmediated cancers. It is worthwhile to note that mutation predictions made in mouse
models of cancer can be extended to human studies insofar as the receptor crystal
structures are homologous in mouse and human (which, for the ErbB kinases, they are).
Our multiscale models of ErbB kinase activity, which investigate the molecular
regulatory mechanisms in the ErbB kinases, will help to elucidate structure-function
relationships in drug-resistant cell lines and motivate the development of more
efficacious TKI therapies targeting ErbB-mediated cancers. A clinically valuable feature
of our multiscale modeling approach is that the flow of information between models
occurs in a bidirectional manner, so that it is possible to apply the results obtained from
one scale to the generation of new hypotheses at another scale, and vice versa. We have
demonstrated that modeling a biological system at multiple levels of resolution
constitutes another type of model ‘validation’, which should be appreciated in
conjunction with experimental validation. Multiscale modeling provides a powerful and
quantitative platform for investigating the complexity inherent in intracellular signaling
pathways and rationalizing the effects of molecular perturbations on downstream
signaling events and ultimately, on the cell phenotype.

6.2 Extensions and future work

6.2.1 Future work: Construction and simulation of macromolecular complexes
The work presented in this thesis focuses on the structure and dynamics of the
monomeric (or dimeric) forms of the ErbB tyrosine kinases. In order to extend our
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models to downstream signaling events, the formation of multi-protein complexes must
be considered. For example, upon ligand-induced activation and phosphorylation of the
HER4 kinase, various adaptor proteins, such as STAT5a, are recruited to the kinase
domain. Precisely how these proteins interact with HER4 remains an open question.
However, structural modeling can be utilized to investigate and predict likely
conformations for these macromolecular complexes. This will be an important step in
extending our multiscale model of ErbB activity, as it will promote the investigation of
the effects of molecular perturbations not only on the ErbB kinases, but on the multiprotein complexes formed by the ErbB kinases and their downstream signaling
mediators.
We applied our modeling method to construct a protein complex consisting of the
HER4 kinase and the STAT5a transcription factor. As discussed in Chapters 4 and 5, one
of the first events to occur following HER4 activation is recruitment of STAT5a. Several
studies have revealed a physical association between HER4 and STAT5a 32, 197, and have
also demonstrated that HER4 serves as a chaperone to shuttle STAT5a into the nucleus.
Indeed, STAT5a is incapable of nuclear translocation in the absence of HER4197.
However, the physical nature of the HER4-STAT5a association is unknown. Both
STAT5a and HER4 form dimers when activated, and it is uncertain how these dimers
associate with each other. Elucidating the mechanism of HER4-STAT5a binding will
help to predict the effects of molecular perturbations, such as mutations, on the
downstream signaling events that are induced by the HER4-STAT5a complex.
To construct such a complex, we first required structures for both HER4 and
STAT5a. As no active STAT5a crystal structure currently exists, we homology modeled
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the STAT5a protein based on the highly homologous STAT1 family member, for which a
crystal structure of the active conformation does exist25. Here we note a few points
regarding the active STAT structure. The unphosphorylated and phosphorylated STAT
monomers essentially have the same structure; no conformational change occurs within
the STAT core fragment upon phosphorylation. Rather, the role of phosphorylation is to
alter the STAT dimerization mode: unphosphorylated STAT proteins dimerize in one of
two modes (antiparallel or parallel), while phosphorylated STAT proteins dimerize as a
‘pair of pliers’. This ‘pliers’ interface is necessary for subsequent DNA-binding in the
nucleus. In this active conformation, the SH2 domains and phosphotyrosine residues of
two STAT monomers form a reciprocal interaction such that the dimer is shaped like a
pair of pliers. This mode of dimerization allows for high-affinity DNA-binding.
We generated the active STAT5a structure based on the STAT1 crystal structure,
and constructed the active HER4 dimer as described in Chapter 4. We then applied
various alignment algorithms to construct several preliminary HER4-STAT5a complexes,
based on the structure of STAT bound to phosphotyrosine residues located in its SH2
domain. We also based our structures on the experimental evidence indicating that
STAT5a interacts with HER4 via the STAT SH2 domain.
Once our structures have been ranked and further refined, we aim to answer
questions such as: is it possible for HER4 to phosphorylate STAT5a directly, or is a
protein mediator required? This is an important question, as there has been controversy
regarding the role of HER4 in phosphorylation of STAT5a; indeed, one view is that
HER4 may serve as a scaffold protein to indirectly promote the phosphorylation of
STAT5a by JAK2123. Thus our structure will be employed to sort through possibilities
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regarding the nature of the HER4-STAT5a interaction, and also help to delineate the
sequence of signaling events downstream of HER4 activation (e.g., does STAT5a
dimerize and then bind to HER4, or do STAT5a monomers bind to HER4 and
subsequently dimerize?). We also plan to extend our analysis protocol to the construction
of other macromolecular complexes involved in the ErbB signaling network, including
the EGFR-STAT5b interaction.

6.2.2 Future work: Transcriptional regulatory network analysis of the anti-cancer
HER4 signaling pathway in mammary cells
As studies of gene expression analysis have become increasingly high-dimensional and
multiplexed, so have studies of gene regulation by transcriptional regulatory networks. A
computational program called Promoter Analysis and Interaction Network Toolset
(PAINT) was recently developed by Vadigepalli et al.192, and combines bioinformatics
with statistical significance testing to predict candidate regulatory interactions between
TFs and the transcriptional regulatory elements (TREs) of differentially expressed genes.
PAINT retrieves upstream TREs from the TRANSFAC database114 of promoter
sequences of known or predicted genes in several eukaryotic species, including human,
mouse, and rat, and has been successfully applied to the generation of candidate
transcriptional regulatory networks in a wide range of biological systems86, 89, 139, 148, 149.
Specifically, given a gene expression data set, PAINT will: (1) fetch potential promoter
sequences for the genes in the list, (2) find TF-binding sites on the sequences, (3) analyze
the TF-binding site occurrences for over/under-representation compared with a reference,
and (4) generate multiple visualizations for these analyses. PAINT is currently available
as an online, web-based service located at: http://www.dbi.tju.edu/dbi/tools/paint.
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As a sample dataset, we applied the PAINT method to microarray data that had
been collected to investigate gene expression downstream of HER4 activation in several
mammary cell lines3, 4. In this study, the molecular mechanisms contributing to the
functional differences in HER2 versus HER4 overexpression in breast cancer were
investigated using microarray analysis. Specifically, agonistic antibodies were employed
to activate HER2 and HER4 in isolation from the other ErbBs in breast cancer cells, and
gene expression was performed to identify transcriptional targets of receptor activation. It
was demonstrated that there are receptor-specific targets that are preferentially regulated
by each receptor, and moreover, that two ligands acting via the same receptor dimer may
induce expression of different subsets of genes.
To extend the microarray study to the transcriptional regulatory networks
operating in HER2 versus HER4-stimulated cells, we applied the PAINT analysis to the
gene expression dataset. We first clustered the differentially expressed genes based on the
corresponding stimulatory ligand and identified TREs positioned 5000 base pairs
upstream of the transcriptional start site of each gene. A Feasnet was then produced,
which is a matrix consisting of each gene and its putative TREs/TFs. The Feasnet was
then subjected to further PAINT analysis in order to obtain only the most statistically
important TREs. In this refined matrix, each gene is assigned to its respective cluster (for
example, genes that are upregulated by the ligand HB-EGF versus genes that are
upregulated by the HER4 Ab). To determine which TREs are over-represented in each
cluster, PAINT requires some type of reference file. We designated the entire list of
genes included in the microarray as our reference set, as this selection removes any bias
inherent in the microarray relative to the entire genome. The enrichment analysis results
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were filtered using p-value ranges of 0<p<0.01 and 0.01<p<0.05 to derive the regulatory
network hypotheses (Figure 6.1).
We observed over-representation of several regulatory elements in the interaction
matrix, which suggests their potential role in regulation of specific gene clusters. The
Ingenuity Pathways Analysis software (Ingenuity® Systems, www.ingenuity.com),
which aids in gene ontology annotation and construction of putative signaling pathways,
was applied to assign functional properties to the genes and TFs included in our analysis
(Fig. 6.2). Specifically, we identified several TFs associated with cellular endocytosis,
including LRF and its target gene SCAMP3, which is a component of the endosomal
sorting machinery, and YIF1A, which is required for vesicle transport from the
endoplasmic reticulum to the Golgi stack. It is plausible that these TFs are upregulated to
facilitate internalization of the ErbB receptors in response to ligand binding. Intriguingly,
stimulation of the mammary cell lines with the HER4 ligands NRG and HB-EGF resulted
in different sets of activated genes and PAINT TF predictions, although the putative TFs
perform similar functional roles in endocytosis. Hence different ligands signaling through
the same receptor, in this case, the HER4 homodimer, generate differential TF regulatory
patterns that nonetheless culminate in equivalent cellular outcomes.
In addition to endocytosis, we observed enrichment of several regulatory elements
involved in the estrogen receptor (ER) pathway, including the TFs ARNT and COUPTF.
This finding is in agreement with previous studies, which have demonstrated the
formation of a HER4-ER complex and its translocation to the nucleus, resulting in
upregulation of ER target genes. As both HER4 and ER are nuclear receptors with
transcriptional properties, it is plausible that the crosstalk between the HER4 and ER
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signaling pathways produces a synergistic effect at the level of TFs to direct mammary
gland development. Hence our preliminary PAINT analysis of the ErbB dataset generated

Figure 6.1. PAINT interaction matrix describing interactions in HER4-stimulated cells.
The list of differentially expressed genes is displayed on the y-axis, and the putative TREs are
displayed on the x-axis at top. TREs which are over-represented in a specific gene subset are
highlighted in red; TREs which are under-represented in a specific gene subset are in cyan.
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testable hypotheses regarding the role of specific regulatory elements in the ErbB
pathway in mammary carcinoma cells. Additionally, we optimized several PAINT
parameters for implementation in our analysis of the forthcoming HC11 cell datasets.
Future studies will focus on microarray analysis and the application of PAINT to datasets
obtained from HER4-stimulated HC11 cells during mammary differentiation, using the
ligands NRG and HB-EGF. A subset of the genes predicted by PAINT to be differentially
regulated by the activated TFs will be validated by qRT-PCR and clustered according to
time point or type of ligand stimulation. Promoter regions of genes in these clusters will
then be examined for shared TF binding sites by comparing the over-representation of
each binding site relative to a reference set of genes. Appropriate statistical thresholds
will be implemented in PAINT to rank the likelihood of involvement of individual TFs in
each cluster and to refine the list of co-regulated genes. Cluster analysis of the genes is an
important step because it links each TF binding event with either activation or
suppression of specific genes involved in the HER4-mediated signaling pathway. The
hypothesis motivating the PAINT analysis is that co-expressed genes share binding
elements in their promoters, leading to co-regulation of the genes by specific TFs. Hence
genes sharing identical TREs can be associated in a molecular network that may
represent key pharmacological targets for modulating or exploiting the HER4 pathway in
malignant cells.
To elucidate the linkage between differential gene expression and cell decisionmaking during HC11 cell differentiation, genes will be categorized according to their
functional annotations (gene ontology). We predict increased expression of genes
associated with cell differentiation concomitant with decreased expression of genes
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involved in proliferation, depending on the ligand used for cell stimulation, as we have
shown that NRG and HB-EGF produce slightly different functional outcomes. In
particular, NRG has been demonstrated to produce more pronounced morphological signs
of differentiation, whereas HB-EGF may stimulate a slightly weaker response due to coactivation of proliferation pathways.

Figure 6.2. Transcription factor interaction matrix generated in Cytoscape159.
The TFs postulated to play a role in the biological network of interest are associated with specific
biological functions (cell cycle, trafficking, tumor suppressor) using gene ontology.
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